NZ626199B2 - Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors - Google Patents
Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors Download PDFInfo
- Publication number
- NZ626199B2 NZ626199B2 NZ626199A NZ62619912A NZ626199B2 NZ 626199 B2 NZ626199 B2 NZ 626199B2 NZ 626199 A NZ626199 A NZ 626199A NZ 62619912 A NZ62619912 A NZ 62619912A NZ 626199 B2 NZ626199 B2 NZ 626199B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- optionally substituted
- piperidy1
- thieno
- 6alkyl
- pyrimidin
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract description 51
- 239000003112 inhibitor Substances 0.000 title abstract description 23
- 102000004257 potassium channel family Human genes 0.000 title abstract description 12
- 108020001213 potassium channel family Proteins 0.000 title abstract description 12
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 247
- 102100013904 KCNJ5 Human genes 0.000 abstract description 56
- 108060004084 KCNJ5 Proteins 0.000 abstract description 56
- 102100013909 KCNJ3 Human genes 0.000 abstract description 45
- 108060004082 KCNJ3 Proteins 0.000 abstract description 45
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 30
- 201000010099 disease Diseases 0.000 abstract description 29
- 125000001424 substituent group Chemical group 0.000 abstract description 22
- 230000001404 mediated Effects 0.000 abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 229910052705 radium Inorganic materials 0.000 abstract description 7
- 229910052701 rubidium Inorganic materials 0.000 abstract description 7
- 208000008787 Cardiovascular Disease Diseases 0.000 abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 2
- 101700058821 RARB Proteins 0.000 abstract 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 abstract 1
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical class C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 abstract 1
- -1 Nal Chemical class 0.000 description 183
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 130
- 125000000547 substituted alkyl group Chemical group 0.000 description 97
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 96
- 238000006243 chemical reaction Methods 0.000 description 94
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 86
- 150000003230 pyrimidines Chemical class 0.000 description 78
- 239000000203 mixture Substances 0.000 description 73
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- 125000005936 piperidyl group Chemical group 0.000 description 58
- 229910003827 NRaRb Inorganic materials 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 54
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 52
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 51
- 125000001072 heteroaryl group Chemical group 0.000 description 50
- 239000002904 solvent Substances 0.000 description 50
- 206010003658 Atrial fibrillation Diseases 0.000 description 49
- 125000003386 piperidinyl group Chemical group 0.000 description 49
- 125000004093 cyano group Chemical group *C#N 0.000 description 47
- 125000005843 halogen group Chemical group 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical class N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 46
- 239000003814 drug Substances 0.000 description 43
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 39
- 125000004432 carbon atoms Chemical group C* 0.000 description 38
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 37
- 238000010992 reflux Methods 0.000 description 37
- 125000000217 alkyl group Chemical group 0.000 description 36
- 125000003107 substituted aryl group Chemical group 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 239000002585 base Substances 0.000 description 35
- 239000002253 acid Substances 0.000 description 31
- 125000003118 aryl group Chemical group 0.000 description 31
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- 125000002757 morpholinyl group Chemical group 0.000 description 29
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- 125000005415 substituted alkoxy group Chemical group 0.000 description 28
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 229910052760 oxygen Inorganic materials 0.000 description 26
- 230000001746 atrial Effects 0.000 description 24
- 125000004429 atoms Chemical group 0.000 description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- 125000003545 alkoxy group Chemical group 0.000 description 20
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 19
- 150000002500 ions Chemical class 0.000 description 19
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 19
- 125000000714 pyrimidinyl group Chemical group 0.000 description 19
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 18
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 125000004193 piperazinyl group Chemical group 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- 239000001184 potassium carbonate Substances 0.000 description 15
- 229910000027 potassium carbonate Inorganic materials 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 14
- 230000000051 modifying Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 12
- 125000003106 haloaryl group Chemical group 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 12
- 125000004953 trihalomethyl group Chemical group 0.000 description 12
- 229910006069 SO3H Inorganic materials 0.000 description 11
- 210000001013 Sinoatrial Node Anatomy 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 230000003288 anthiarrhythmic Effects 0.000 description 11
- 125000002393 azetidinyl group Chemical group 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 229940079593 drugs Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 229940113083 morpholine Drugs 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 11
- 125000005968 oxazolinyl group Chemical group 0.000 description 11
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 11
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 11
- 125000006004 trihaloethyl group Chemical group 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 10
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 125000006008 trihaloethoxy group Chemical group 0.000 description 10
- 230000001515 vagal Effects 0.000 description 10
- 206010003662 Atrial flutter Diseases 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 210000004027 cells Anatomy 0.000 description 9
- 230000001808 coupling Effects 0.000 description 9
- 238000006073 displacement reaction Methods 0.000 description 9
- 230000004064 dysfunction Effects 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical compound NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000002194 synthesizing Effects 0.000 description 9
- 125000004951 trihalomethoxy group Chemical group 0.000 description 9
- OHDMIERTIPXMBO-CFCGPWAMSA-N 5-acetyl-3-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-2-one Chemical compound O=C1NC(C(=O)C)=CN1[C@@H]1O[C@H](CO)C(O)C1 OHDMIERTIPXMBO-CFCGPWAMSA-N 0.000 description 8
- 229960004373 Acetylcholine Drugs 0.000 description 8
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 8
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 8
- 125000003725 azepanyl group Chemical group 0.000 description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 230000002354 daily Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrugs Drugs 0.000 description 8
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229910052720 vanadium Inorganic materials 0.000 description 8
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 7
- 108090000862 Ion Channels Proteins 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 125000005842 heteroatoms Chemical group 0.000 description 7
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- 230000000269 nucleophilic Effects 0.000 description 7
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 7
- 238000007634 remodeling Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 206010003119 Arrhythmia Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000002015 acyclic group Chemical group 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- HTJDQJBWANPRPF-UHFFFAOYSA-N cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000005017 substituted alkenyl group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 208000005189 Embolism Diseases 0.000 description 5
- 206010015037 Epilepsy Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 208000001435 Thromboembolism Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000000546 pharmaceutic aid Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 4
- 108020004999 Messenger RNA Proteins 0.000 description 4
- 210000003492 Pulmonary Veins Anatomy 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N Pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 150000001562 benzopyrans Chemical class 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 229920002106 messenger RNA Polymers 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 150000002829 nitrogen Chemical group 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 230000001734 parasympathetic Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 4
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 4
- KZXDZXHQWUXWGK-UHFFFAOYSA-N propan-1-amine Chemical compound CC[CH-]N KZXDZXHQWUXWGK-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000036279 refractory period Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 3
- OAISYTVEIFLVFW-UHFFFAOYSA-N 5-phenyl-2-[4-(2-pyrrolidin-1-ylethoxymethyl)piperidin-1-yl]thieno[2,3-d]pyrimidine Chemical compound C1CN(C=2N=C3SC=C(C3=CN=2)C=2C=CC=CC=2)CCC1COCCN1CCCC1 OAISYTVEIFLVFW-UHFFFAOYSA-N 0.000 description 3
- 206010002855 Anxiety Diseases 0.000 description 3
- 206010057666 Anxiety disease Diseases 0.000 description 3
- 206010003671 Atrioventricular block Diseases 0.000 description 3
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- 210000001772 Blood Platelets Anatomy 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241001562081 Ikeda Species 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- FEWLNYSYJNLUOO-UHFFFAOYSA-N N-Formylpiperidine Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 3
- 206010034636 Peripheral vascular disease Diseases 0.000 description 3
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 3
- 102000006877 Pituitary Hormones Human genes 0.000 description 3
- 108010047386 Pituitary Hormones Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 101700006198 TERT Proteins 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- 102000003734 Voltage-gated potassium channels Human genes 0.000 description 3
- 108090000013 Voltage-gated potassium channels Proteins 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 210000002072 atrial myocyte Anatomy 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000012320 chlorinating reagent Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000002057 chronotropic Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000001091 dromotropic Effects 0.000 description 3
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000960 hypophysis hormone Substances 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 230000000977 initiatory Effects 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000000955 neuroendocrine Effects 0.000 description 3
- 230000000926 neurological Effects 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 3
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 3
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 3
- 239000003638 reducing agent Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NRAOLILGQIRZBT-UHFFFAOYSA-N thieno[2,3-d]pyrimidin-2-amine Chemical compound NC1=NC=C2C=CSC2=N1 NRAOLILGQIRZBT-UHFFFAOYSA-N 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
- YLDJMNFQDUEVHZ-UHFFFAOYSA-N 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine Chemical compound C1CNCCC1COCCN1CCCC1 YLDJMNFQDUEVHZ-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- HFGUINASBGDWLY-UHFFFAOYSA-N 4-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical class C1CNCCN1C1=NC=NC2=C1C=CS2 HFGUINASBGDWLY-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- DANYIYRPLHHOCZ-UHFFFAOYSA-N Acacetin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 2
- 210000001992 Atrioventricular Node Anatomy 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 210000003403 Autonomic Nervous System Anatomy 0.000 description 2
- VBUWHHLIZKOSMS-UHFFFAOYSA-N Aviptadil Chemical compound C=1C=C(O)C=CC=1CC(NC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)C(C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(N)CC=1NC=NC=1)C(C)C)C(C)O)C(=O)NC(C(C)O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCC(N)=O)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 VBUWHHLIZKOSMS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 CARBACHOL Drugs 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N Carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010007554 Cardiac failure Diseases 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N Dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 description 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N Ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 2
- 229960002767 Ethosuximide Drugs 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methane sulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 108091006011 G proteins Proteins 0.000 description 2
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- 206010019280 Heart failure Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102100013903 KCNJ6 Human genes 0.000 description 2
- 108060004085 KCNJ6 Proteins 0.000 description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000008466 Metabolic Disease Diseases 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 102000008037 Myeloid-Lymphoid Leukemia Protein Human genes 0.000 description 2
- 108010075393 Myeloid-Lymphoid Leukemia Protein Proteins 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N Phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N Quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 description 2
- 206010040639 Sick sinus syndrome Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 229960000553 Somatostatin Drugs 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N Tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N Trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- 101700003320 VIP Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 102000034433 acetylcholine receptors Human genes 0.000 description 2
- 108020000715 acetylcholine receptors Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000002429 anti-coagulation Effects 0.000 description 2
- 230000000702 anti-platelet Effects 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 230000002567 autonomic Effects 0.000 description 2
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000001713 cholinergic Effects 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229940082627 class III Antiarrhythmics Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 2
- 229960002084 dronedarone Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- UAVOCTDYPKOULU-UHFFFAOYSA-N methylchloranuidyl formate Chemical compound C[Cl-]OC=O UAVOCTDYPKOULU-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000007799 mixed lymphocyte reaction Methods 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000001314 paroxysmal Effects 0.000 description 2
- 230000002085 persistent Effects 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000001817 pituitary Effects 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000003450 potassium channel blocker Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- MKYRMMMSZSVIGD-UHFFFAOYSA-N thieno[3,2-c]pyridine Chemical class N1=CC=C2SC=CC2=C1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 201000011528 vascular disease Diseases 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 1
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2S)-6-amino-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (E)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- XFNJVJPLKCPIBV-UHFFFAOYSA-N 1,3-Diaminopropane Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 1
- PNHGJPJOMCXSKN-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanamine Chemical compound CN1CCCC1CCN PNHGJPJOMCXSKN-UHFFFAOYSA-N 0.000 description 1
- ZWRMSOMIVOVMQX-UHFFFAOYSA-M 2-(2-aminoethyldisulfanyl)ethanamine;palladium(2+);chloride Chemical compound [Cl-].[Pd+2].NCCSSCCN ZWRMSOMIVOVMQX-UHFFFAOYSA-M 0.000 description 1
- FCVODZIMSKRWEF-UHFFFAOYSA-N 2-(2-azabicyclo[2.2.1]heptan-5-yloxy)ethanol Chemical compound C1C2C(OCCO)CC1NC2 FCVODZIMSKRWEF-UHFFFAOYSA-N 0.000 description 1
- CHDSRMIDIQABTP-UHFFFAOYSA-N 2-[2-[[[2-(4-methoxyphenyl)acetyl]amino]methyl]phenyl]-N-(2-pyridin-3-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1=CC=CC=C1C1=CC=CC=C1C(=O)NCCC1=CC=CN=C1 CHDSRMIDIQABTP-UHFFFAOYSA-N 0.000 description 1
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 1
- SLHBEQHYHUZCKF-UHFFFAOYSA-N 2-phenylthieno[2,3-d]pyrimidine Chemical compound N1=C2SC=CC2=CN=C1C1=CC=CC=C1 SLHBEQHYHUZCKF-UHFFFAOYSA-N 0.000 description 1
- CXUVLSLHMJMSCJ-UHFFFAOYSA-N 2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical class C1CNCCN1C1=NC=C(C=CS2)C2=N1 CXUVLSLHMJMSCJ-UHFFFAOYSA-N 0.000 description 1
- ZXAZWXJOKVUXST-UHFFFAOYSA-N 3'-methyl-N-(3'-methylspiro[1,3-dithiolane-2,4'-6,7-dihydro-5H-1-benzofuran]-2'-carbonyl)-N-(2-morpholin-4-ylethyl)spiro[1,3-dithiolane-2,4'-6,7-dihydro-5H-1-benzofuran]-2'-carboxamide Chemical compound C1=2C(C)=C(C(=O)N(CCN3CCOCC3)C(=O)C3=C(C=4C5(SCCS5)CCCC=4O3)C)OC=2CCCC21SCCS2 ZXAZWXJOKVUXST-UHFFFAOYSA-N 0.000 description 1
- GRJXNQIZQDSQPC-UHFFFAOYSA-N 4-[4-[2-(1-methylpyrrolidin-2-yl)ethoxymethyl]piperidin-1-yl]thieno[2,3-d]pyrimidine Chemical compound CN1CCCC1CCOCC1CCN(C=2C=3C=CSC=3N=CN=2)CC1 GRJXNQIZQDSQPC-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 description 1
- 108091005518 5-HT3 receptors Proteins 0.000 description 1
- 102000035257 5-HT3 receptors Human genes 0.000 description 1
- 108091005482 5-HT6 receptors Proteins 0.000 description 1
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 1
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 1
- 229960004676 ANTITHROMBOTIC AGENTS Drugs 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N Aluminium hydride Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229940059260 Amidate Drugs 0.000 description 1
- 229960005260 Amiodarone Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N Amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 235000010751 Asperula odorata Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N Atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 Atropine Drugs 0.000 description 1
- 102000003852 Autoantibodies Human genes 0.000 description 1
- 108090000206 Autoantibodies Proteins 0.000 description 1
- 210000000467 Autonomic Pathways Anatomy 0.000 description 1
- CUFNKYGDVFVPHO-UHFFFAOYSA-N Azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940053197 Benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 229940054023 Benzodiazepine derivative anxiolytics Drugs 0.000 description 1
- 229940053995 Benzodiazepine derivative hypnotics and sedatives Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- XHOLNRLADUSQLD-UHFFFAOYSA-N Betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 description 1
- 229950011103 Betrixaban Drugs 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 208000006218 Bradycardia Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- CODNYICXDISAEA-UHFFFAOYSA-N Bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N Butyramide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101700067048 CDC13 Proteins 0.000 description 1
- LADJRPDOKVCQCG-NZQKXSOJSA-N CHEMBL602070 Chemical compound C1([C@@H]2C(=C(NC3=CC=NN32)C)C(=O)N2[C@@H](CCC2)C=2C=CC(F)=CC=2)=CC=C(Cl)C(Cl)=C1 LADJRPDOKVCQCG-NZQKXSOJSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- WDECIBYCCFPHNR-UHFFFAOYSA-N Chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- 229960003009 Clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- VPUGDVKSAQVFFS-UHFFFAOYSA-N Coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-Galacturonic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 229960003850 Dabigatran Drugs 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940019337 Direct thrombin inhibitors Drugs 0.000 description 1
- 201000010374 Down syndrome Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 229960000449 Flecainide Drugs 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N Fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108040006927 G protein-coupled serotonin receptor activity proteins Proteins 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 102100006616 GRM2 Human genes 0.000 description 1
- 102000034446 Gi proteins Human genes 0.000 description 1
- 108091006085 Gi proteins Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 241001086018 Homo heidelbergensis Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229960004053 Ibutilide Drugs 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- 206010027665 Immune disorder Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N Indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000009785 Inferior Wall Myocardial Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 description 1
- 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 description 1
- 102100011739 KCNJ9 Human genes 0.000 description 1
- 108060004087 KCNJ9 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000004731 Long QT Syndrome Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100019218 MEN1 Human genes 0.000 description 1
- 101700045140 MEN1 Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N Maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 102000007205 Muscarinic M2 Receptor Human genes 0.000 description 1
- 108010008407 Muscarinic M2 Receptor Proteins 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 210000004413 Myocytes, Cardiac Anatomy 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 208000004296 Neuralgia Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N Nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 229960001158 Nortriptyline Drugs 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- LSQODMMMSXHVCN-UHFFFAOYSA-N Ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
- 102100019727 P2RY1 Human genes 0.000 description 1
- 101700062635 P2RY1 Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102400001170 Pancreatic hormone Human genes 0.000 description 1
- 229940055726 Pantothenic Acid Drugs 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N Phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N Phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N Phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- GBROPGWFBFCKAG-UHFFFAOYSA-N Picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N Propadiene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N Propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- BBEAQIROQSPTKN-UHFFFAOYSA-N Pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 1
- 230000036885 QTc Effects 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N Quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N Rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- GOTMKOSCLKVOGG-UHFFFAOYSA-N SCH 23390 Chemical compound C1N(C)CCC2=CC(Cl)=C(O)C=C2C1C1=CC=CC=C1 GOTMKOSCLKVOGG-UHFFFAOYSA-N 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 208000002131 Short Qt Syndrome Diseases 0.000 description 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 Sotalol Drugs 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000004304 Subcutaneous Tissue Anatomy 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N Sulfanilic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 210000001186 Vagus Nerve Anatomy 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 229960005080 Warfarin Drugs 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000009962 acacetin Nutrition 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003504 ach effect Effects 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 230000003281 allosteric Effects 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000020127 ayran Nutrition 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzyl-dodecyl-dimethylazanium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 238000011087 biopharmaceutical technology Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 230000002999 depolarising Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic Effects 0.000 description 1
- RJGHQTVXGKYATR-UHFFFAOYSA-L dibutyl(dichloro)stannane Chemical compound CCCC[Sn](Cl)(Cl)CCCC RJGHQTVXGKYATR-UHFFFAOYSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OPCPRUQQEJNFIV-UHFFFAOYSA-N disodium;cyanoboron(1-) Chemical compound [Na+].[Na+].[B-]C#N.[B-]C#N OPCPRUQQEJNFIV-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037024 effective refractory period Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002332 fibrillatory Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003944 flavones Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000036747 functional refractory period Effects 0.000 description 1
- KQGXYVJZOMKLSA-UHFFFAOYSA-N furo[2,3-d]pyrimidine Chemical class N1=CN=C2OC=CC2=C1 KQGXYVJZOMKLSA-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KGZLFTWMCMEEJR-UHFFFAOYSA-N heptane;hydrochloride Chemical compound Cl.CCCCCCC KGZLFTWMCMEEJR-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002467 indacenes Chemical class 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003122 modulative effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 201000008895 mood disease Diseases 0.000 description 1
- 230000003232 mucoadhesive Effects 0.000 description 1
- 230000003551 muscarinic Effects 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001272 neurogenic Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- MIPHRQMEIYLZFZ-UHFFFAOYSA-N oxolan-3-amine Chemical compound NC1CCOC1 MIPHRQMEIYLZFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000030074 regulation of atrial cardiomyocyte membrane repolarization Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000002930 sinoatrial node disease Diseases 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical class C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- DYTQGJLVGDSCLF-UHFFFAOYSA-N thieno[2,3-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1C=CS2 DYTQGJLVGDSCLF-UHFFFAOYSA-N 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 125000005289 uranyl group Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
- 229960001522 ximelagatran Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Disclosed herein are thieno and furo pyridine and pyrimidine compounds of formula (I) wherein R3 is N(RaRb)J where Ra and Rb form a ring with the nitrogen to which they are attached and the remainder of the substituents are as are defined herein. The compounds are potassium channel inhibitors intended for use in treatment of diseases or conditions that are mediated by KI3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof such as cardiovascular diseases. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). ed for use in treatment of diseases or conditions that are mediated by KI3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof such as cardiovascular diseases. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I).
Description
THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS
POTASSIUM CHANNEL INHIBITORS
TECHNICAL FIELD
The present invention relates to compounds of a (I) which are potassium channel
inhibitors. Pharmaceutical compositions comprising the compounds, their use in therapy and
s of treatment employing the compounds are also provided.
BACKGROUND ART
Ion channels are proteins that span the lipid bilayer of the cell membrane and provide an
aqueous y through which specific ions such as Nal, Kl, Ca2+ and Cl" can pass (Hille
er al., 1999). Potassium channels represent the t and most diverse sub-group of ion
channels and they play a central role in regulating the membrane potential, cell volume,
signal transduction lling cellular excitability (Armstrong & Hille, 1998). Potassium
channels have been categorized into gene families based on their amino acid sequence and
their biophysical properties (for nomenclature see (Gutman er al., 2003) and
http://www.iuphar-db.org/DATABASE/ReceptorFamiliesForward?type=IC).
Compounds which te potassium channels have multiple therapeutic applications in a
number of areas/disorders including vascular, neuronal, renal, metabolic, endocrine,
auditory, pain, respiratory, immunological, inflammation, gastrointestinal, reproduction,
cancer and cell proliferation, (for reviews see (Ehrlich, 2008;Wulff & Zhorov,
2008;Kobayashi & Ikeda, 2006;Mathie & Veale, 2007;Wulff er al., 2009;Camerino er al.,
2008;Shieh er al., 2000;Ford er al., 2002;Geibel, 2005). More specifically potassium
channels such as those formed by Kir3.x, Kv4.x, Kir2.x, Kir6.x, Kv11.x, Kv7.x, KCa, sz,
and Kvl.x along with their ancillary subunit are involved in the risation phase of the
action ial in cardiac myocytes (Tamargo er al., 2004). These potassium channels
subtypes have been associated with vascular diseases and disorders including atrial
arrhythmias, ventricular arrhythmias, cardiomyopathy, hypertrophy long QT syndrome,
short QT syndrome, Brugada me; and all of which can cause cardiac failure and
fatality n, 2002;Novelli er al., 2010;Tamargo er al., 2004).
Inwardly rectifying potassium channels are members of a large superfamily comprised of
Kirl .x to Kir7.x. The Kir3.x subfamily are G-protein d inwardly rectifying potassium
ion channels comprised of 4 mammalian subunit members Kir3.l to Kir3.4. These subunits
form homo- or - tetrameric ion channels ed in potassium flux across the
membrane. Kir3.x ion channels are expressed in the cardiovascular system (Kir3.1 and
Kir3 .4), central nervous system (Kir3.1, Kir3.2, Kir3.3 > Kir3.4), gastrointestinal tract
(Kir3.1 and Kir3.2) and have been implicated in a number of disease areas including cardiac
arrhythmias, pain, Parkinson’s disease, Down’s Syndrome, epilepsy/seizure, addiction,
depression and ataxia (Luscher & Slesinger, 2010;Tamargo er al., 2004)
The human G-protein coupled ly-rectifying potassium channel subunits Kir3.1 and
Kir3.4 are inantly expressed in the supraVentricular regions (including atria, nodal
tissue, pulmonary sleeve) and conduction system of the heart and are believed to offer
therapeutic opportunities for the management of atrial fibrillation for several ent
reasons (see review of ch, 2008):
(1) Kir3.1/3.4 underlies IKACh: There is eVidence that a eric assembly of Kir3.1
and/or Kir3.4 subunits underlies the cardiac acetylcholine/adenosine activated inwardly-
rectifying potassium current o referred to as IKACh) in the heart due to similar
biophysical (Kraininsky er al., 1995;Duprat et al., 1995;Corey & CLAPHAM,
1998;Corey er al., 1998) and pharmacological (Jin & Lu, 1998;Jin er al., 1999;Jin & Lu,
rici er al., 2000;Cha er al., 2006;DobreV er al., oigt er al., 2010b)
properties (for review see (Hibino er al., 2010;Be1ardinelli er al., 1995)).
(2) IKACh is ed in AF: The Kir3.1 subunit cannot form a functional homotetramer
or cannot traffic to the ne pson er al., 1995;Hedin er al., 1996;Woodward
er al., 1997) and as such genetic knockout of Kir3.4 gene in the mouse results in the
lack of a functional IKACh in the atria (Wickman et al., 1998). This genetic ablation of
IKACh results in resistance to atrial fibrillation (Kovoor er al., 2001). These data
support the notion of an ly of Kir3.1/3.4 and the importance of IKACh in the
initiation and sustaining of AF. Furthermore, single nucleotide polymorphisms of Kir3.4
gene have been correlated with paroxysmal lone AF in a Chinese population (Zhang et
al. no on has been ascribed to these polymorphisms.
, 2009). However,
(3) IKACh is an atrial-specific target: High levels of Kir3.1 and Kir3.4 gene expression
(Gaborit et al., 2007b) and large IKACh are found in both the left and right human atria
(DobreV er al., 2001;DobreV er al., 2005;Voigt er al., 2010b;Wettwer et al., 2004;Bosch
er al., 1999;Voigt et al., 2010a). This contrasts with the human ventricle, where mRNA
(Gaborit et al., 2007b) and current expression are considerable smaller, and the number
of cells expressing IKACh and the ACh ivity is small compared to the atria
(Koumi & Wasserstrom, 1994;Koumi et al., 1994). In conjunction with a lower density
of parasympathetic innervations (Kent et al., 1974), this argues t a functional role
of IKACh in human ventricles (Brodde & Michel, 1999;Be1ardinelli er al., 1995). This is
further supported by the lack of effect of selective IKACh inhibitors on cular
repolarisation in in vitro (Cha er al., 2006) and in viva dog studies (Hashimoto er al.,
2006;Hashimoto er al., 2008;Machida er al., 2011). The predominant expression of
IKACh in the atria cf. the ventricle provides a mechanism to modulate atrial
risation without ering with ventricular repolarisation and potentially
inducing fatal ventricular arrhythmia (Hashimoto er a1. , 2006).
(4) Constitutive-activation of IKACh in chronic AF: The carbachol-induced IKACh
recorded from atrial myocytes from ts with chronic AF is smaller than those from
patients in sinus rhythm, a phenomenon initially thought to be due to decreased Kir3.4
mRNA and protein levels (Bosch er al., 1999;Brundel er al., 2001a;Brunde1 er al.,
2001b;Dobrev er al., 2001). However, it was later demonstrated that the blunted
response to carbachol is due to IKACh being constitutively active in the absence of
agonist (Dobrev er al., 2005). Similar observations have also been reported in the atria
and pulmonary vein in the tachypaced-dog model ofAF (Cha er al., 2006;Ehrlich er a1.
2004;Voigt er al., akary er al., 2011). Ionic remodeling (for review see
(Schotten er al., 2011;Workman er al., 2008), including the constitutive —activation of
IKACh, contributes to the shortening of action ial duration observed in chronic
AF human patients (Dobrev er al., obrev et al., 2005;Bosch er al., 1999;Wettwer
er al., 2004) and tachypaced dog atrial myocytes (Ehrlich er al., 2004;Ehrlich er al.,
2007;Cha er al., 2006), which, in turn, causes a reduction in the atrial effective
refractory period (Brundel er al., 2002b;Brundel er al., Workman er al., 2008)
predisposing to the generation of arrhythmias. In on, the geneous
distribution (Gaborit er al., 2007a;Lomax er al., 2003;Sarmast er al., 2003;Voigt er al.,
2010b) of constitutively active IKACh (Dobrev er al., 2005;Cha er al., 2006;Ehrlich et
al., 2004) across the atria is expected to increase the dispersion of atrial
repolarization/refractoriness (Liu & Nattel, 1997;Kabell er al., 1994;Schauerte er al.,
2000;Chiou er a1. , 1997) and in turn increase vulnerability to transient atrial arrhythmias
(Liu & Nattel, 1997;Kabell er al., 1994). Pharmacological studies have shown that
selective inhibition of IKACh has as a more pronounced prolonging effect on action
potential on in the remodeled dog atria (Cha er al., 2006;Ehrlich er al., 2007).
Prolonging the action potential duration by inhibiting IKACh or the tutive IKACh
could present safer pharmacological interventions for protecting against atrial
arrhythmias such as chronic atrial fibrillation and atrial flutter ed to traditional
class III antiarrhythmics by prolonging the atrial refractory period while leaving
ventricular refractoriness red (Cha er al., 2006;Tanaka & oto,
2007;Hashimoto er al., 2007;Machida er al., 2011).
(5) IKACh Inhibitors in AF: Class III antiarrhythmics have been widely reported as a
red method for treating cardiac arrhythmias (Colatsky er al., 1990). Traditional
and novel class III antiarrhythmic potassium channel blockers have been reported to
have a mechanism of action that includes the direct tion of Kir3.1/3.4 or IKACh.
The known antiarrhythmics dronedarone (Altomare er al., 2000;Guillemare er al.,
2000), rone (Watanabe et al., 1996;Guillemare et al., 2000), propafenone (Voigt
er al., 2010a) and flecainide (Voigt er al., 2010a), ibutilide (Borchard er al., 2005)
quinidine (Kurachi er al., 1987;Hara & , 2002), verapamil o er al., 2010),
AVE0118 (Gogelein er al., 2004;Voigt er al., 2010a) NIP-142 (Matsuda er al.,
2006;Hashimoto er al., 2007;Tanaka & Hashimoto, 2007), NIP-151 moto er al.,
2008), NTC-801(Machida er al., 2011) have all been reported as potassium channel
blockers of Kir3.1/3.4 or IKACh in atrial myocytes. A benzopyran derivative, NIP-142,
preferentially blocks Kir3.1/3.4 with selectivity over other c channels, prolongs
the atrial refractory period and terminates atrial fibrillation and flutter in in viva canine
models (Nagasawa er al., 2002;Tanaka & Hashimoto, 2007). From the same chemical
class, both NIP-151 and NTC-801 are highly selective IKACh inhibitors and have been
shown to be effective in terminating AF in the vagal-induced and ine-induced
canine models of AF moto er al., 2008;Machida er al., 2011). The latter, NTC-
801, has also been shown to prevent the induction of AF in an atrial-tachypacing dog
model of persistent AF (AT-AF) (Machida er al., 2011) in which the atria exhibit
electrical ling akin to chronic AF in man (Cha er al., hrlich er al.,
2004;Voigt er al., 2008;Makary er al., 2011). The selective IKACh inhibitor peptide
tertiapin (Jin & Lu, 1998;Drici er al., 2000) has also been shown to be effective in
terminating AF in both vagal-induced and acontine-induced canine models of AF
(Hashimoto er al., 2006). None of the agents were shown to affect ventricular
repolarisation (QTc or VERP) at therapeutically relevant doses. These data support the
utility of IKACh inhibitors for the cardioversion and prevention of recurrence of
supraventricular arrhythmias such as AF and atrial flutter without effecting ventricular
function. A combination of anti-arrhythmics with other ion channel modulating drugs
may also provide greater gistic) benefit in the treatment of atrial arrhythmias as
shown for the non-selective anti-arrhythmics drugs amiodarone/dronedarone and
ranolozine (Burashnikov er al., 2010;Sicouri er al., 2009) and the combination of the
IKr inhibitor sotalol with an IKur inhibitor BMS-394136 (Sun et al., 2010). As such, the
combination of a selective IKACh inhibitor with other ion channel or ion ger
modulating drugs could provide added clinical benefit.
(6) IKACh inhibition in stroke tion in AF: Atrial fibrillation is associated with a
5-fold increased risk for stroke and in the United States approximately 15% to 25% of
all strokes can be attributed to AF (Steinberg, 2004). Regardless of the ch to
arrhythmias ent (rate, rhythm, ablation), the prevention of thromboembolism is a
cornerstone of clinical treatment of atrial arrhythmias. Constitutive activation of IKACh
has been reported to contribute to the contractile deficit associated with AF in the
tachypaced-atrial dog model of AF. tion of IKACh could be a novel target to
prevent hypocontractility-related thrombo-embolic complications (Koo er al., 2010).
IKACh inhibitors alone or in combination with other anti-platelet or anti-coagulant
therapies may significant reduce the risk of stroke and thromboembolism in AF.
(7) Role of autonomic system in AF: Clinical (Coumel, 1994;Coumel, 1996;Pappone et
al., 2004;Tan er al., 2006;Yamashita er al., 1997;Huang er al., 1998) and experimental
(Liu & Nattel, 1997;Ogawa er al., 2007;Sharifov er al., 2004;Jayachandran er al.,
cherlag er al., 2005;Horikawa—Tanami er al., 2007;Po er al., 2006) observations
highlight the importance of the autonomic nervous system and in ular
parasymthpathetic / vagal activation in AF. The electrophysiologic ate of AF is
often latent until vagal activation which is sufficient to induce and maintain AF via
IKACh activation. IKACh inhibitors are expected to be effective in the treatment of
paroxysmal AF with a neurogenic (vagal) component.
(8) Autonomic system in the initiation of AF: Ectopic activity arising from the pulmonary
veins and sleeves (PV) has been shown to play a prominent role in the tion and
maintenance of AF (Haissaguerre er al., 1998;Pappone er al., 2000). Pulmonary vein
isolation is a procedure used frequently to ate the triggers g from the
pulmonary veins. Electrical activity, originating from PV s following
parasympathetic and/or sympathetic stimulation, has been proposed as a potential
trigger in the initiation of AF (Burashnikov & Antzelevitch, 2006;Patterson er al.,
2005;Patterson er al., 2006;Wongcharoen er al., 2007;Lo er al., 2007). Studies in animal
models have shown an increase in the time-dependent IKACh in the pulmonary sleeve
of the AT-AF dog (Ehrlich er al., 2004). Autonomic nerve stimulation reduces PV-
sleeve action potential on and causes triggered PV firing that is suppressed by
muscarinic cholinergic receptor blockade (Patterson er al., 2005). Fibrillatory cycle
length shortening in response to vagal stimulation points to ACh effects on PV drivers
(Takahashi er al. , 2006). Thus, inhibition of IKACH could remove vagally enhanced PV
drivers that initiate and maintain AF.
(9) Autonomic nervous system in atrial remodeling: Auto-antibodies to the muscarinic
M2 receptor have been shown to increase sion of Kir3.1 and Kir3.4 mRNA and
Kir3.4 protein in the rabbit heart, resulting in both ical and structural remodeling
creating a substrate for AF (Hong et al., 2009). Increased vagal-nerve activity has been
shown to promote atrial electrical remodeling in atrial tachypaced dogs; this effect was
partially revered by atropine and fully reversed by a combination of cholinergic block
and a vasoactive intestinal polypeptide (VIP) nist (Yang et al., 2011). Clinical
studies have also shown that parasympathetic block may promote the recovery from
AERP shortening associated with rapid atrial pacing (Miyauchi er al., 2004). Although
the mechanism that underlies these observations is not fully elucidated, inhibition of
IKACH alone or in combination with other agents could prevent or e atrial
remodeling associated with AF.
Beyond use in the treatment of atrial arrhythmias, Kir3.1/3.4 inhibitors may have utility in a
number of other indications:
(1) IKACh and sinoatrial and atrioventricular node function: Acetylcholine (ACh) is
an important neuromodulator of cardiac function that is released upon stimulation of the
vagus nerve. Negative tropic and ropic effects are cardiovascular features
ated with ACh e upon mpathetic stimulation. In the mammalian heart,
cholinergic parasympathetic fibres are extensively distributed to the sinus node, to the
atria and to the atrioventricular (AV) node. Vagal stimulation produces a negative
chronotropic and dromotropic effect on the heart and can induce or pose to atrial
arrhythmias due to shortening of the atrial ERP. Vagal stimulation increases AV-ERP
(ALANIS er al., 1958;ALANIS er al., 1959), prolongs atrial conduction time n,
1977) and es a negative dromotropic effect. Selective inhibition of IKACh with
tertiapin has been shown to inhibit the dromotropic and blunts the chronotropic effects
of ACh on the heart and relieve AV block (Drici et al., 2000). The nce of Kir3.1
and Kir3.4, is reported to be equal in the sinus node and atrial muscle (Tellez er al.,
2006). Activation of IKACh causes decreased spontaneous activity, hyperpolarization
of the maximum lic potential, and a decrease in the diastolic depolarization rate
of the SA node contributing to the negative chronotropic effect of ACh (Dobrzynski et
2012/052842
al., 2007;Han & Bolter, 2011;Rodriguez-Martinez er al., 2011). Atrial fibrillation is
associated with structure and ionic remodelling in the atria (for review see (Schotten et
al., 2011;Workman er al., 2008) and damage to the SAN (Thery er al., 1977). al
studies have shown that sick sinus syndrome is frequently associated with AF and atrial
flutter (Ferrer, 1968;Gomes er al., 1981). Sinoatrial node dysfunction is a heterogeneous
disorder of unknown etiology characterized by a variety of supraventricular arrhythmias
with symptoms of persistent bradycardia, tachycardia, syncope, palpitations, and
ess. The mechanism underlying the abnormal rhythm is incompletely understood.
However, ne, a muscarinic antagonist, is used in the treatment of sick sinus
syndrome. However, side-effects preclude its long term use (1973). Taken together,
these data highlight both the presence and functional importance of IKACh in the SAN
and AVN and indicate the potential of an IKACh inhibitor to te AV conduction
in setting of hypervagotony or early inferior myocardial infarctions (Drici er al., 2000)
and provide a novel mechanism in the treatment of sinus node dysfunction.
(2) Kir3.1/3.4 inhibitors and prevention of thromboembolism: Current ches to the
prevention of thromboembolism e the use of anti-platelet therapy (6.g. aspirin) or
anticoagulation y including the use vitamin K antagonist warfarin, and oral
agents, ing direct thrombin inhibitors such as dabigatran, ximelagatran and factor
Xa inhibitors such as apixaban, rivaroxaban, and an, betrixaban and YM150 (for
review see (Ezekowitz er al., . d blood vessels, red blood cells and
platelets release ADP and induce platelet aggregation. Pathological thrombosis
formation can lead to vascular occlusion, resulting in ic insults. The et ADP
receptor designated P2Y12, the target of the antithrombotic agents like clopidogrel,
activates Kir3.x channels via Gi/o proteins (Hollopeter er al., 2001). Human platelets
have been shown to express both Kir3.1 and Kir3.4 protein by Western blot (Shankar et
al., 2004). Kir3.1/3.4 inhibitors, such as SCH23390 and ethosuximide, can inhibit ADP-
and thrombin-mediated platelet aggregation (Shankar er al., 2004;Kobayashi er al.,
2009). Therefore, Kir3.1/3.4 inhibitors may be effective for preventing thrombosis and
thromboembolic diseases including stroke, myocardial tion and peripheral
vascular diseases (Kobayashi & Ikeda, 2006).
(3) Kir3.4 and atic function: Although predominantly expressed in the heart Kir3.4
has been cloned from the human pancreas (Chan et al., 1996) and has been detected in
0., B, 5 cells of the mouse pancreas (Yoshimoto er al., 1999;Ferrer er al., 1995;1wanir &
Reuveny, 2008). Electrophysiological studies have shown that somatostatin and 0.2-
adrenoceptor agonists activate sulfonylurea-insensitive K+ channels by a G protein-
dependent mechanisms, and thereby inhibit activity of Kir3.4-expressing s
(Rorsman er al., 1991), (Yoshimoto er al., 1999), suggesting that activation of Kir3
channels may inhibit insulin secretion. Additionally, somatostatin released from 5 cells
activates Kir3 channels in glucagon-expressing or cells (Yoshimoto er al., 1999). The
line-induced hyperpolarisation of mouse pancreatic cells has been shown to be a
tertiapin-sensitive inwardly—rectifying potassium t (Iwanir & Reuveny, 2008).
Therefore, pancreatic Kir3.4 channels may be related to control of pancreatic hormone
secretion and have utility in the treatment of diabetes mellitus alone or in combination
with sulfonylureas and other oral agents (Kobayashi & Ikeda, 2006).
(4) Kir3.1/3.4 in the central nervous system: In on to expression in the heart, Kir3.1
and Kir3.4 mRNA have been detected in the parts of the brain (Wickman er al.,
2000;Mark & Herlitze, 2000;Hibino er al., 2010). A number of psychotropic and anti-
depressant drugs have been shown to inhibit the Kir3.1/3.4 ls including
paroxetine (Kobayashi et al., 2006), fluoxetine (Kobayashi et al., 2003), tine
(Kobayashi et al., 2010), atomoxetine (Kobayashi et al., 2010), mipramine,
desipramine, amitriptyline, nortriptyline, ramine, maprotiline, citalopram
(Kobayashi et al., 2004), and ethosuximide (Kobayashi et al., 2009). This suggests that
the Kir3.x inhibition may underlie some of the therapeutic effects related to the CNS.
As such, Kir3.1/3.4 inhibits may have utility in the treatment of neurological and
neuropsychiatric ers es including pain, depression, anxiety, attention-
deficit/hyperactivity disorder, and epilepsy.
(5) Kir3.1/3.4 and pituitary function: Kir3.1 and Kir3.4 have been detected in the
pituitary cells of the rat rson er al., 2001;Wu1fsen er al., 2000) where they
potentially play a critical role in excitation-secretion coupling. As such, Kir3.1/3.4
inhibitors could be used to modulate neuro-endocrine function and the secretion of
pituitary hormones. However, corroborative data in man is currently lacking.
(6) Kir3.1/3.4 and cancer: In addition, other s have cloned Kir3.1 and Kir3.4 from
human breast cancer cell line (Wagner er al. and suggest they may be ed in
, 2010)
cellular signaling and cancer (Dhar & Plummer, III, 2006;Plummer, III et al., 2004).
Although additional data are required to establish a causal link, ing Kir3.1/3.4
could be useful in the ent of breast cancer.
Nissan al Industries have reported a series of substituted yrans as atrial-
specific antiarrythmics.
In WO 01/21610 Nissan discloses a series of benzopyran derivatives which are d to
increase the functional refractory period in an ex vivo preparation of guinea pig atrial tissue
with potential use as atrial-specific antiarrythmics.
In WO 02/064581, WO 03/000675 and Nissan discloses a series of 4-
amino tuted benzopyran derivatives which are claimed to selectively prolong the atrial
refractory period in an in vivo dog model of vagal-induced atrial fibrillation with potential
use as atrial-specific antiarrythmics.
In Nissan discloses a series of fused tricyclic benzopyran derivatives
which are claimed to selectively prolong the atrial refractory period in an in vivo dog model
of vagal-induced atrial fibrillation with potential use as atrial-specific antiarrythmics.
The above Nissan patents do not specify a biological , but in subsequent publications
(Hashimoto er al, 2008) compounds of these documents have been disclosed as blockers of
the Kir3.l/3.4 channel and the IKACh c t.
discloses a series of derivatives of the flavone acacetin which are
claimed inter alia as blockers of the cardiac acetylcholine-activated current (IKACh) with
potential use as atrial-specific antiarrythmics.
In WC 2009/104819 Otsuka Pharmaceuticals discloses a series of benzodiazepine
derivatives which are claimed as blockers of the Kir3.l/3.4 channel with potential use as
atrial-specific antiarrythmics.
pyrimidines, pyrimidines and thienopyridines have been shown to modulate
ligand-gated and voltage-gated ion channels as well as GPCRs.
U82005/0222175 and U82005/022176 disclose ridylamino substituted thieno[2,3-
midines which te the 5-HT receptor, in particular, the 5-HT2b receptor for the
treatment of pulmonary arterial hypertension, heart failure, and hypertension.
U82007/02877l7 (Vertex) discloses 2-phenyl substituted thieno[2,3-d] pyrimidines which
modulate voltage-gated sodium and calcium channels for the treatment of various disorders
including epilepsy and neuropathic pain.
U82009/0270405 and W02011/053292 disclose quinuclidine substituted thieno[2,3-d]
pyrimidines which modulate the alphanicotinic acetylcholine receptor for the treatment of
affective and neurodegenerative disorders.
W02004/11057 (Xention) discloses 4-alkylamino and 4-alkoxy thieno[2,3-d]pyrimidines as
blockers of the KVl.5 voltage-gated potassium channel for the treatment of Atrial
Fibrillation.
/121149 (Xention) discloses furano[2,3-d]pyrimidines as blockers of the KVl.5
voltage-gated potassium l for the ent of Atrial Fibrillation.
/066127 on) discloses 4-aminoalkyl and 4-alkoxy substituted thieno[3,2-
c]pyridines as blockers of the KVl,5 voltage-gated potassium channel for the treatment of
Atrial Fibrillation and also as blockers of the KVl .3 voltage-gated potassium l for the
ent of autoimmune disorders.
W02006/06l642 (Xention) discloses 4-alkylamino tuted thieno[2,3-b]pyridines as
blockers of the KVl,5 e-gated potassium channel for the treatment of Atrial
Fibrillation and also as blockers of the Kvl.3 voltage-gated potassium channel for the
treatment of autoimmune disorders.
Ramakrishna er al disclose fused thieno[2,3-d]pyrimidines and 4-alkoxythineo[2,3-
d]pyrimidines which act as antagonists of the 5-HT6 receptor.
Modica er al (2004) disclose 4-piperazinyl thieno[2,3-d]pyrimidines which behave as
competitive antagonists of the 5-HT3 receptor.
Thienopyrimidines have also been shown to be useful against other biological targets.
U82003/0153556 ses 4-piperazinyl and 4-homopiperazinyl substituted thieno[2,3-
d]pyrimidines for the treatment of thrombosis.
W02006/0799l6, W02006/103555, /103545, W02006/103544, and
/ l 00591 acia and Upjohn) discose 2-aminopiperidyl substituted
thieno[2,3-d]pyrimidines for the inhibition of ADP-mediated platelet ation.
USZOl 1/0166121 (LG Lifesciences) ses fused 4-piperidinyl and 4-piperazinyl
thieno[2,3-d] pyrimidines for the inhibition of platelet aggregation.
/029054 (University of Michigan) discloses 4-piperazinyl and 4-homopiperazinyl
theino[2,3-d]pyrimidines which inhibit the interaction of menin with the oncogene
Mixed Lineage Leukemia (MLL).
W02004/014850 (Predix ceuticals) discloses 4-(aminopiperidyl) substituted
thieno[2,3-d]pyrimidines as Neurokinin antagonists.
W02004/06539l (Almirall Prodespharma) discloses 4-aminocarbonitrile substituted
thieno[2,3-d]pyrimidines as tors of PDE7 for the treatment of T-cell mediated immune
disorders.
/03003l (Janssen/Addex) discloses 4-alkylamino substituted thieno[2,3-
d]pyrimidines as positive allosteric modulators of the mGluR2 receptor.
W02006/07l988 (Memory Pharmaceuticals) discloses 4-alkoxy, 4-alkyl, and 4-aminoalkyl
thieno[2,3-d]pyrimidines as inhibitors of PDE10.
W02009/007115 (Syngenta) discloses 4-tropanyl substituted thieno[2,3-d]pyrimidines that
are claimed to have usefulness as pesticides.
Gorja er al (2011) disclose 4-alkynyl substituted tricyclic thieno[2,3-d]pyrimidines which
were tested for cytotoxic activity against the chronic myelogenous leukemia (CML) cell line.
2012/052842
Jang er al (2010) disclose a series of 4-N—piperazinyl thieno[2,3-d]pyrimidines which were
tested for immunosuppressive activity in a mixed lymphocyte reaction (MLR) assay.
Tasler er al (2010) disclose a series of 4-(4-aminopiperidyl) substituted thieno[2,3-
d]pyrimidines which act as agonists for the BS-adrenoreceptor.
DISCLOSURE OF THE INVENTION
A first aspect of the invention provides a compound of formula (I)
R2 l I
2% (I)
or a pharmaceutically able derivative thereof, wherein:
A is O or S;
X is N or CR3H;
V is N or CR3 111;
ZisNor CR31V;
n one or two of V, X and Z are N;
R1 is selected from optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted aryl, and optionally substituted heteroaryl;
R2 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl,
optionally tuted alkoxy, , —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —
CONR4R5, , optionally substituted oxazolinyl, —SR14, —S(O)R14 and —S(O)2R14;
R31 is selected from H, halo, —CN, trifluoromethyl, ally substituted alkyl,
optionally substituted alkoxy, optionally substituted cycloalkoxy, —NR6C(O)R7, —
)2R7, —S(O)2NR4R5, —CONR4R5, —COZR7, —NR8R9, —CEC—J, optionally substituted
cycloalkyl-J and —(NRaRb)—J;
Each of R311, R3111, and R3“; is independently selected from H, halo, —CN,
trifluoromethyl, optionally substituted alkyl, optionally substituted alkoxy, optionally
substituted heterocycloalkoxy, optionally substituted heterocycloalkylalkyl, —NR6C(O)R7, —
NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, optionally substituted —alkylene—CONR4R5, —
C02R7, —NR1°R“, —CEC—J, ally substituted cycloalkyl-J and —(NRcRd)—J,
provided that R31 is —CEC—J, optionally tuted cycloalkyl-J or —(NRaRb)—J,
and/or at least one of R311, R3111, and R3“; is present as —CEC—J, optionally substituted
cycloalkyl-J or —(NRcRd)—J;
wherein Ra and Rb are linked to form an optionally substituted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1.
zalkylene, —NR6—, —O—, or —S(O)Z—, wherein the optionally d, optionally substituted
heterocycloalkyl ring is selected from the group consisting of azetidinyl, pyrrolidinyl,
piperidinyl, linyl, tetrahydro-l,3-oxazinyl, hexahydropyrimidinyl, l,4-thiazanyl,
azepanyl, 1,4-oxaazepanyl, and l,4-thieazepanyl;
wherein Rc and Rd are linked to form an optionally substituted 4 to 7 ed
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1.
zalkylene, —NR6—, —0—, or —S(O)Z—;
J is selected from H and —(CR12R13)q—L—M—W,
wherein
q is 0, 1 or 2;
L is —O— or —N(G)—; and
G is selected from hydrogen, optionally substituted alkyl and ally substituted
cycloalkyl;
M is —(CR12R13)t—;
tis0,1,2or3;
W is selected from the group consisting of optionally substituted alkyl, optionally
substituted alkoxy, optionally substituted alkenyl, optionally tuted cycloalkyl,
optionally substituted heterocycloalkyl, optionally tuted aryl, optionally substituted
heteroaryl and —NR8R9,
n when W is optionally substituted cycloalkyl it may optionally be bridged by
a bond or optionally substituted C1_2alkylene, and
wherein when W is optionally tuted heterocycloalkyl it may optionally be
bridged by a bond, optionally substituted C1_2alkylene, —NR6—, —O—, or —S(O)Z—;
atively, when L = —N(G)—, L, G, M and W may be linked to form an optionally
substituted heterocycloalkyl, an ally substituted heterocycloalkenyl, or an optionally
substituted heteroaryl;
z is 0, l or 2;
R4 and R5 are, at each instance, independently selected from H, optionally
substituted alkyl, optionally tuted aryl, optionally substituted heteroaryl, and optionally
substituted cycloalkyl, or are linked to form an optionally substituted cycloalkyl;
R6 and R7 are, at each instance, independently selected from H and optionally
substituted alkyl, or are linked to form an optionally substituted heterocycloalkyl;
R8 and R9 are, at each instance, independently ed from optionally substituted
alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, ally
substituted heteroaryl, and ally substituted cycloalkyl;
R10 and R11 are, at each instance, independently ed from H, optionally
substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl,
optionally substituted aryl, and optionally substituted cycloalkyl;
R12 and R13 are, at each instance, independently selected from H, hydroxy, and
optionally substituted alkyl, or may be linked to form an optionally substituted cycloalkyl
ring, or may together form =0; and
R14 is ally substituted alkyl,
wherein the optional substituents are independently selected from halo,
omethyl, trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOz, -CN, -COzH, -COZC1_
6alkyl, -SO3H, -SOC1_6alkyl, -SOZC1_6alkyl, -NHSOZC1_6alkyl, -NC1_6alkylSOZC1_6alkyl,
-SOzNH2, -SOzNHC1_6alkyl, -SOZN(C1_6alkyl)2, -NHSOZNH2, -NHSOZNHC1_6alkyl,
-NHSOZN(C1_6alkyl)2, -NC1_6alkylSOzNH2, -NC1.6alkylSOZNHC1_6alkyl, -NC1_
6alkylSOZN(C1_6alkyl)2, -C(=O)H, -C(=O)C1_6alkyl, -NHC(=O)C1_6alkyl, -NC1_
6alkle(=O)C1_6alkyl, C1_6alkylenedioxy, =O, -N(C1_6alkyl)2, -C(=O)NH2,
NHC1_6alkyl, -C(=O)N(C1_6alkyl)2, -NHC(=O)NH2, O)NHC1_6alkyl,
-NHC(=O)N(C1_6alkyl)2, -NC1_6alkle(=O)NH2, -NC1-6alkle(=O)NHC1.6alkyl, -NC1_
6alkle(=O)N(C1.6alkyl)2, -C(=NH)NH2, -C(=NH)NHC1_6alkyl, )N(C1_6alkyl)2,
-C(=NC1_6alkyl)NH2, -C(=NC1-6alkyl)NHC1_6alkyl, -C(=NC1-6alkyl)N(C1_6alkyl)2, -C1_6alkyl,
-C3_6cycloalkyl, -C3_6heterocycloalkyl, 2-imidazolidinonyl, l-C1-6alkylimidazolidinon-
3-yl, C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, -C1_6alkylene—NHSOZC1_
6alkyl, -C1-6alkylene—NC1.6alkylSOZC1_6alkyl, -C1_6alkylene—SOZNH2, -C1_6alkylene—
SOZNHC1_6alkyl, -C1-6alkylene—SOZN(C1.6alkyl)2, —ZtH, —Zt-C1_6alkyl, -C1_6alkylene—ZIH, —
Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is independently O, S, NH or
N(C1_6alkyl).
In one embodiment, A is S, Z is N and V is CR3 111- In a further embodiment, X is N. In a
further embodiment, R1 is phenyl. In a further embodiment, R2 is selected from H,
trifluoromethyl, tuted alkyl, optionally substituted alkoxy, —NR4R5, O)R7, —
S(O)2NR4R5, —CONR4R5, , optionally substituted oxazolinyl, —SR14, 14 and —
S(O)2R14. In a further embodiment, R31 is selected from trifluoromethyl, optionally
substituted alkyl, optionally substituted alkoxy, optionally substituted heterocycloalkoxy, —
NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, —COZR7, —NR8R9 optionally
substituted cycloalkyl-J and —(NRaRb)—J. In a r embodiment, R3111, is selected from H,
halo, —CN, trifluoromethyl, optionally substituted alkyl, optionally substituted alkoxy,
optionally substituted heterocycloalkoxy, optionally substituted heterocycloalkylalkyl, —
NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, optionally substituted —alkylene—
CONR4R5, —C02R7, —NR1°R“, optionally substituted cycloalkyl-J and —(NRcRd)—J. In a
further embodiment, R31 is —(NRaRb)—J. In a further embodiment, R31 is —(NRaRb)—J, V is
CR3111 and R3111 is H or —(NRcRd)—J and, in at least one instance, I is—(CR12R13)q—L—M—W.
In a r embodiment, q is 0 or 1. In a further embodiment, q is 1. In a further
embodiment, t is 0, l or 2. In a further embodiment, t is 2. In a further ment, L is O,
or, in an alternative embodiment, L is —N(G)—. In a further embodiment, R12 and R13 are, at
each ce, H. In a further embodiment, W is ally tuted heterocycloalkyl.
A second aspect of the invention provides a ceutical composition comprising at least
one compound of formula (I) and, optionally, one or more pharmaceutically able
excipients.
A third aspect of the invention provides a compound of formula (I) or a composition
sing at least one compound of formula (I) for use in therapy.
A fourth aspect of the invention provides a method for the treatment of a disease or
ion that is mediated by Kir3.l and/or Kir3.4 or any heteromultimers thereof, or that
requires inhibition of Kir3.l and/or Kir3.4 or any heteromultimers thereof, comprising
administering to a subject an ive amount of at least one compound of formula (I) or
ition comprising at least one compound of formula (I).
A fifth aspect of the invention provides a compound of formula (I) or a ition
comprising at least one compound of formula (I) for use in a method for the treatment of a
disease or condition that is mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof,
or that es inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof, comprising
administering to a subject an effective amount of at least one compound of formula (I) or
composition comprising at least one compound of formula (I).
A sixth aspect of the invention provides the use of a compound of formula (I) for the
manufacture of a medicament for use in the treatment of a disease or condition that is
mediated by Kir3.l and/or Kir3.4 or any multimers thereof, or that requires inhibition
of Kir3.1 and/or Kir3.4 or any heteromultimers thereof
In the first, second and third aspects of the invention, the compound of formula (I) is not:
2-Benzylmethylmorpholinyl-thieno [2, 3 -d] pyrimidinecarbonitrile,
[l-(5-phenyl-thieno[2,3-d]pyrimidinyl)-piperidinyl]-carbamic acid tert-butyl ester,
[l-(6-methylphenyl-thieno [2,3 -d]pyrimidinyl)-piperidinyl] -carbamic acid utyl
ester,
{1- [5-(4-bromo-phenyl)-thieno [2,3 -d]pyrimidinyl] -piperidinyl} -carbamic acid tert-
butyl ester,
[l-(5-p-tolyl-thieno[2,3-d]pyrimidinyl)-piperidinyl]-carbamic acid tert-butyl ester,
[l-(5-methyl-thieno[2,3-d]pyrimidinyl)-piperidinyl]-carbamic acid tert-butyl ester,
l-(5-phenyl-thieno[2,3-d]pyrimidineyl)-piperidinylamine,
l-(6-methylphenyl-thieno[2,3-d]pyrimidineyl)-piperidinylamine,
l-(5-(4-bromo-phenyl)-thieno[2,3-d]pyrimidineyl)-piperidinylamine,
l-(5-p-tolyl-thieno[2,3-d]pyrimidineyl)-piperidinylamine,
ethyl-thieno [2,3 -d]pyrimidineyl)-piperidinylamine,
l-(5-phenyl-thieno[2,3-d]pyrimidinyl)-piperidinone,
l-[5-(4-bromo-phenyl)-thieno[2,3-d]pyrimidinyl]-piperidinone,
-tolyl-thieno[2,3-d]pyrimidinyl)-piperidinone,
l-(6-methylphenyl-thieno[2,3-d]pyrimidinyl)-piperidinone,
2- { l - [5 -(4-bromo-phenyl)-thieno [2,3 -d]pyrimidinyl] -piperidinylamino} -cyclohexanol,
2- { l -(5 -p-tolyl-thieno [2,3 -d]pyrimidinyl)-piperidinylamino} -cyclohexanol,
2- { l thylphenyl-thieno [2,3 -d]pyrimidinyl)-piperidin-4ylamino} -cyclohexanol,
l-benzyloxy—3-[ l enyl-thieno[2,3-d]pyrimidinyl)-piperidinylamino]-propanol,
2-[ l -(5-phenyl-thieno[2,3-d]pyrimidinyl)-piperidinylamino]-cyclohexanol,
-methoxy {[ l -(5-phenyl-thieno[2,3-d]pyrimidinyl)-piperidinylamino]methyl} -
phenol,
bis-(2-fluoro-benzyl)-[ l enyl-thieno[2,3-d]pyrimidinyl)-piperidinyl]-amine,
2-fluoro {[l-(6-methylphenyl-thieno[2,3-d]pyrimidinyl)-piperidin
ylamino]methyl} -phenol,
2-( { l -[5-(4-bromo-phenyl)-thieno[2,3-d]pyrimidinyl]-piperidinylamino}methyl)
fluoro-phenol,
2-fluoro {[1-(5-p-tolyl-thieno [2,3 imidinyl)-piperidinylamino]methyl} -phenol
(3 -Benzyloxyhydroxy-propyl)-[ l -(5-phenyl-thieno [2,3 -d]pyrimidinyl)-piperidinyl] -
ammonium; chloride,
4- {4- [2-(4-Fluoro-phenoxymethyl-morpholinyl] -piperidin- l -yl} phenyl-thieno [2,3 -
d]pyrimidine,
4- {4- [2-(Benzo[ l ,3 ] dioxolyloxymethyl)-morpholinyl] -piperidin- l -yl} phenyl-
thieno[2,3-d]pyrimidine, or
6-(Benzo[ l ,3]dioxolyloxymethyl)[ l -(5-phenyl-thieno[2,3-d]pyrimidinyl)-piperidin-
morpholinone.
As discussed above, inhibition of Kir3.l and/or Kir3.4 (or heteromultimers thereof) has
implications in:
0 the diagnosis and ent of cardiovascular diseases, such as atrial ation
(AF), atrial flutter (AFL), atrioventricular (AV) dysfunction and sinoatrial node
(SAN) dysfunction;
0 the prevention of recurrence of supraventriclar arrhythmias including AF and AFL;
0 the maintenance of sinus rhythm;
0 the termination and cardioversion of supraventriclar arrhythmias;
o the treatment of sinus node dysfunction;
0 the treatment of AV node ction, ing AV block;
0 the treatment of conduction dysfunction;
0 the tion or reversal of atrial structural and ionic remodeling;
o the prevention of thrombosis, thromboembolism and thromboembolic diseases, such
as stroke, dial infarction, and peripheral vascular diseases;
0 the improvement of cardiac contractility;
o the treatment of metabolic diseases, such as diabetes mellitus;
0 the modulation of neuro-endocrine function;
0 the modulation of the secretion of pituitary hormones;
0 the treatment of neurological and neuropsychiatric ers, such as pain,
depression, anxiety, attention deficit/hyperactivity disorder and epilepsy; and
o the treatment of cancer, such as breast cancer.
DETAILED DESCRIPTION OF THE INVENTION
At various places in the present specification, tuents of compounds of the invention are
disclosed in groups or in ranges. It is specifically intended that the invention include each
and every individual subcombination of the members of such groups and ranges. For
example, the term “CM alkyl” is specifically intended to individually disclose methyl, ethyl,
C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
For compounds of the invention in which a variable appears more than once, each variable
can be a different moiety selected from the h group defining the variable. For
example, where a structure is described having two R groups that are simultaneously present
on the same compound; the two R groups can represent different moieties selected from the
Markush group defined for R.
It is further appreciated that certain features of the invention, which are, for clarity,
described in the context of separate embodiments, can also be provided in ation in a
single embodiment. sely, various es of the ion which are, for brevity,
described in the context of a single embodiment, can also be ed separately or in any
suitable subcombination.
However, combinations of es are sible only if such combinations result in stable
compounds. Compounds of the invention are typically stable and isolatable at room
temperature and pressure. A “stable” compound is sufficiently robust to e isolation to
a useful degree of purity from a reaction mixture, and formulation into an efficacious
therapeutic agent.
In one embodiment, A is S. In another embodiment, A is O.
In one embodiment, Z is N. In another embodiment, X is N. In one embodiment, Z is N,
and V is CR3 111- In another embodiment, Z is N, X is N, and V is CR3 111- In another
embodiment, z is N, x is CR3H, and v is CR3HI.
In one ment, V is N, X is CR311, and Z is CR3IV. In another embodiment, X is N, V is
CR3111, and Z is CR31V. In another embodiment, Z is N, V is N, and X is CR3 11- In another
embodiment, V is N, X is N, and Z is CR31V.
In a specific embodiment, A is S, Z is N, X is N, and V is CR31H, i.e. the compounds are
thienopyrimidines.
In one embodiment, R31 is —CEC—J or —(NRaRb)—J, and/or at least one of R311, R3111, and R3IV
is t as —CEC—J or d)—J. In another embodiment, R31 is ally substituted
cycloalkyl—J or —(NRaRb)—J, and/or at least one of R311, R3111, and R3 IV is present as optionally
tuted cycloalkyl—J or —(NRcRd)—J. In another embodiment, R31 is —(NRaRb)—J and/or at
least one of R311, R3111, and R3 IV is present as —(NRcRd)—J.
In one embodiment, R31 is selected from H, halo, —CN, trifluoromethyl, optionally
substituted alkyl, optionally substituted alkoxy, —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5,
—CONR4R5, —COZR7, —NR8R9, —CEC—J, optionally substituted cycloalkyl-J and —(NRaRb)—J.
In another embodiment, R31 is selected from trifluoromethyl, optionally substituted alkyl,
optionally substituted alkoxy, optionally substituted heterocycloalkoxy, —NR6C(O)R7, —
NR6S(O)2R7, NR4R5, —CONR4R5, —COZR7, —NR8R9, optionally substituted
cycloalkyl-J and —(NRaRb)—J. In another embodiment, R31 is selected from H, —(NRaRb)—J,
optionally substituted cycloalkyl-J and —CEC—J. In another embodiment, R31 is selected
from b)—J, and —CEC—J. In another embodiment, R31 is selected from —(NRaRb)—J,
and optionally substituted cycloalkyl-J. In another ment, R31 is —(NRaRb)—J. In
another embodiment, R31 is —(NRaRb)—J and J is (CR12R13)q—L—M—W.
In one embodiment, each of R311, R3111, and R3IV is independently selected from H, halo, —CN,
trifluoromethyl, optionally substituted alkyl, optionally tuted alkoxy, —NR6C(O)R7, —
NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, —COZR7, —NR1°R“, —CEC—J, optionally substituted
cycloalkyl-J and d)—J. In another embodiment, each of R311, R3111, and R3IV is
independently selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl,
optionally tuted , optionally substituted heterocycloalkoxy, optionally
substituted cycloalkylalkyl, O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5,
optionally substituted —alkylene—CONR4R5, —COZR7, —NR10R11, optionally substituted
cycloalkyl-J and —(NRcRd)—J. In another embodiment, each of R311, R3111, and R3IV is
independently selected from H, halo, —CN, trifluoromethyl, optionally substituted alkoxy, —
NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, —COZR7, —NR10R“, ,
optionally tuted cycloalkyl-J and —(NRcRd)—J. In another ment, each of R311,
R3111, and R3 IV is independently selected from H, —NR10R11, —CEC—J, optionally tuted
cycloalkyl-J and —(NRcRd)—J. In one embodiment, each of R311, R3111, and R3IV is
independently selected from H, —NR10R“, —CEC—J and —(NRCRd)—J. In another
WO 72694
embodiment, R311 and R3IV are H. In another embodiment, R311, R3111 and R31V, are
independently selected from —CEC—J, optionally tuted cycloalkyl-J and —(NRCRd)—J.
In another embodiment, R3111 is selected from H, halo, —CN, trifluoromethyl, optionally
substituted alkyl, optionally substituted , optionally substituted heterocycloalkoxy,
optionally substituted heterocycloalkylalkyl, O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —
CONR4R5, optionally substituted —alkylene—CONR4R5, —COZR7, —NR1°R“, optionally
substituted cycloalkyl-J and —(NRcRd)—J. In another embodiment, R3111 is independently
ed from H, —NR1°R“, —CEC—J, ally substituted cycloalkyl-J and —(NRcRd)—J. In
another embodiment, R3111 is selected from —CEC—J, optionally substituted cycloalkyl-J and —
(NRcRd)—J. In another embodiment, R3111 is selected from optionally substituted cycloalkyl-J
and —(NRcRd)—J. In another embodiment, R3111 is d)—J.
In one embodiment, R31 is —(NRaRb)—J, V is CR3 111 and R3111 is —(NRcRd)—J. In another
embodiment, R31 is —(NRaRb)—J, V is CR3HI and R3111 is —(NRcRd)—J and, in at least one
instance, I is R13 q—L—M—W. In another embodiment, R31 is —(NRaRb)—(CR12R13)q—
L—M—W, V is CR3III and R3III is —(NRcRd)—H.
In one embodiment, ifX is N, then R31 is not —NR8R9. In another embodiment, ifX is CR3 11
and Z is N, then R31 is not H, halo or —NR8R9.
In one ment, each of R311, R3111, and R3“; is independently selected from —
NR6S(O)2R7, —S(O)2NR4R5, —CEC—J, and optionally substituted cycloalkyl-J. In another
embodiment, if V is N, then R311 and R3IV are independently selected from H, halo, —CN,
trifluoromethyl, optionally tuted alkyl, optionally tuted , —NR6C(O)R7, —
NR6S(O)2R7, NR4R5, —CONR4R5, —COZR7, —NR1°R“, —CEC—J, optionally substituted
cycloalkyl-J and —(NRcRd)—J.
In one embodiment, R1 is selected from optionally substituted alkyl, optionally substituted
aryl and optionally substituted aryl. In another embodiment, R1 is selected from
optionally substituted alkyl and optionally substituted aryl. In another embodiment, R1 is
selected from optionally substituted heteroaryl and optionally substituted aryl. In another
embodiment, R1 is selected from optionally substituted alkyl and optionally substituted
phenyl. In another embodiment, R1 is selected from optionally substituted methyl,
optionally substituted ethyl, optionally substituted yl, and optionally substituted
phenyl. In another embodiment, R1 is selected from methyl, ethyl, i-propyl, and phenyl,
wherein phenyl is ally substituted by one or more of halo, —N02 and —SOZN(C1_
6alkyl)2. In another embodiment, R1 is selected from methyl, ethyl, i-propyl, and phenyl,
wherein phenyl is ally substituted by one or more of F, —N02 and —SOZNMe2. In
another embodiment, R1 is optionally substituted . In r embodiment, R1 is
phenyl. In another embodiment, R1 is substituted . In another embodiment, R1 is
selected from methyl, ethyl and i-propyl. In embodiments in which R1 is substituted phenyl,
it may be substituted at the 2-, 3-, 4-, 5- and/or 6- position(s). In one embodiment, R1 is 2-
tuted phenyl and in a further embodiment, the 2-substituent is methoxy.
In one embodiment, R2 is ed from halo, —CN, trifluoromethyl, optionally substituted
alkyl, optionally tuted alkoxy, , —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —
CONR4R5, —COZR7, optionally tuted oxazolinyl,—SR14,—S(O)R14 and —S(O)2R14. In
another embodiment, R2 is selected from H, halo, —CN, trifluoromethyl, optionally
substituted alkyl, optionally substituted alkoxy, —NR4R5, —NR6C(O)R7, —S(O)2NR4R5, —
CONR4R5, —COZR7, optionally substituted oxazolinyl,—SR14,—S(O)R14 and —S(O)2R14. In
another embodiment, R2 is selected from H, trifluoromethyl, substituted alkyl, optionally
substituted alkoxy, —NR4R5, —NR6C(O)R7, —S(O)2NR4R5, —CONR4R5, —COZR7, optionally
substituted oxazolinyl, —SR14, —S(O)R14 and —S(O)2R14. In another ment, R2 is
selected from H, halo, —CN, optionally substituted alkyl, —NR4R5, —NR6C(O)R7, and —
CONR4R5. In another embodiment, R2 is selected from H, halo, —CN, optionally substituted
methyl, ethyl, and i-propyl, —NR4R5, O)R7, and —CONR4R5. In another
embodiment, R2 is selected from H, bromo, —CN, methyl, ethyl, i-propyl, —NR4R5, —
NR6C(O)R7, and —CONR4R5. In another embodiment, R2 is selected from H, —NR6C(O)R7,
and —CONR4R5. In another embodiment, R2 is selected from H and —CONR4R5. In another
ment, R2 is H. In one embodiment, optionally substituted oxazolinyl is optionally
substituted 2-oxazolinyl.
In one embodiment, R2 is not —CN. In another ment, if R2 is —CN then R3111 is not
substituted alkyl.
In a specific embodiment, R1 is phenyl and R2 is H.
In one embodiment, NRaRb forms an optionally bridged, ally substituted ring of
formula (II):
K j ) 11D\/
wherein
n is 0, l or 2;
D is selected from —CH2—, —CHJ—, and —O—.
In one embodiment, D is —CHJ—. In one embodiment, n is 0 or 1. In r embodiment, n
is 1. In another embodiment, n is 0.
In one embodiment, NRaRb is optionally bridged by bond, CH2 C2H4 or CH] . In
r embodiment, NRaRb is optionally bridged by bond, —CH2— or —CHJ—. In another
embodiment, NRaRb is bridged by bond, CH2 CH] In another embodiment,
, C2H4 or .
NRaRb is bridged by bond, —CH2— or —CHJ—. In another embodiment, NRaRb is not d.
In one embodiment, NRaRb is ed from optionally substituted pyrrolidinyl, optionally
tuted piperidinyl, optionally substituted morpholinyl, optionally substituted
azabicyclohexanyl, optionally substituted azabicycloheptanyl, and optionally substituted
azabicyclooctanyl. In another embodiment, NRaRb is selected from optionally substituted
pyrrolidinyl, optionally substituted piperidinyl, optionally substituted morpholinyl,
optionally substituted azabicyclo[3 . l .0]hexanyl, optionally substituted
azabicyclo[2.2.l]heptanyl, and optionally substituted azabicyclo[3.2.l]octanyl. In another
embodiment, NRaRb is selected from optionally substituted pyrrolidinyl, optionally
tuted dinyl, optionally substituted morpholinyl, optionally substituted 3-
azabicyclo[3.l.0]hexanyl, optionally substituted 2-azabicyclo[2.2.l]heptanyl, and optionally
substituted 8-azabicyclo[3.2.l]octanyl. In r embodiment, NRaRb is selected from
pyrrolidinyl, piperidinyl, and 3-azabicyclo[3.l.0]hexanyl. In another embodiment, NRaRb is
selected from pyrrolidinyl, and piperidinyl. In one embodiment, NRaRb is pyrrolidinyl. In
another embodiment, NRaRb is piperidinyl.
2012/052842
In one embodiment, if R31 is cycloalkyl—J or —(NRaRb)—J, wherein NRaRb is piperidinyl, q is
0, and L is —N(G)—, then R3111 is not H, ally substituted C1_4alkyl or optionally
substituted cycloalkyl—J. In r embodiment, if R31 is —(NRaRb)—J, wherein NRaRb is
piperidinyl, q is 0, and L is —N(G)—, then R3111 is not H, optionally substituted C1_4alkyl or
optionally substituted cycloalkyl—J. In another embodiment, if R31 is —(NRaRb)—J, wherein
NRaRb is piperidinyl, q is 0, and L is —N(G)—, then R3111 is not H. In another embodiment, if
R31 is —(NRaRb)—J, wherein NRaRb is substituted piperidinyl and J is H, then R3111 is not H.
I may be attached to any atom on the ring or, if present, the bridge. In one embodiment,
NRaRb is pyrrolidinyl and J is present at the 3-position. In another embodiment, NRaRb is
piperidinyl and J is t at the 4-position.
Rc and Rd are linked to form an optionally substituted 4 to 7 membered heterocycloalkyl
ring, which is optionally bridged by a bond, optionally substituted C1_2alkylene, —NR6—, —O—
or —. I may be attached to any atom on the ring or, if present, the bridge. In one
embodiment, NRCRd forms an optionally bridged, optionally tuted heterocycloalkyl
selected from the group ting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl,
tetrahydro-l,3-oxazinyl, piperazinyl, hexahydropyrimidinyl, l,4-thiazanyl, azepanyl, 1,4-
oxaazepanyl, l,4-thieazepanyl and 1,4-diazepanyl. In one embodiment, NRCRd forms an
optionally bridged, optionally substituted ring of formula (II):
K jlnD\/J
ii... (I,
wherein
nis0, l or2;
Dis selected from CH2 CHJ O and
, , , N(H) N(J) .
In one embodiment, D is ed from —CHJ— and —N(J)—. In one ment, n is 0 or 1.
In one embodiment, n is 1. In another embodiment, n is 0.
In one embodiment, NRCRd is optionally bridged by bond,
CH2 , C2H4 or CH] . In
r embodiment, NRCRd is optionally d by bond, —CH2— or —CHJ—. In another
embodiment, NRCRd is bridged by bond, CH2 CH] . In another embodiment,
, C2H4 or
NRCRd is bridged by bond, —CH2— or —CHJ—. In another embodiment, NRCRd is not bridged.
In one embodiment, NRCRd is ed from ally substituted pyrrolidinyl, optionally
substituted dinyl, optionally substituted morpholinyl, optionally substituted
piperazinyl, optionally substituted azabicyclohexanyl, optionally substituted
azabicycloheptanyl, and optionally substituted azabicyclooctanyl. In another embodiment,
NRCRd is selected from optionally substituted pyrrolidinyl, optionally substituted piperidinyl,
optionally substituted morpholinyl, optionally substituted piperazinyl, optionally substituted
yclo[3.l.0]hexanyl, optionally substituted azabicyclo[2.2.l]heptanyl, and optionally
substituted azabicyclo[3.2.l]octanyl. In another embodiment, NRCRd is selected from
ally substituted pyrrolidinyl, optionally substituted piperidinyl, ally tuted
morpholinyl, optionally substituted piperazinyl, optionally substituted 3-
yclo[3.l.0]hexanyl, optionally substituted 2-azabicyclo[2.2.l]heptanyl, and optionally
substituted icyclo[3.2.l]octanyl. In another embodiment, NRCRd is selected from
optionally substituted pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and 3-
azabicyclo[3.l.0]hexanyl. In another embodiment, NRCRd is selected from pyrrolidinyl,
piperidinyl, piperazinyl, and 3-azabicyclo[3.l.0]hexanyl. In another embodiment, NRCRd is
selected from pyrrolidinyl, piperidinyl, and zinyl. In another embodiment, NRCRd is
selected from pyrrolidinyl and piperidinyl. In one embodiment, NRCRd is idinyl. In
another embodiment, NRCRd is piperidinyl.
I may be attached to any atom on the ring or, if present, the . In one embodiment,
NRCRd is pyrrolidinyl and J is present at the 3-position. In another embodiment, NRCRd is
piperidinyl and J is present at the 4-position.
In one embodiment, J is —(CR12R13 q—L—M—W. In another embodiment, J is H. In another
embodiment, if more than one I group is present, then, in at least one instance I is present as
—(CR12R13 W.
In one embodiment, q is 0 or 1. In another embodiment, q is l or 2. In another embodiment,
q is 0 or 2. In another embodiment, q is 0. In another embodiment, q is 1. In another
embodiment, q is 2. In another embodiment, q is l or 2 and R12 and R13 are independently
selected from H and alkyl. In another embodiment, q is l or 2 and R12 and R13 are both H.
In r embodiment, q is l and R12 and R13 are both H.
In one embodiment, L is O. In another embodiment, L is —N(G)—.
In one embodiment, L is —N(G)— and L, G, M and W may be linked to form an optionally
substituted heterocycloalkyl. In one ment, L is —N(G)— and L, G, M and W are
linked to form an optionally substituted heterocycloalkyl. In another ment, L is —
N(G)— and L, G, M and W are linked to form optionally substituted azetidinyl, optionally
substituted pyrrolidinyl, optionally substituted piperidinyl or optionally substituted
morpholinyl. In another embodiment, L is —N(G)— and L, G, M and W are linked to form
azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl, wherein each of pyrrolidinyl, piperidinyl
and linyl is optionally substituted by one or more groups selected from halo,
trihalomethyl, -OH, lkyl, —O-C1_6alkyl, -N(C1_6alkyl)2, lkylene—OH, aryl,
haloaryl, -C(=O)NH2 and -C3_6heterocycloalkyl. In another embodiment, L is —N(G)— and L,
G, M and W are linked to form pyrrolidinyl, piperidinyl or morpholinyl substituted by one or
more groups selected from pyrrolidinyl, OH, F, Me, OMe, CHZOH, —CF3, —NMe2,
phenyl, F-phenyl, —CONH2.
In one embodiment, G is selected from hydrogen, and optionally substituted alkyl. In
another embodiment, G is selected from H, optionally tuted methyl and optionally
substituted ethyl. In another embodiment, G is selected from H, methyl and ethyl, wherein
ethyl is optionally substituted by —OH or —O—C1_6alkyl. In another embodiment, G is
selected from H, methyl and ethyl, wherein ethyl is optionally substituted by —OH or —0—
Me. In another embodiment, G is selected from H and methyl.
In one embodiment, t is 0, l or 2. In another ment, t is 0. In another embodiment, t
is 1. In another embodiment, t is 2. In another embodiment, t is 3. In another embodiment,
M is selected from bond, (CH2) , (CH2)2 , (CH2)3 , cycloalkyl—, —CHOH—CH2—, —
CH2—CHOH—,—CHz-C(alkyl)2 , (CH2) C(—O) In another embodiment,
, C(—O) (CH2) .
M is ed from bond, (CH2) , (CH2)2 , (CH2)3 , entyl—, —CHOH—CH2—, —
CH2-C(Me)2—, —(CH2)—C(=O)—. In another embodiment, M is selected from bond, —(CH2)—,
2— and —(CH2)3—.
In one embodiment, W is selected from the group consisting of substituted alkyl, alkoxy,
alkenyl, cycloalkyl, optionally substituted heterocycloalkyl, aryl, heteroaryl. In another
embodiment, W is selected from substituted alkyl, alkoxy, cyclopropyl, cyclobutyl,
optionally substituted pyrrolidinyl, optionally substituted dinyl, optionally substituted
piperazinyl, optionally substituted morpholinyl, ydrofuran, furan, thiophene, phenyl,
and pyridine. In another embodiment, W is selected from alkyl substituted by one or more
groups ed from halo, -OH, -NH2, and -N(C1_6alkyl)2, alkoxy, cyclopropyl, cyclobutyl,
pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuran, furan, ene,
, and pyridine, wherein each of pyrrolidinyl, piperidinyl, piperazinyl, and linyl
is optionally substituted by one or more groups selected from halo, C1_6alkyl, -C(=O)C1_
, -COZC1_6alkyl, -N(C1_6alkyl)2, O)C1_6alkyl, -C(=O)NH2, and :0. In another
embodiment, W is selected from alkyl substituted by one or more groups selected from -F,
-OH, -NH2, and -N(Me)2, alkoxy, cyclopropyl, cyclobutyl, idinyl, piperidinyl,
piperazinyl, morpholinyl, tetrahydrofuran, furan, ene, phenyl, and pyridine, wherein
each of pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl is optionally substituted by
one or more groups selected from -F, -Me, -Et, -iPr, -C(=O)Me, -COztBu, -NHC(=O)Me,
-C(=O)NH2, and :0. In another embodiment, W is selected from ropyl, cyclobutyl,
pyrrolidinyl, and piperidinyl, wherein each of pyrrolidinyl and piperidinyl is optionally
substituted by one of -Me, -Et and -iPr. In another embodiment, W is selected from
pyrrolidinyl, and piperidinyl, wherein each of pyrrolidinyl and piperidinyl is optionally
substituted by one of -Me, -Et and —iPr. In one embodiment, W is l-methylpyrrolidinyl.
In one embodiment, z is 0. In another embodiment, z is 1. In another embodiment, z is 2.
In one embodiment, R4 and R5 are, at each instance, independently ed from H and
ally substituted alkyl, or are linked to form an optionally substituted heterocycloalkyl.
In another embodiment, R4 and R5 are, at each ce, independently selected from H,
optionally substituted methyl, optionally substituted ethyl, optionally substituted i-propyl,
and optionally substituted pyrrolidinyl. In another embodiment, R4 and R5 are, at each
instance, ndently selected from H, methyl, ethyl, yl, and pyrrolidinyl optionally
substituted by :0.
R6 and R7 are, at each instance, independently selected from H and optionally substituted
alkyl, or, in the groups —NR6C(O)R7, —NR6S(O)2R7, may be linked to form an optionally
tuted heterocycloalkyl.
In one embodiment, R6 is, at each instance, independently selected from H and optionally
substituted alkyl. In r embodiment, R6 is H.
In one embodiment, R7 is, at each ce, independently selected from H and optionally
substituted alkyl. In another embodiment, R7 is alkyl. In another embodiment, R7 is methyl.
In one embodiment, R8 and R9 are, at each instance, ndently selected from optionally
substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally
substituted cycloalkyl. In one embodiment, R8 and R9 are, at each instance, independently
selected from optionally substituted alkyl, and optionally substituted cycloalkyl. In another
embodiment, R8 and R9 are, at each instance, independently selected from optionally
substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl.
In one ment, R10 and R11 are, at each instance, independently selected from H,
optionally substituted alkyl, optionally substituted aryl, ally substituted heteroaryl, and
optionally substituted cycloalkyl. In one embodiment, R10 and R11 are, at each instance,
independently selected from H, optionally substituted alkyl, and ally substituted
cycloalkyl. In another embodiment, R10 and R11 are, at each instance, independently selected
from H, optionally substituted methyl, ally substituted ethyl, and optionally
substituted i-propyl. In another embodiment, R10 and R11 are, at each instance,
independently selected from ally substituted methyl, optionally substituted ethyl, and
optionally substituted yl. In another embodiment, R10 and R11 are, at each instance,
independently selected from H, methyl, ethyl, and i-propyl, wherein each of methyl, ethyl,
and yl is ally substituted by one or more of —OH, —O-C1_6alkyl, -C3_6cycloalkyl,
-C3_6heterocycloalkyl and -C(=O)NH2. In another embodiment, R10 and R11 are, at each
instance, independently selected from H, methyl, ethyl, and yl, wherein each of
methyl, ethyl, and i-propyl is ally substituted by one or more of —OH, —OMe,
cyclopropyl, pyrrolidinyl and -C(=O)NH2. In another embodiment, R10 and R11 are, at each
instance, independently selected from H, methyl, ethyl, and i-propyl, wherein each of
methyl, ethyl, and i-propyl is substituted by one or more of —OH, —OMe, ropyl,
pyrrolidinyl and -C(=O)NH2. In one embodiment, R10 is H.
In one embodiment, R12 is H and R13 is, at each instance, independently selected from
hydroxy, and optionally substituted alkyl, or R12 and R13 are linked to form an optionally
substituted cycloalkyl ring, or together form :0. In another embodiment, R12 and R13 are, at
each instance, independently ed from H, hydroxy, and optionally substituted alkyl. In
another embodiment, R12 and R13 are, at each instance, independently selected from H,
hydroxy, optionally substituted methyl, and optionally tuted ethyl. In another
ment, R12 and R13 are, at each instance, H.
In one embodiment, R14 is alkyl. In another ment, R14 is methyl.
In one embodiment, the compound is not a compound of WO 2004/014850 or
W02004/06539l.
In one embodiment, the compound is not
NHZ NHBoc 6%
N N
RI R1 R]
R2 l I
//I R, /S 1 I) R2 J
S S
N N N
or a hydrochloride salt thereof, or
, ,
n R1 is optionally substituted aryl and R2 is H or optionally substituted alkyl.
Specific embodiments
In one embodiment:
A is S;
X is N;
V is CR3HI;
Z is N;
R1 is selected from optionally substituted alkyl, ally substituted cycloalkyl,
optionally substituted aryl, and optionally substituted heteroaryl;
R2 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl,
optionally substituted alkoxy, —NR4R5, —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —
, —COZR7, ally substituted oxazolinyl, —SR14, —S(O)R14 and —S(O)2R14;
R31 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl,
optionally substituted alkoxy, optionally substituted heterocycloalkoxy, —NR6C(O)R7, —
NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, , —NR8R9, —CEC—J, optionally substituted
cycloalkyl-J and —(NRaRb)—J;
R3111 is selected from H, halo, —CN, trifluoromethyl, ally substituted alkyl,
optionally substituted alkoxy, optionally substituted heterocycloalkoxy, optionally
substituted heterocycloalkylalkyl, —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, R5,
optionally substituted ene—CONR4R5, —COZR7, —NR1°R“, —CEC—J, optionally
tuted cycloalkyl-J and —(NRCRd)—J,
ed that R31 is —CEC—J, optionally substituted cycloalkyl-J or —(NRaRb)—J,
and/or R3111 is —CEC—J, optionally substituted cycloalkyl-J or —(NRcRd)—J;
wherein Ra and Rb are linked to form an optionally substituted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1.
zalkylene, —NR6—, —O—, or —S(O)Z—, wherein the optionally bridged, optionally substituted
heterocycloalkyl ring is selected from the group consisting of azetidinyl, pyrrolidinyl,
piperidinyl, morpholinyl, tetrahydro-l,3-oxazinyl, hexahydropyrimidinyl, l,4-thiazanyl,
azepanyl, 1,4-oxaazepanyl, and l,4-thieazepanyl;
wherein Rc and Rd are linked to form an ally substituted 4 to 7 membered
heterocycloalkyl ring, which is optionally d by a bond, optionally substituted C1.
ene, —NR6—, —0—, or —S(O)Z—;
J is selected from H and —(CR12R13)q—L—M—W,
n
q is 0, 1 or 2;
L is —O— or —N(G)—; and
G is selected from hydrogen, optionally substituted alkyl and optionally substituted
cycloalkyl;
M is —(CR12R13)t—;
tis0,1,20r3;
W is ed from the group consisting of optionally substituted alkyl, optionally
substituted alkoxy, optionally substituted alkenyl, optionally tuted cycloalkyl,
optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted
heteroaryl and —NR8R9,
wherein when W is optionally substituted cycloalkyl it may optionally be bridged by
a bond or optionally substituted C1_2alkylene, and
wherein when W is optionally substituted heterocycloalkyl it may optionally be
bridged by a bond, optionally substituted C1_2alkylene, —NR6—, —O—, or —S(O)Z—;
alternatively, when L = —N(G)—, L, G, M and W may be linked to form an optionally
substituted heterocycloalkyl, an optionally substituted cycloalkenyl, or an optionally
tuted heteroaryl;
z is 0, l or 2;
R4 and R5 are, at each instance, independently selected from H, ally
tuted alkyl, optionally tuted aryl, optionally substituted heteroaryl, and optionally
substituted cycloalkyl, or are linked to form an optionally substituted heterocycloalkyl;
R6 is, at each instance, independently selected from H and optionally substituted
alkyl;
R7 is, at each instance, ndently selected from H and optionally substituted
alkyl;
R8 and R9 are, at each instance, independently selected from optionally substituted
alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally
substituted heteroaryl, and ally substituted cycloalkyl;
R10 and R11 are, at each instance, independently selected from H, optionally
substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl,
ally substituted heteroaryl, and optionally substituted cycloalkyl;
R12 and R13 are, at each instance, independently selected from H, hydroxy, and
optionally substituted alkyl, or may be linked to form an ally substituted cycloalkyl
ring, or may together form =0; and
R14 is optionally substituted alkyl,
wherein the optional substituents are independently selected from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOZ, -CN, -COzH, -COZC1_6alkyl, -SO3H,
-SOC1_6alkyl, -SOZC1_6alkyl, -NHSOZC1_6alkyl, -NC1_6alkylSOZC1_6alkyl, -SOZNH2,
-SOzNHC1_6alkyl, -SOZN(C1_6alkyl)2, -NHSOZNH2, -NHSOZNHC1_6alkyl, -NHSOZN(C1_
)2, -NC1_6alkylSOZNH2, -NC1.6alkylSOZNHC1_6alkyl, -NC1.6alkylSOZN(C1_6alkyl)2,
H, -C(=O)C1_6alkyl, -NHC(=O)C1_6alkyl, -NC1-6alkle(=O)C1_6alkyl, C1.
enedioxy, =O, -N(C1_6alkyl)2, -C(=O)NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2,
-NHC(=O)NH2, O)NHC1_6alkyl, -NHC(=O)N(C1_6alky1)2, -NC1_6alky1C(=O)NH2,
-NC1.6alkle(=O)NHC1-6alkyl, -NC1-6alkle(=O)N(C1-6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
-C(=NC1.6alkyl)NHC1_6alkyl, -C(=NC1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl,
-C3_6heterocycloalkyl, 2-imidazolidinon—3 -yl, l-C1-6alkylimidazolidinon-3 -yl,
C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, —ZtH, —Zt-C1_6alkyl, -C1_
6alkylene—ZtH, —Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is
independently O, S, NH or N(C1_6alkyl).
In one embodiment:
A is S;
X is N;
V is CR3HI;
Z is N;
R1 is selected from optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted aryl, and optionally substituted heteroaryl;
R2 is selected from H, trifluoromethyl, substituted alkyl, ally substituted
alkoxy, —NR4R5, —NR6C(O)R7, —S(O)2NR4R5, —CONR4R5, —COZR7, optionally substituted
oxazolinyl, —SR14, —S(O)R14 and —S(O)2R14;
R31 is ed from H, halo, —CN, romethyl, optionally substituted alkyl,
optionally substituted , ally substituted heterocycloalkoxy, —NR6C(O)R7, —
NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5, —COZR7, —NR8R9, —CEC—J, optionally substituted
cycloalkyl-J and b)—J;
R3111 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl,
optionally substituted alkoxy, optionally substituted heterocycloalkoxy, optionally
substituted heterocycloalkylalkyl, —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5,
optionally substituted —alkylene—CONR4R5, —COZR7, “, , optionally
tuted lkyl-J and —(NRCRd)—J,
provided that R31 is —CEC—J, optionally substituted cycloalkyl-J or b)—J,
and/or R3111 is —CEC—J, optionally substituted cycloalkyl-J or —(NRcRd)—J;
wherein Ra and Rb are linked to form an optionally substituted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1.
zalkylene, —NR6—, —O—, or —S(O)Z—, wherein the optionally d, optionally substituted
heterocycloalkyl ring is selected from the group consisting of azetidinyl, pyrrolidinyl,
piperidinyl, morpholinyl, tetrahydro-l,3-oxazinyl, hexahydropyrimidinyl, l,4-thiazanyl,
azepanyl, 1,4-oxaazepanyl, and l,4-thieazepanyl;
n Rc and Rd are linked to form an optionally tuted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1.
zalkylene, —NR6—, —0—, or —S(O)Z—;
J is selected from H and —(CR12R13)q—L—M—W,
wherein
q is 0, 1 or 2;
L is —O— or —N(G)—; and
G is selected from hydrogen, optionally substituted alkyl and optionally tuted
cycloalkyl;
M is —(CR12R13),—;
,2or3;
W is selected from the group consisting of optionally substituted alkyl, optionally
substituted alkoxy, optionally substituted alkenyl, optionally substituted cycloalkyl,
optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted
heteroaryl and ,
wherein when W is optionally substituted cycloalkyl it may optionally be bridged by
a bond or optionally substituted C1_2alkylene, and
wherein when W is optionally substituted heterocycloalkyl it may optionally be
bridged by a bond, optionally substituted C1_2alkylene, —NR6—, —O—, or —;
alternatively, when L = —N(G)—, L, G, M and W may be linked to form an ally
substituted cycloalkyl, an optionally tuted heterocycloalkenyl, or an ally
tuted heteroaryl;
z is 0, l or 2;
R4 and R5 are, at each instance, independently selected from H, optionally
substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally
substituted cycloalkyl, or are linked to form an optionally substituted heterocycloalkyl;
R6 is, at each instance, independently selected from H and optionally substituted
alkyl;
R7 is, at each instance, independently selected from H and optionally substituted
alkyl;
R8 and R9 are, at each instance, independently selected from optionally substituted
alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, ally
substituted heteroaryl, and optionally substituted cycloalkyl;
R10 and R11 are, at each instance, independently selected from H, optionally
substituted alkyl, optionally substituted aryl, optionally tuted heterocycloalkyl,
optionally substituted heteroaryl, and optionally substituted cycloalkyl;
R12 and R13 are, at each instance, independently selected from H, hydroxy, and
optionally tuted alkyl, or may be linked to form an optionally substituted cycloalkyl
ring, or may together form :0; and
R14 is optionally substituted alkyl,
wherein the optional substituents are independently selected from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOz, -CN, -COzH, -COZC1_6alkyl, -SO3H,
-SOC1_6alkyl, -SOZC1_6alkyl, -NHSOZC1_6alkyl, -NC1_6alkylSOZC1_6alkyl, -SOzNH2,
-SOzNHC1_6alkyl, -SOzN(C1_6alkyl)2, -NHSOzNH2, -NHSOzNHC1_6alkyl, -NHSOzN(C1_
)2, alkylSOZNH2, -NC1-6alkylSOZNHC1_6alkyl, alkylSOZN(C1_6alkyl)2,
-C(=O)H, -C(=O)C1_6alkyl, -NHC(=O)C1_6alkyl, -NC1-6alkle(=O)C1_6alkyl, C1.
6alkylenedioxy, =O, 6alkyl)2, -C(=O)NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2,
-NHC(=O)NH2, -NHC(=O)NHC1_6alkyl, -NHC(=O)N(C1_6alkyl)2, -NC1_6alkle(=O)NH2,
-NC1-6alkle(=O)NHC1-6alkyl, -NC1_6alkle(=O)N(C1.6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
-C(=NC1.6alkyl)NHC1_6alkyl, -C(=NC1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl,
-C3_6heterocycloalkyl, 2-imidazolidinon-3 -yl, l-C1-6alkylimidazolidinon-3 -yl,
C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, koxyaryl, —ZtH, —Zt-C1_6alkyl, -C1_
6alkylene—ZtH, —Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is
independently O, S, NH or N(C1_6alkyl).
In one embodiment:
A is S;
X is N;
V is CR3HI;
Z is N;
R1 is selected from optionally substituted alkyl, optionally tuted cycloalkyl,
optionally substituted aryl, and ally substituted heteroaryl;
R2 is selected from H, trifluoromethyl, substituted alkyl, optionally substituted
alkoxy, —NR4R5, —NR6C(O)R7, —S(O)2NR4R5, —CONR4R5, —COZR7, optionally substituted
oxazolinyl, —SR14, —S(O)R14 and —S(O)2R14;
R31 is selected from trifluoromethyl, optionally substituted alkyl, optionally
substituted alkoxy, optionally substituted cycloalkoxy, —NR6C(O)R7, —NR6S(O)2R7, —
R4R5, —CONR4R5, —COZR7, —NR8R9, optionally substituted cycloalkyl-J and —
(NRaRb—J;
R3111 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl,
optionally substituted , ally substituted heterocycloalkoxy, optionally
substituted heterocycloalkylalkyl, —NR6C(O)R7, O)2R7, —S(O)2NR4R5, —CONR4R5,
optionally substituted —alkylene—CONR4R5, —COZR7, —NR10R11, optionally substituted
lkyl-J and d)—J,
provided that R31 is optionally substituted cycloalkyl-J or —(NRaRb)—J, and/or R3111 is
optionally substituted lkyl-J or —(NRcRd)—J;
wherein Ra and Rb are linked to form an optionally substituted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1.
zalkylene, —NR6—, —O—, or —S(O)Z—, wherein the optionally bridged, optionally substituted
cycloalkyl ring is selected from the group consisting of azetidinyl, pyrrolidinyl,
piperidinyl, morpholinyl, ydro-l,3-oxazinyl, hexahydropyrimidinyl, l,4-thiazanyl,
azepanyl, 1,4-oxaazepanyl, and l,4-thieazepanyl;
wherein Rc and Rd are linked to form an optionally substituted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1.
zalkylene, —NR6—, —0—, or —S(O)Z—;
J is selected from H and —(CR12R13)q—L—M—W,
wherein
q is 0 or 1;
L is —O— or —N(G)—; and
G is selected from hydrogen, optionally substituted alkyl and optionally tuted
cycloalkyl;
M is —(CR12R13)t—;
t is 0, l, or 2;
W is selected from the group consisting of optionally tuted alkyl, optionally
substituted alkoxy, optionally substituted alkenyl, optionally substituted cycloalkyl,
optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted
heteroaryl and —NR8R9,
wherein when W is ally substituted cycloalkyl it may optionally be bridged by
a bond or optionally substituted C1_2alkylene, and
wherein when W is optionally substituted heterocycloalkyl it may optionally be
bridged by a bond, optionally substituted C1_2alkylene, —NR6—, —O—, or —S(O)Z—;
alternatively, when L = —N(G)—, L, G, M and W may be linked to form an optionally
tuted heterocycloalkyl, an optionally substituted heterocycloalkenyl, or an optionally
substituted heteroaryl;
z is 0, l or 2;
R4 and R5 are, at each instance, independently selected from H, optionally
substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally
substituted cycloalkyl, or are linked to form an optionally substituted heterocycloalkyl;
R6 is, at each instance, independently selected from H and ally substituted
alkyl;
R7 is, at each instance, independently selected from H and ally substituted
alkyl;
R8 and R9 are, at each instance, independently selected from optionally substituted
alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally
substituted aryl, and optionally substituted cycloalkyl;
R10 and R11 are, at each instance, independently selected from H, optionally
substituted alkyl, ally substituted aryl, optionally substituted heterocycloalkyl,
optionally substituted heteroaryl, and ally substituted cycloalkyl;
R12 and R13 are, at each instance, independently selected from H, hydroxy, and
ally tuted alkyl, or may be linked to form an optionally substituted cycloalkyl
ring, or may together form =0; and
R14 is optionally substituted alkyl,
wherein the optional substituents are independently selected from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOZ, -CN, -COzH, -COZC1_6alkyl, -SO3H,
6alkyl, -SOZC1_6alkyl, -NHSOZC1_6alkyl, -NC1_6alkylSOZC1_6alkyl, -SOZNH2,
-SOzNHC1_6alkyl, -SOZN(C1_6alkyl)2, -NHSOZNH2, -NHSOZNHC1_6alkyl, -NHSOZN(C1_
)2, -NC1_6alkylSOZNH2, -NC1.6alkylSOZNHC1_6alkyl, alkylSOZN(C1_6alkyl)2,
-C(=O)H, -C(=O)C1_6alkyl, O)C1_6alkyl, -NC1-6alkle(=O)C1_6alkyl, C1.
6alkylenedioxy, =O, 6alkyl)2, -C(=O)NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2,
-NHC(=O)NH2, O)NHC1_6alkyl, O)N(C1_6alky1)2, -NC1_6alkle(=O)NH2,
-NC1-6alkle(=O)NHC1.6alkyl, -NC1.6alkle(=O)N(C1.6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
-C(=NC1.6alkyl)NHC1_6alkyl, -C(=NC1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, ycloalkyl,
-C3_6heterocycloalkyl, 2-imidazolidinon—3 -yl, l-C1-6alkylimidazolidinon-3 -yl,
C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, —ZtH, —Zt-C1_6alkyl, -C1_
6alkylene—ZtH, —Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is
independently O, S, NH or N(C1_6alkyl).
In one embodiment:
A is S;
X is N;
V is CR3HI;
Z is N;
R1 is selected from ally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted aryl, and optionally substituted heteroaryl;
R2 is selected from H, trifluoromethyl, substituted alkyl, optionally substituted
alkoxy, —NR4R5, —NR6C(O)R7, —S(O)2NR4R5, —CONR4R5, —COZR7, optionally substituted
oxazolinyl, —SR14, —S(O)R14 and R14;
R3I is —(NRaRb)—J;
R3111 is selected from H, halo, —CN, trifluoromethyl, optionally tuted alkyl,
ally substituted alkoxy, optionally tuted heterocycloalkoxy, optionally
substituted heterocycloalkylalkyl, —NR6C(O)R7, —NR6S(O)2R7, —S(O)2NR4R5, —CONR4R5,
optionally substituted —alkylene—CONR4R5, —COZR7, —NR10R11, optionally substituted
cycloalkyl-J and —(NRcRd)—J,
wherein Ra and Rb are linked to form an optionally tuted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, ally substituted C1.
zalkylene, —NR6—, —O—, or —S(O)Z—, wherein the optionally bridged, optionally substituted
heterocycloalkyl ring is selected from the group consisting of azetidinyl, pyrrolidinyl,
piperidinyl, morpholinyl, tetrahydro-l,3-oxazinyl, hexahydropyrimidinyl, l,4-thiazanyl,
azepanyl, 1,4-oxaazepanyl, and l,4-thieazepanyl;
wherein Rc and Rd are linked to form an optionally tuted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, ally substituted C1.
zalkylene, —NR6—, —0—, or —S(O)Z—;
J is selected from H and —(CR12R13 q—L—M—W,
wherein
q is 0 or 1;
L is —O— or —N(G)—; and
G is selected from hydrogen, optionally substituted alkyl and optionally substituted
cycloalkyl;
M is —(CR12R13),—;
t is 0, l, or 2;
W is selected from the group ting of optionally substituted alkyl, optionally
substituted alkoxy, optionally substituted alkenyl, optionally substituted cycloalkyl,
optionally substituted heterocycloalkyl, ally substituted aryl, optionally substituted
heteroaryl and —NR8R9,
wherein when W is optionally substituted cycloalkyl it may optionally be bridged by
a bond or optionally substituted C1_2alkylene, and
wherein when W is optionally substituted heterocycloalkyl it may optionally be
d by a bond, optionally substituted C1_2alkylene, —NR6—, —O—, or —S(O)Z—;
atively, when L = —N(G)—, L, G, M and W may be linked to form an optionally
substituted heterocycloalkyl, an optionally tuted heterocycloalkenyl, or an optionally
tuted heteroaryl;
z is 0, l or 2;
R4 and R5 are, at each instance, independently selected from H, optionally
substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally
substituted cycloalkyl, or are linked to form an optionally tuted heterocycloalkyl;
R6 is, at each instance, ndently selected from H and optionally substituted
alkyl;
R7 is, at each instance, ndently selected from H and optionally substituted
alkyl;
R8 and R9 are, at each instance, independently selected from optionally substituted
alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally
tuted aryl, and optionally substituted cycloalkyl;
R10 and R11 are, at each instance, independently selected from H, optionally
substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl,
optionally substituted heteroaryl, and optionally substituted cycloalkyl;
2012/052842
R12 and R13 are, at each instance, independently selected from H, hydroxy, and
optionally substituted alkyl, or may be linked to form an optionally substituted cycloalkyl
ring, or may together form =0; and
R14 is optionally tuted alkyl,
wherein the optional substituents are independently selected from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOZ, -CN, -COzH, -COZC1_6alkyl, -SO3H,
6alkyl, -SOZC1_6alkyl, -NHSOZC1_6alkyl, alkylSOZC1_6alkyl, -SOZNH2,
-SOzNHC1_6alkyl, -SOZN(C1_6alkyl)2, -NHSOZNH2, -NHSOzNHC1_6alkyl, -NHSOZN(C1_
6alkyl)2, -NC1_6alkylSOZNH2, -NC1.6alkylSOZNHC1_6alkyl, -NC1-6alkylSOZN(C1_6alkyl)2,
-C(=O)H, -C(=O)C1_6alkyl, -NHC(=O)C1_6alkyl, -NC1.6alkle(=O)C1_6alkyl, C1.
6alkylenedioxy, =O, -N(C1_6alkyl)2, -C(=O)NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2,
O)NH2, -NHC(=O)NHC1_6alkyl, -NHC(=O)N(C1_6alkyl)2, -NC1_6alkle(=O)NH2,
-NC1-6alkle(=O)NHC1.6alkyl, -NC1.6alkle(=O)N(C1-6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
1-6alkyl)NHC1_6alkyl, -C(=NC1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl,
-C3_6heterocycloalkyl, 2-imidazolidinon-3 -yl, l-C1-6alkylimidazolidinon-3 -yl,
kle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, —ZtH, —Zt-C1_6alkyl, -C1_
6alkylene—ZtH, —Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is
independently O, S, NH or N(C1_6alkyl).
In one ment:
A is S;
Z is N and V is CR3HI;
R31 is selected from H, —(NRaRb)—J, optionally substituted cycloalkyl-J and —CEC—J;
Each of R311, R3111, and R3 IV is independently selected from H, —NR10R11, —CEC—J, optionally
substituted cycloalkyl-J and —(NRCRd)—J;
R1 is selected from optionally substituted alkyl and optionally substituted phenyl;
R2 is selected from H, halo, —CN, optionally substituted alkyl, —NR4R5, —NR6C(O)R7, —
CONR4R5;
NRaRb and NRCRd each form an optionally bridged, optionally substituted ring of formula
(II):
K j ) 11D\/
W (11)
wherein n and D are defined in each case above;
J is present in at least one instance as—(CR12R13)q—L—M—W;
q is l or 2;
G is selected from H, optionally substituted methyl and optionally substituted ethyl;
M is selected from bond, (CH2) , (CH2)2 , (CH2)3 , cycloalkyl—, —CHOH—CH2—, —
CHz—CHOH—, —CH2-C(alky1)2 , (CH2) C(—0) , C(—O) (CH2) ;
W is selected from substituted alkyl, alkoxy, cyclopropyl, cyclobutyl, optionally substituted
pyrrolidinyl, optionally substituted piperidinyl, ally substituted piperazinyl, optionally
tuted morpholinyl, tetrahydrofuran, furan, thiophene, , and pyridine;
alternatively, when L = —N(G)—, L, G, M and W may be linked to form an ally
substituted heterocycloalkyl;
R4 and R5 are, at each instance, independently selected from H and optionally tuted
alkyl, or are linked to form an optionally substituted heterocycloalkyl;
R6 is H;
R7 is alkyl; and
R10 and R11 are, at each instance, independently selected from H, optionally substituted
methyl, optionally substituted ethyl, and optionally substituted i-propyl,
wherein the optional substituents are independently selected from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOZ, -CN, -COzH, _6alkyl, -SO3H,
-SOC1_6alkyl, -SOZC1_6alkyl, -NHSOZC1_6alkyl, -NC1_6alkylSOZC1_6alkyl, -SOZNH2,
-SOzNHC1_6alkyl, C1_6alkyl)2, -NHSOZNH2, -NHSOZNHC1_6alkyl, -NHSOZN(C1_
6alkyl)2, -NC1_6alkylSOZNH2, -NC1.6alkylSOZNHC1_6alkyl, -NC1.6alkylSOZN(C1_6alkyl)2,
H, -C(=O)C1_6alkyl, O)C1_6alkyl, -NC1.6alkle(=O)C1_6alkyl, C1-
6alkylenedioxy, =O, -N(C1_6alkyl)2, NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2,
-NHC(=O)NH2, -NHC(=O)NHC1_6alkyl, -NHC(=O)N(C1_6alkyl)2, -NC1_6alkle(=O)NH2,
-NC1_6alkle(=O)NHC1.6alkyl, -NC1.6alkle(=O)N(C1-6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
1_6alkyl)NHC1-6alkyl, -C(=NC1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl,
-C3_6heterocycloalkyl, 2-imidazolidinonyl, l-C1-6alkylimidazolidinon—3-yl,
WO 72694
C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, —ZtH, —Zt-C1_6alkyl, -C1_
6alkylene—ZtH, —Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is
independently O, S, NH or N(C1_6alkyl).
In one embodiment:
A is S;
Z is N and V is CR3HI;
R31 is selected from b)—J, and —CEC—J;
R311 and R3IV are H;
R3111 is ndently selected from H, —NR10R11, —CEC—J, optionally tuted cycloalkyl-
J and —(NRcRd)—J;
R1 is selected from methyl, ethyl, i-propyl, and phenyl, wherein phenyl is optionally
substituted by one or more of halo, —N02 and —SOZN(C1_6alkyl)2;
R2 is ed from H, bromo, —CN, methyl, ethyl, i-propyl, —NR4R5, —NR6C(O)R7, —
CONR4R5;
NRaRb is selected from optionally substituted pyrrolidinyl, piperidinyl, morpholinyl, and 3-
azabicyclo[3 . l .0]hexanyl;
NRCRd is selected from optionally substituted pyrrolidinyl, piperidinyl, morpholinyl,
piperazinyl, and 3-azabicyclo[3 . l .0]hexanyl;
J is present in at least one instance as—(CR12R13)q—L—M—W;
q is l;
G is selected from H, methyl and ethyl, wherein ethyl is ally substituted by —OH or —
O—C1_6alkyl;
M is ed from bond, (CH2) , (CH2)2 , (CH2)3 , cyclopentyl—, —CHOH—CH2—, —
CHz-C(Me)2-, -(CH2)-C(=O)-;
W is selected from alkyl substituted by one or more groups selected from halo, -OH, -NH2,
and -N(C1_6alkyl)2, alkoxy, cyclopropyl, utyl, pyrrolidinyl, piperidinyl, piperazinyl,
morpholinyl, ydrofuran, furan, thiophene, phenyl, and pyridine, wherein each of
pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl is optionally substituted by one or
more groups selected from halo, C1_6alkyl, -C(=O)C1_6alkyl, -COZC1_6alkyl, -N(C1_6alkyl)2,
O)C1_6alkyl, -C(=O)NH2, and :0;
alternatively, when L is —N(G)—, L, G, M and W may be linked to form azetidinyl,
pyrrolidinyl, piperidinyl or morpholinyl, wherein each of pyrrolidinyl, piperidinyl and
morpholinyl is optionally substituted by one or more groups selected from halo,
trihalomethyl, -OH, , -C1_6alkyl, —O-C1_6alkyl, -N(C1_6alkyl)2, -C1_6alkylene—OH, aryl,
haloaryl, -C(=O)NH2 and -C3_6heterocycloalkyl;
R4 and R5 are, at each instance, independently selected from H, methyl, ethyl, i-propyl, and
pyrrolidinyl optionally substituted by :0;
R6 is H;
R7 is ; and
R10 and R11 are, at each instance, independently selected from H, methyl, ethyl, and i-propyl,
wherein each of , ethyl, and i-propyl is optionally substituted by one or more of —OH,
—O-C1_6alkyl, -C3_6cycloalkyl, -C3_6heterocycloalkyl and -C(=O)NH2,
wherein the optional substituents are independently selected from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOZ, -CN, -COzH, -COZC1_6alkyl, -SO3H,
-SOC1_6alkyl, _6alkyl, -NHSOZC1_6alkyl, alkylSOZC1_6alkyl, -SOZNH2,
-SOzNHC1_6alkyl, -SOZN(C1_6alkyl)2, -NHSOZNH2, -NHSOZNHC1_6alkyl, -NHSOZN(C1_
6alkyl)2, -NC1_6alkylSOZNH2, -NC1.6alkylSOZNHC1_6alkyl, -NC1.6alkylSOZN(C1_6alkyl)2,
-C(=O)H, -C(=O)C1_6alkyl, O)C1_6alkyl, -NC1.6alkle(=O)C1_6alkyl, C1-
6alkylenedioxy, =O, 6alkyl)2, -C(=O)NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2,
-NHC(=O)NH2, -NHC(=O)NHC1_6alkyl, -NHC(=O)N(C1_6alkyl)2, -NC1_6alkle(=O)NH2,
-NC1_6alkle(=O)NHC1.6alkyl, -NC1-6alkle(=O)N(C1-6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
-C(=NC1_6alkyl)NHC1-6alkyl, -C(=NC1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl,
-C3_6heterocycloalkyl, 2-imidazolidinon-3 -yl, l-C1-6alkylimidazolidinon-3 -yl,
C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, —ZtH, —Zt-C1_6alkyl, -C1_
6alkylene—ZtH, —Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is
independently O, S, NH or N(C1_6alkyl).
In one embodiment:
A is S;
dXisN;
R3I is —(NRaRb)—J and J is 13)q—L—M—W;
R311 and R3IV are H;
R3III is —(NRcRd)—J;
R1 is phenyl;
R2 is H;
NRaRb and NRCRd are each ed from pyrrolidinyl and piperidinyl;
2012/052842
J is present in at least one instance as—(CRIZR13 q—L—M—W;
q is l;
G is selected from H and methyl;
M is ed from bond, (CH2) and
, (CH2)2 (CH2)3 ; and
W is selected from pyrrolidinyl, and piperidinyl, wherein each of pyrrolidinyl and
piperidinyl is optionally substituted by one of -Me, -Et and —iPr;
alternatively, when L is —N(G)—, L, G, M and W may be linked to form pyrrolidinyl,
piperidinyl or morpholinyl substituted by one or more groups ed from idinyl, —
OH, —F, —Me, —OMe, , —CF3, —NMe2, phenyl, F-phenyl, —CONH2.
In one embodiment, the nd of the invention is ed from:
4-[4-[2-(1-methylpyrrolidinyl)ethoxymethyl]-l-piperidyl]phenyl-thieno[2,3 -
d]pyrimidine
-methyl [4- [2-( l -methylpyrrolidinyl)ethoxymethyl] - l -piperidyl]thieno [2,3 -
d]pyrimidine
4-[4-[2-(1-methylpyrrolidinyl)ethoxymethyl]-l-piperidyl]thieno[2,3 -d]pyrimidine
,6-dimethyl [4- [2-( l -methylpyrrolidinyl)ethoxymethyl] - l -piperidyl]thieno [2,3 -
d]pyrimidine
-phenyl [4-(2-pyrrolidin— l -ylethoxymethyl)- l -piperidyl]thieno [2,3 -d]pyrimidine
4- [2- [[ l -(5 -phenylthieno[2,3 -d]pyrimidinyl)piperidyl]methoxy] ethyl]morpholine
4- [4- [( l -methylpyrrolidinyl)methoxymethyl] - l -piperidyl] phenyl-thieno [2,3 -
d]pyrimidine
N,N—dimethyl-3 - [[ l -(5-phenylthieno [2,3 -d]pyrimidinyl)piperidyl] methoxy]propan- l -
amine
4- [4-(cyclobutoxymethyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidine
4-[4-[2-(1-methylpiperidyl)ethoxymethyl]-l-piperidyl]phenyl-thieno[2,3 -d]pyrimidine
methyl [[ l -(5-phenylthieno[2,3 -d]pyrimidinyl)piperidyl]methoxy]ethanamine
4- [4- [( l -methylpyrrolidin-3 -yl)oxymethyl] - l -piperidyl] phenyl-thieno [2,3 -d]pyrimidine
4- [4- [( l -methylpiperidyl)oxymethyl] - l -piperidyl] nyl-thieno [2,3 -d]pyrimidine
l- [4- [4-(2-dimethylaminoethyloxymethyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidin
yl]pyrrolidine-3 -carboxamide
4- [4-(isopropoxymethyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidine
-phenyl [4-(tetrahydrofuran-3 -yloxymethyl)- l -piperidyl]thieno [2,3 -d]pyrimidine
-(3 pheny1)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidine
-ethy1methy1[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thieno[2,3 -d]pyrimidine
4-[2-[[1-(6-isopropy1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy]ethy1]morpholine
-(4-fluorophenyl)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -
d]pyrimidine
4- [2- [[ 1 - [5 -(4-fluor0pheny1)thieno[2,3 -d]pyrimidin—4-y1]—4-
piperidy1]methoxy]ethyl]morpholine
4- [4- [2-(3 -fluor0pyrrolidin—1-y1)eth0xymethy1]—1-piperidyl]pheny1-thien0[2,3 -
d]pyrimidine
4-[2-[[1-(5-ethy1methy1-thien0[2,3 -d]pyrimidiny1)
piperidy1]methoxy]ethyl]morpholine
-ethy1—6-methy1—4-[4-[2-(1-methy1pyrro1idiny1)ethoxymethy1]piperidy1]thien0[2,3 -
d]pyrimidine
6-isopropy1[4-[2-(1-methy1piperidy1)ethoxymethyl]piperidy1]thieno[2,3 -
d]pyrimidine
4- [4- [2-(3 ,3 -difluoropyrrolidiny1)eth0xymethy1]—1-piperidy1]pheny1—thien0[2,3 -
d]pyrimidine
-[2-[[1-(5-pheny1thieno[2,3 imidin—4-y1)piperidy1]methoxy] ethyl] —5 -
azabicyc10[2.2. 1]heptane
4-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] ethy1]piperazinone
1-[2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] ethy1]pyrr01idine-3 -
carboxamide
N—[l-[2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-yl)piperidy1]methoxy]ethy1]pyrrolidin-3 -
y1]acetamide
1-[2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] ethy1]pyrrolidine
carboxamide
4- [4- [2- [(3R)-3 -fluoropyrrolidiny1]eth0xymethy1]—1-piperidyl]pheny1-thien0[2,3 -
d]pyrimidine
4- [4- [2- [(3 S)-3 -fluoropyrrolidiny1]eth0xymethy1]— ridy1]pheny1—thien0[2,3 -
d]pyrimidine
-ethy1—6-methy1—4-[4-[2-(1-methy1—2-piperidyl)eth0xymethy1]piperidy1]thien0[2,3 -
d]pyrimidine
-(3 -flu0r0pheny1)[4-[2-(1-methylpyrr01idin—2-y1)eth0xymethy1]piperidyl]thien0[2,3 -
d]pyrimidine
-(3 -fluoropheny1)[4-[2-(1-methy1—2-piperidy1)eth0xymethyl]piperidy1]thien0[2,3 -
d]pyrimidine
-pheny1—4-[6-(2-pyrr01idin—1-yleth0xymethy1)azabicyc10[3. 1 .0]hexan—3-y1]thien0[2,3-
d]pyrimidine
4-[2-[[3-(5-pheny1thien0[2,3-d]pyrimidin—4-yl)azabicyc10[3.1.0]hexan—6-
yl]methoxy]ethy1]m0rpholine
4-[6-[2-(1-methy1pyrro1idin—2-y1)eth0xymethy1]azabicyc10[3.1 .0]hexan—3-y1]—5-pheny1-
thieno[2,3-d]pyrimidine
4-[6-[2-[(3 S)flu0r0pyrrolidiny1]ethoxymethyl]azabicyc10[3.1.0]hexan—3-y1]—5-
phenyl-thieno [2,3 -d]pyrimidine
2-[(3R)fluor0pyrrolidin—1-y1]eth0xymethy1]azabicyc10[3.1 .0]hexan—3-y1]—5-
-thieno [2,3 -d]pyrimidine
(2R)[2-[[3-(5-pheny1thien0[2,3-d]pyrimidin—4-y1)azabicyc10[3. 1 .0]hexan—6-
y1]meth0xy]ethy1]pyrr01idinecarboxamide
(2S)[2-[[3-(5-pheny1thien0[2,3-d]pyrimidinyl)azabicyc10[3.1.0]hexan—6-
y1]meth0xy]ethy1]pyrr01idinecarboxamide
N,N—dimethy1[4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—
5-y1]benzenesulfonamide
(2R)[2-[[3-[5-(4-flu0r0pheny1)thieno[2,3-d]pyrimidin—4-y1]azabicyc10[3.1 .0]hexan—6-
h0xy]ethy1]pyrr01idinecarboxamide
itropheny1)[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidine
-(4-flu0r0pheny1)[6-[2-[(3 S)flu0r0pyrr01idin— 1-y1]eth0xymethy1]—3-
azabicyc10[3.1.0]hexan—3-y1]thien0[2,3-d]pyrimidine
-[2-[[3-[5-(4-fluor0pheny1)thieno[2,3-d]pyrimidin—4-y1]azabicyc10[3.1.0]hexan—6-
y1]meth0xy]ethyl] 0xa—5-azabicyc10 [2 .2. 1 ]heptane
1-cyc10pr0py1-N—[[ 1 -(5-pheny1thien0[2,3-d]pyrimidin—4-y1)
piperidyl]methy1]methanamine
4- [4- [(3 -methy1pyrrolidin—1-y1)methy1]—1-piperidy1]pheny1—thieno[2,3 -d]pyrimidine
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methy1]pr0panamine
fluor0-N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methyl]ethanamine
2-meth0xy-N—(2-methoxyethy1)-N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
WO 72694
[1-[[1-(5-pheny1thieno[2,3 imidin—4-y1)
piperidyl]methy1amino]cyclopentyl]methanol
1- [[ 1 -(5 -pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methy1]piperidin-3 -01
2-pheny1—4-[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidyl]methy1]morpholine
3 -pheny1 [[ 1 -(5-pheny1thien0 [2,3 -d]pyrimidinyl)piperidy1]methylamino]pr0pan—1-01
2-(1 -methy1pyrr01idin—2-y1)-N-[[ 1 eny1thieno[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
2-methy1m0rpholin0-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidyl]methy1]propan— 1 -amine
N,N—dimethy1—1-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methyl]piperidin—3 -
amine
1-(2-fury1)-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]methanamine
N',N'-diisopr0py1—N— [[ 1 -(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]ethane-
1 ,2-diamine
N'-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methyl]ethane-1 mine
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]cyclobutanamine
[1-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]pyrrolidin—2-yl]methanol
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl](2-pyridy1)methanamine
(3 S ,4S)[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methy1] pyrr01idin— 1 -y1-
pyrrolidin01
4- [4- [(3 -meth0xypyrrolidin—1-y1)methy1]—1-piperidy1]pheny1—thien0[2,3 -d]pyrimidine
N—[[1-(5-pheny1thieno[2,3 imidin—4-y1)piperidy1]methyl](2-thieny1)methanamine
4- [4- [ [3 -(4-fluor0pheny1)pyrrolidin—1-y1]methy1]—1-piperidy1]pheny1—thien0[2,3 -
d]pyrimidine
N,N,N'-trimethy1-N'-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl] ethane-
1 ,2-diamine
-trimethy1-N'-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methy1]pr0pane-
1 ,3 -diamine
4-[4-(azetidin—1-y1methy1)piperidy1]pheny1—thieno[2,3 -d]pyrimidine
3 0 N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]cyclopropanamine
N,N—dimethy1—1-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidyl]methy1]piperidin
amine
-pheny1 [4- [(3 -pyrr01idin—1-y1pyrr01idin—1-y1)methy1]—1-piperidy1]thieno[2,3 -
d]pyrimidine
2012/052842
N— [[ 1 - [5-(4-flu0r0pheny1)thieno [2,3 -d]pyrimidin—4-y1]—4-
piperidy1]methy1]cyclopropanamine
N— [[ 1 - [5-(4-flu0r0pheny1)thieno [2,3 -d]pyrimidin—4-yl]piperidy1]methy1]cyclobutanamine
1- [[ 1 - [5 -(4-fluor0pheny1)thieno [2,3 -d]pyrimidin—4-y1] piperidy1]methy1] -N,N-dimethy1—
piperidin—3 -amine
2-(1 -methy1—2-piperidy1)-N—[[ 1 -(5-pheny1thieno[2,3 imidin—4-y1)
piperidy1]methy1]ethanamine
(3R)-N,N—dimethy1—1-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)
piperidyl]methy1]pyrrolidinamine
tert-butyl2-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)
piperidyl]methylamino]ethy1]pyrr01idinecarb0xylate
N—methyl[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1] -N-(pyrr01idin—2-
ylmethyl)methanamine
N—[(1-methy1pyrro1idin—2-y1)methy1][1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidy1]methanamine
N—[[1-(5-pheny1thieno[2,3 imidin—4-y1)piperidy1]methyl]pyrr01idin—2-y1—
ethanamine
N—methyl-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1]methyl]pyrr01idin—2-
anamine
2-(1-ethy1pyrr01idin—2-y1)-N-methy1-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidy1]methy1]ethanamine
2-(1-is0pr0py1pyrrolidin—2-yl)-N-methy1—N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)
dy1]methy1]ethanamine
1-[2-[2-[methy1—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)
piperidyl]methyl]amino] ethy1]pyrr01idiny1] ethanone
(3 S)[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]piperidin—3-amine
1-methy1[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methylamino]pyrrolidin—
2-one
4- [4- [ [(3 S)-3 -flu0r0pyrrolidiny1]methy1]—1-piperidyl]pheny1-thieno[2,3 -d]pyrimidine
2-[methy1—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methy1]amino]
idiny1-ethan0ne
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methy1]pr0penamine
[1-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]pyrr01idin—3 -yl]methan01
N—[1-[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1] ethyl]cyclopropanamine
1-methy1—N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidyl]methy1]piperidin
amine
(2,5-dimethylpyrrolidiny1)methy1]—1-piperidy1]pheny1-thien0[2,3 -d]pyrimidine
-pheny1—4-[4-[[4-(triflu0r0methy1)piperidy1]methy1]—1-piperidyl]thien0[2,3 imidine
2-[(2S)methy1pyrrolidin—2-yl]-N-[[1-(5-phenylthien0[2,3 -d]pyrimidin—4-y1)
piperidy1]methy1]ethanamine
y1(1-methy1pyrr01idin—2-y1)-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidyl]methyl] tetrahydr0furan—2-y1-
ethanamine
2-cyc10pr0py1—N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]ethanamine
2-(1-methy1pyrrolidin—3 -y1)-N-[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methylamino]pyrr01idin—1-y1—
ethanone
(2S)[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1]methy1]pyrrolidine
carboxamide
2-[2-hydr0xyethy1-[[1-[2-(4-methy1piperazin—1-y1)-5 -pheny1-thieno [2,3 -d]pyrimidiny1]—4-
piperidyl]methyl]amino] ethanol
4-[4-[(isopropylamin0)methy1]piperidy1]pheny1—N—(2-pyrr01idin—1-ylethy1)thieno[2,3 -
d]pyrimidin—2-amine
4-[4-[(2-methoxyethylamino)methy1]piperidy1]pheny1—N—(2-pyrr01idin— 1 -
ylethy1)thien0[2,3 -d]pyrimidin—2-amine
4-[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—N—(2-
pyrrolidinylethy1)thieno[2,3 imidin—2-amine
N,1-dimethy1—N—[[1-[2-(4-methy1piperazin—1-y1)pheny1—thieno[2,3 -d]pyrimidin—4-y1]—4-
piperidyl]methy1]pyrrolidinamine
N,1-dimethy1—N—[[1-(5-pheny1—2-piperazin—1-y1-thieno[2,3 -d]pyrimidiny1)
piperidyl]methy1]pyrrolidinamine
[1-[[1-[2-(4-methy1piperazin—1-y1)pheny1—thieno[2,3 -d]pyrimidiny1]—4-
piperidyl]methy1amino]cyclopentyl]methanol
[2-(4-methy1piperazin—1-y1)pheny1—thien0[2,3 -d]pyrimidiny1]—4-
piperidy1]methyl] ( 1 -methylpyrr01idin—2-y1)ethanamine
2012/052842
N,N—dimethy1—1-[[1-[2-(4-methy1piperazin—1-y1)pheny1—thieno[2,3 -d]pyrimidin—4-y1]—4-
piperidyl]methyl]piperidin—3-amine
N—[[1-[2-(4-methy1piperazin—1-y1)pheny1—thien0[2,3 -d]pyrimidiny1]—4-
piperidyl]methyl]cyclobutanamine
4- [4- [ [3 -(dimethy1amin0)piperidy1]methy1] piperidy1] pheny1-N—(2-pyrrolidin
ylethy1)thien0[2,3 -d]pyrimidin—2-amine
N—(2-methoxyethy1) [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]—5-
phenyl-thieno [2,3 -d]pyrimidin—2-amine
N—(cyclopropylmethy1)[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]—
5-pheny1-thieno [2,3 -d]pyrimidinamine
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
2-[methyl-[4-[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amino] methyl] piperidy1] pheny1-
thieno [2,3 imidin—2-y1] amino] acetamide
[2-[4-(2-methoxyethyl)piperazin—1-y1]pheny1-thieno[2,3 -d]pyrimidiny1]—4-
piperidy1]methyl] -N, 1 -dimethy1—pyrrolidin—3 -amine
1- [4- [4- [ [3 -(dimethy1amino)piperidy1]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
4- [4- [ [3 -(dimethy1amin0)piperidy1]methy1] piperidy1] -N-(2-methoxyethy1)pheny1-
thieno [2,3 imidin—2-amine
4-[4-[4-[(cyclobutylamino)methy1]piperidy1]pheny1-thien0[2,3 -d]pyrimidin—2-
yl]piperazin—2-one
4-[4-[(cyclobutylamino)methyl]piperidy1]-N-(2-meth0xyethy1)pheny1—thieno[2,3 -
d]pyrimidin—2-amine
4-[4-[(cyclobutylamin0)methyl]piperidy1]pheny1—N—(2-pyrrolidin—1-ylethy1)thieno[2,3 -
d]pyrimidin—2-amine
4-[(cyclobutylamin0)methyl]piperidy1]pheny1—thieno[2,3 -d]pyrimidin—2-
y1]pyrr01idine-3 -carb0xamide
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
midin—2-y1]piperidinecarboxamide
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
N—methy1 [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1] piperidy1] pheny1-
thieno [2,3 -d]pyrimidinecarboxamide
N—isopropy1 [4- [ [methyl-( 1 -methy1pyrrolidin-3 ino]methy1] piperidy1] pheny1-
thieno [2,3 -d]pyrimidinecarboxamide
-isopropyl-N,N—dimethy1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
r0py1—N—methy1—4-[4-(2-pyrrolidinylethoxymethy1)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
N,N—dimethy1phenyl[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
N,N—dimethy1—4-[4-[[methy1-(1-methy1pyrr01idiny1)amino]methy1] piperidy1] pheny1—
thieno [2,3 -d]pyrimidinecarboxamide
-(3 -flu0r0pheny1)-N—isopropy1[4-(2-pyrr01idin— 1 -yleth0xymethy1)
piperidy1]thien0 [2,3 -d]pyrimidinecarboxamide
-(3 pheny1)-N,N—dimethy1[4-(2-pyrr01idin— 1-ylethoxymethyl)
piperidy1]thien0 [2,3 -d]pyrimidinecarboxamide
[5-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-y1]—
pyrrolidiny1—methanone
N—isopropyl-S-pheny1[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
N—methyl-S-pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidyl]thien0[2,3 -
d]pyrimidinecarboxamide
3 -pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -b]pyridine
0pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -b]pyridine
3 -pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -b]pyridine
carbonitrile
5-pheny1—2-[4-(2-pyrr01idin—1-ylethy1)piperaziny1]thien0[2,3 -d]pyrimidine
2-(1-methy1pyrro1idin—2-y1)-N—[[1-(5-phenylthien0[2,3 imidiny1)
piperidy1]methy1]ethanamine
(2R)[2-[4-(5-pheny1thieno[2,3 -d]pyrimidin—2-y1)piperazin— 1 -y1] ethy1]pyrr01idine
carboxamide
5-pheny1[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thien0[2,3 -d]pyrimidine
-pheny1 [3 -(2-pyrr01idin—1-ylethoxymethy1)pyrr0lidiny1]thien0[2,3 -d]pyrimidine
(3R)[2-[4-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperazin—1-y1]ethy1]pyrr01idine-3 -
carboxamide
2- [4- [2- [(3R)-3 -fluoropyrrolidiny1]eth0xymethy1]—1-piperidyl]pheny1—thien0[2,3 -
d]pyrimidine
-(4-fluorophenyl)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -
d]pyrimidine
1-[2-[[1-(5-pheny1thien0[2,3 imidin—2-y1)piperidy1]methoxy] pyrr01idine-3 -
carboxamide
-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—2-y1)piperidy1]methoxy] ethyl] 0xa—5 -
azabicyclo [2 .2. 1]heptane
N—[5-pheny1—2- [4-(2-pyrr01idin— 1 -yleth0xymethy1)piperidy1]thieno [2,3 -d]pyrimidin—6-
y1]acetamide
1-[5-pheny1—2-[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-
yl]pyrr01idin—2-0ne
-isopr0py1—2-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -d]pyrimidine
1-[5-pheny1—2-[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-
yl]pyrr01idin—2-0ne
-isopr0py1—2-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -d]pyrimidine
4- [3 -[(1 1pyrr01idin—3 -y1)methoxy]propyny1]pheny1—thien0[2,3 -d]pyrimidine
-pheny1—4- [3 -(2-pyrr01idin—1-yleth0xy)pr0pyny1]thien0[2,3 -d]pyrimidine
N—[5-pheny1—4- [4-(2-pyrr01idin— 1 -yleth0xymethy1)piperidy1]thieno [2,3 -d]pyrimidin—6-
y1]acetamide
1-[5-pheny1—4-[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 imidin—6-
yl]pyrr01idin—2-0ne
-pheny1—4- [(1 S ,5R)-3 -(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2.1]0ctan—8-
y1]thieno[2,3 -d]pyrimidine
[8-(4-m0rph01inopheny1—thieno [2,3 -d]pyrimidin—2-y1)azabicyclo [3 .2. 1] octan—3 -
y1]methan01
1-methy1pyrro1idin—2-y1)ethyl](5-pheny1thien0[2,3 -d]pyrimidiny1)piperidine
carboxamide
-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thien0[2,3 -d]pyrimidine
carbonitrile
N—benzyl-S-pheny1[4-(2-pyrr01idinyleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidin—6-amine
N,N—dimethy1—1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidin—4-amine
1-(2-ethy1—5-pheny1—thien0 [2,3 -d]pyrimidin—4-y1)-N,N-dimethy1—piperidin—4-amine
2012/052842
2-[ l - [5-(4-fluorophenyl)(2-hydroxyethylamino)thieno [2,3 -d]pyrimidin—4-yl]
piperidyl] ethanol
4- [4-(methoxymethyl)- l idyl] phenyl-thieno [2,3 -d]pyrimidine
4-(methoxymethyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidinyl] -N',N'-
dimethyl-ethane- l ,2-diamine
4- [4-(methoxymethyl)- l idyl] (4-methylpiperazin— l -yl)phenyl-thieno [2,3 -
d]pyrimidine
4- [4-(methoxymethyl)- l -piperidyl] phenyl-N-(2-pyrrolidin- l -ylethyl)thieno [2,3 -
d]pyrimidin—2-amine
4- [4-(4-methoxyphenyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidine
-cyclohexyl [4-(methoxymethyl)- l -piperidyl] -N- [2-( l -methylpyrrolidin—2-
yl)ethyl]thieno [2,3 -d]pyrimidin—2-amine
4-(3 -benzyloxypyrrolidin— l -yl)phenyl-thieno [2,3 -d]pyrimidine
4- [4-(dimethylamino)- l -piperidyl] phenyl-N-(2-pyrrolidin- l -ylethyl)thieno [2,3 -
d]pyrimidin—2-amine
-phenyl [4-(3 -pyridyloxymethyl)- l -piperidyl]thieno [2,3 -d]pyrimidine
-phenyl [3 -( l -piperidyl)pyrrolidin— l -yl]thieno[2,3 imidine
2- [4- [4-(methoxymethyl)- l idyl] phenyl-thieno [2,3 -d]pyrimidinyl] -N-(2-
pyrrolidin- l -ylethyl)acetamide
2- [4- [4-(methoxymethyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidinyl] - l -pyrrolidin— l -
yl-ethanone
-(4-fluorophenyl)[4-(methoxymethyl)- l -piperidyl] (2-pyrrolidin- l -ylethyl)thieno [2,3 -
d]pyrimidine
2- [ [4- [4-(methoxymethyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidinyl] -(2-pyrrolidin—
l -ylethyl)amino] ethanol
2- [2-hydroxyethyl- [[ l -(5-phenylthieno [2,3 imidin—4-yl)
piperidyl]methyl]amino] ethanol
N— [[ l -(5-phenylthieno [2,3 -d]pyrimidin—4-yl)piperidyl]methyl]propan—2-amine
l- [4- [4-(dimethylamino)- l -piperidyl] phenyl-thieno [2,3 imidinyl]pyrrolidin—3 -ol
1- [5 -phenyl(2-pyrrolidin— l -ylethylamino)thieno [2,3 -d]pyrimidinyl]pyrrolidin—3 -ol
(3 S)- l - [[ l -(5 lthieno [2,3 -d]pyrimidin—4-yl)piperidyl]methyl]pyrrolidin-3 -ol
[1- [4- [4-(methoxymethyl)- l -piperidyl] phenyl-thieno [2,3 -d]pyrimidinyl]
piperidyl]methanol
2-meth0xy-N—[[1-[4-[4-(meth0xymethy1)piperidy1]pheny1-thien0[2,3 -d]pyrimidin
piperidy1]methy1]ethanamine
4-[4-(meth0xymethy1)piperidy1]—N—methy1—N—(1-methy1pyrr01idin-3 -y1)pheny1-
thieno [2,3 -d]pyrimidin—2-amine
-cyc10hexy1[4-(meth0xymethy1)piperidy1]—2-piperazin—1-y1-thien0[2,3 -d]pyrimidine
1-(5-pheny1thien0[2,3 -d]pyrimidinyl)(pyrr01idin—1-y1methy1)piperidin—4-01
N—[[1-(5-cyclohexy1thien0[2,3 -d]pyrimidin—4-yl)piperidyl]methyl]pr0pan—2-amine
4-[[1-(5-cyc10hexy1thieno[2,3 -d]pyrimidin—4-y1)piperidyl]methyl] imethy1—
morpholine
4- [4- [(3 1pyrrolidiny1)methy1]pheny1-pyrr01idiny1]pheny1-thien0[2,3 -
d]pyrimidine
2- [5-(4-fluoropheny1)(2-pheny1pyrr01idin— 1 -y1)thien0 [2,3 -d]pyrimidin—2-y1]—N—(2-
pyrrolidiny1ethy1)acetamide
1-[[1-(5-cyc10hexy1thien0[2,3 -d]pyrimidin—4-y1)piperidyl]methyl]pyrr01idin—3 -01
2-[[1-(5-cyc10hexy1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl-(2-
hydroxyethy1)amino]ethanol
N,1-dimethy1—N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidyl]methyl]pyrr01idin—3 -
amine
N—methyl-N— [[ 1 -(5-pheny1thien0[2,3 imidiny1)piperidy1]methyl]tetrahydrofuran—
3 -amine
2-(1-methy1pyrro1idiny1)-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)pyrr01idin—3 -
y1]methy1]ethanamine
N,1-dimethy1—N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)pyrr01idin-3 -
y1]methy1]pyrrolidinamine
N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]pyrr01idin—1-y1-
ethanamine
N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-yl)-3 -piperidy1]methy1]cyclobutanamine
N,N—dimethy1—1-[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)-3 idy1]methyl]piperidin—3 -
amine
N— [ [5-methyl(5-pheny1thien0 [2,3 imidiny1)pyrr01idin—3 -y1]methyl] ( 1 -
methylpyrro1idiny1)ethanamine
2-(1-methy1pyrr01idiny1)-N—[[1-(5-methy1thien0[2,3 -d]pyrimidiny1)pheny1—
pyrrolidin-3 -y1]methy1] ethanamine
1-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methy1]piperidinamine
y1 [4- [ [3 -(triflu0r0methy1)piperidy1]methy1]—1-piperidy1]thieno[2,3 imidine
4-[[1-(5-pheny1thien0[2,3 imidin—4-y1)piperidy1]methy1]piperazinone
4-[4-[(4-methylpiperaziny1)methy1]—1-piperidy1]—5 -pheny1-thieno [2,3 -d]pyrimidine
(3 S)-N,N—dimethyl[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidyl]methyl]piperidin—3-amine
(3R)-N,N—dimethy1—1-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)
piperidyl]methyl]piperidin—3-amine
N',N'-dimethy1-N— [[ 1 -(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1]methy1]propane-
1 ,3 -diamine
5-pheny1 [4- [ [3 -(1-piperidy1)pyrrolidiny1]methy1]—1-piperidy1]thien0[2,3 -d]pyrimidine
2-(1-methy1pyrro1idin—2-y1)-N—[[1-(5-phenylthien0[2,3 -d]pyrimidiny1)azetidin—3 -
y1]methy1]ethanamine
N—[[1-(5 ,6-dimethy1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl] ( 1 -methy1pyrr01idin—
thanamine
2-(1-methy1imidazoly1)-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidy1]methy1]ethanamine
N,N—dimethy1—1-[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidyl]piperidin—4-amine
1-methy1—N—[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidyl]piperidinamine
N—[2-(1-methy1pyrro1idin—2-y1)ethyl](5-pheny1thien0[2,3 -d]pyrimidiny1)piperidine
carboxamide
1-[4-[4-[[2-dimethylaminoethy1(methy1)amin0]methy1]piperidyl]pheny1-thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
N—[1-[4-[4-[[methy1—(1-methy1pyrrolidin-3 -y1)amin0]methy1] piperidy1] pheny1-
thieno [2,3 imidin—2-y1]pyrro1idin—3 -y1] acetamide
N—methyl[4-[4-[[methy1—(1-methy1pyrrolidin-3 -y1)amino]methy1] piperidy1] pheny1-
thieno [2,3 -d]pyrimidin—2-y1]piperidine-3 -carb0xamide
N,N—diethy1—1-[4-[4-[[methy1-(1-methylpyrrolidin-3 -y1)amin0]methy1]—1-piperidy1]—5-
phenyl-thieno [2,3 -d]pyrimidin—2-y1]piperidine-3 xamide
(2R)[4-[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amino]methy1] piperidy1] pheny1-
3 0 thieno [2,3 -d]pyrimidin—2-y1]pyrrolidinecarboxamide
4-[4-(4-methy1piperazin—1-y1)piperidy1]pheny1-thieno[2,3 imidine
N—methyl-N—( 1 -methy1pyrrolidin-3 -y1)(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidin—4-
amine
N—[[1-(5 ,6-dimethy1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]methy1-piperidin—4-
amine
N—[[1-(5 ,6-dimethy1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl](1-methy1
piperidyl)ethanamine
1-[[1-(5 ,6-dimethy1thieno[2,3 -d]pyrimidin—4-y1)piperidyl]methyl] -N,N-dimethy1—
piperidin—3 -amine
1-[4-[4-[[4-(dimethy1amino)piperidy1]methy1]—1-piperidy1]pheny1-thien0[2,3 -
midin—2-y1]pyrrolidinecarb0xamide
1- [4- [4- [ [(3R)-3 -(dimethylamin0)pyrrolidiny1]methy1]—1-piperidy1]pheny1—thien0[2,3 -
d]pyrimidin—2-y1]pyrr01idinecarb0xamide
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 in0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]azetidinecarb0xamide
1- [4- [4- [ l-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]piperidinecarb0xamide
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]piperidinecarboxamide
1- [5 ,6-dimethy1—4-[4-[[2-(1-methy1piperidy1)ethylamin0]methyl]piperidy1]thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
N—methyl-N—[1-[4-[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]—5thieno[2,3-d]pyrimidin—2-yl]piperidy1]acetamide
N—[[1-(5-isopropy1thieno[2,3 -d]pyrimidiny1)piperidy1]methyl](1 -methy1pyrr01idin—
2-y1)ethanamine
2-(1-methy1pyrro1idin—2-y1)-N—[[1-(5-methy1thieno[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
1-[[4-[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amino]methy1] piperidy1] pheny1-thieno [2,3 -
d]pyrimidin—2-y1]methy1]pyrrolidin0ne
1- [5 -is 0pr0py1—4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amino]methy1]
piperidy1]thien0 [2,3 -d]pyrimidin—2-y1]pyrrolidine-3 -carb0xamide
ethy1[[1-(5-phenylthien0[2,3 -d]pyrimidiny1)piperidy1]methy1]piperidine-3 -
3 0 carboxamide
1- [[ 1 -(5 -pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]pyrrolidinecarb0xamide
N—methyl-N—[ 1 - [[ 1 -(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidyl]methyl]pyrr01idin—3 -
y1]acetamide
N—methyl-N—( 1 -methy1pyrrolidin-3 -y1)(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidine
carboxamide
1-methy1[methy1—[[1-(5-phenylthien0[2,3 -d]pyrimidin—4-y1)
dy1]methy1]amino]pyrrolidin—2-0ne
N—methyl-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1]methyl]cyclobutanamine
2-[cyc10buty1-[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidyl]methyl]amino] -N-
methyl-acetamide
N—[l-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidyl]methyl]pyrr01idin—3 -
y1]acetamide
(2S)-N,N—dimethy1 [[ 1 -(5-pheny1thien0 [2,3 -d]pyrimidin—4-y1)
piperidy1]methoxy]propan— 1 -amine
4-[2-(1-methy1pyrro1idin—2-y1)ethoxymethyl]piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
1- [5-pheny1 [4-(2-pyrr01idin— 1 -yleth0xymethy1)piperidy1]thieno [2,3 imidin—2-
y1]pyrr01idine-3 -carb0xamide
-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidyl]thien0[2,3 -d]pyrimidin—2-
y1]pyrr01idin-3 -y1] acetamide
1-[4-[4-(2-m0rph01inoeth0xymethy1)piperidy1]pheny1—thieno[2,3 -d]pyrimidin—2-
y1]pyrr01idine-3 -carb0xamide
N—[ 1 -[4-[4-(2-m0rph01inoethoxymethy1)piperidy1] pheny1—thieno[2,3 -d]pyrimidin
y1]pyrr01idin-3 -y1] acetamide
N—methyl-l-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidyl]methy1amino]cyclobutanecarboxamide
1- [4- [2- [[ 1 -(5 -pheny1thien0 [2,3 -d]pyrimidiny1)piperidy1]methoxy]ethyl]piperazin—1-
yl] ethanone
-pheny1 [(3R)-3 -(2-pyrr01idin—1-ylethoxymethy1)pyrr01idiny1]thien0[2,3 imidine
y1 [(3 S)-3 -(2-pyrr01idin—1-ylethoxymethy1)pyrr01idiny1]thien0[2,3 -d]pyrimidine
isopropy1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -d]pyrimidine-
6-carboxamide
5-isopropy1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -d]pyrimidine
N—[[1-(6-brom0pheny1—thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl] -N, 1 -dimethy1—
pyrrolidin-3 -amine
1-(5-pheny1thien0 [2,3 -d]pyrimidiny1)-N—(2-pyrrolidin— 1 -ylethy1)piperidine
carboxamide
1-(5-pheny1thien0[2,3 -d]pyrimidiny1)-N—(2-pyrr01idin—1-ylethy1)piperidine-3 -
carboxamide
-pheny1 [3 rr01idin—1-ylethoxy)pyrrolidiny1]thieno[2,3 -d]pyrimidine
1-(5-pheny1thien0[2,3 -d]pyrimidiny1)-N—(2-pyrrolidin— 1 -ylethy1)pyrrolidine-3 -
carboxamide
-pheny1[4-(2-pyrr01idin—1-yleth0xy)piperidy1]thien0[2,3 -d]pyrimidine
-pheny1 [3 -(2-pyrr01idin—1-yleth0xy)piperidy1]thien0[2,3 -d]pyrimidine
-pheny1 [3 rr01idin—1-yleth0xymethy1)azetidin—1-y1]thien0[2,3 -d]pyrimidine
heny1—2-[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidin—4-
y1]pyrr01idine-3 -carb0xamide
N,N-dimethy1pheny1[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thieno[2,3 -
d]pyrimidin—4-amine
4-[5-pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—4-
yl]m0rph01ine
(2S) [2- [ [3 - [5 -(4-flu0r0pheny1)thieno [2,3 -d]pyrimidin—4-y1]—3 -azabicyc10 [3 . 1 an—6-
y1]meth0xy]ethy1]pyrr01idinecarboxamide
-(4-fluoropheny1) [6- [2- [(3R)-3 -fluor0pyrr01idin— 1 -y1]eth0xymethy1]—3 -
azabicyc10[3.1.0]hexan—3-y1]thien0[2,3-d]pyrimidine
2-ch10r0—5-(4-fluoropheny1) [4-(2-pyrr01idinyleth0xymethy1)piperidy1]thieno [2,3 -
d]pyrimidine
N—(2-hydroxyethy1)pheny1[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
[5-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-
han01
N—methyl-N—( 1 -methy1pyrrolidin-3 -y1)(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidine-3 -
carboxamide
-cyc10hexy1[4-(2-pyrr01idin—1-yleth0xymethy1)-1 -piperidy1]thieno [2,3 -d]pyrimidine
-pheny1 [5-(2-pyrr01idin— 1 -yleth0xy)azabicyclo [2 .2. 1 n—2-y1]thieno[2,3 -
d]pyrimidine
N—(2-m0rpholinoethy1)(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidinecarb0xamide
y1 [3 -(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2. 1]0ctan—8-y1]thien0[2,3 -
d]pyrimidine
-is 0pr0py1—4- [3 -(2-pyrr01idin— 1 -yleth0xymethy1)azabicyc10 [3 .2. 1 ]0ctan—8-y1]thieno[2,3 -
d]pyrimidine
2012/052842
-isopropy1[5-(2-pyrr01idin—1-yleth0xy)azabicyclo[2.2.1]heptan—2-y1]thien0[2,3-
midine
y1[3-(2-pyrr01idin—1-yleth0xy)azabicyclo[3.2.1]0ctan—8-y1]thieno[2,3-
d]pyrimidine
1-[2-[[2-(5-pheny1thien0[2,3-d]pyrimidin—4-y1)azabicyclo[2.2. 1]heptan—5-
yl] oxy] ethy1]pyrr01idine-3 -carb0xamide
4-[5-[2-[(3 S)flu0r0pyrrolidiny1]ethoxy]azabicyc10[2.2.1]heptan—2-y1]—5-pheny1—
thieno[2,3-d]pyrimidine
-[2-[[2-(5-isopropy1thien0 [2,3-d]pyrimidin—4-y1)azabicyclo[2.2. 1]heptan—5 -
yl] oxy] ethyl] 0xa—5-azabicyc10 [2 .2. 1 ]heptane
(2R)[2-[[2-(5-pheny1thieno[2,3-d]pyrimidin—4-y1)azabicyclo[2.2.1]heptan—5-
yl]oxy]ethy1]pyrr0lidinecarb0xamide
4-[5-[2-[(3 S)flu0ropyrrolidiny1]ethoxy]azabicyc10[2.2. 1]heptan—2-y1]isopr0py1-
thieno[2,3-d]pyrimidine
4-[5-[2-[(3R)fluor0pyrrolidin—1-y1]ethoxy]azabicyclo[2.2.1]heptan—2-y1]isopr0py1—
thieno[2,3-d]pyrimidine
-pheny1 [4-(3 -pyrr01idin—1-y1pr0p0xy)piperidy1]thien0[2,3 -d]pyrimidine
-isopr0py1—4-[3-(2-pyrr01idin—1-yleth0xy)azabicyclo[3.2.1]0ctan—8-y1]thien0[2,3-
d]pyrimidine
[8-(4-m0rph01in0pheny1-thien0[2,3-d]pyrimidin—2-y1)azabicyclo[3.2.1]0ctan—3-
y1]methan01
8-[4-[4-(meth0xymethy1)- 1 idy1]pheny1-thieno[2,3-d]pyrimidiny1]—8-
azabicyclo[3.2.1]0ctan—3-01
4-[2-[3-(meth0xymethy1)azabicyc10[3.2.1]0ctan—8-y1]pheny1-thieno[2,3-d]pyrimidin—4-
yl]m0rph01ine
8-[2-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—4-y1]—3 -0xa
azabicyclo[3.2.1]0ctane
3 -methy1—N— [5-pheny1—2- [4-(2-pyrr01idin— 1 -yleth0xymethy1)piperidy1]thieno [2,3 -
d]pyrimidin—6-y1]butanamide
2-methy1—N—[5-pheny1—2-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidiny1]pr0panamide
4-[5-pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 imidin—4-
yl]morpholinecarboxamide
1-(4-m0rph01inopheny1-thieno[2,3-d]pyrimidiny1)pyrr01idinecarb0xamide
2-(2-azabicyc10[2.2.1]heptan—5-y10xy)[4-(methoxymethy1)piperidy1]—5-pheny1-
thieno [2,3 -d]pyrimidine
-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]fur0[2,3 -d]pyrimidine
1- [4-(2-oxaazabicyc10 [2 .2. 1 ]heptan—5-y1)pheny1—thieno [2,3 -d]pyrimidin
y1]pyrr01idine-3 -carb0xamide
1- [4- [3 -(hydroxymethy1)azabicyclo [3 .2. 1 ]0ctan—8 -y1] pheny1-thieno [2,3 -d]pyrimidin—2-
y1]pyrr01idine-3 -carb0xamide
-(4-pyridy1)[4-(2-pyrr01idin—1-yleth0xymethy1)-1 -piperidy1]thieno [2,3 -d]pyrimidine
-(3 -meth0xypheny1)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidine
4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]—5-[3 -
(trifluoromethoxy)phenyl]thieno [2,3 -d]pyrimidine
y1[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thien0[2,3 imidin—2-amine
-(3 -fury1)[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thien0[2,3 -d]pyrimidine
5-(2-meth0xy—3 -pyridy1)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -
d]pyrimidine
4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]—5-(3 -thieny1)thien0 [2,3 -d]pyrimidine
N—tert-butylmethy1—4-(5-pheny1thien0 [2,3 -d]pyrimidin—4-y1)but-3 -ynamine
-(1 ,3 di0x01—5-y1)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidine
-(2-pyridy1)[4-(2-pyrr01idin—1-yleth0xymethy1)-1 -piperidy1]thieno [2,3 -d]pyrimidine
N—cyclobutyl(2-cyc10pr0py1—5-pheny1—thieno[2,3 imidin—4-yl)
azabicyc10[3.2.1]0ctan—3-amine
4- [3 -(azetidin—1-y1)azabicyclo[3.2. n—8-y1]cyc10pr0py1—5-pheny1—thieno[2,3 -
d]pyrimidine
N—[[8-(5-pheny1thien0 [2,3 -d]pyrimidin—4-y1)azabicyclo[3.2.1]0ctan—3 -
y1]methy1]cyclobutanamine
-(3 -pyridy1)[4-(2-pyrr01idin—1-yleth0xymethy1)-1 -piperidy1]thieno [2,3 -d]pyrimidine
N—cyclobutyl-S-(S-pheny1thieno [2,3 imidin—4-y1)azabicyclo [3 .2. 1 ]octan—3 -amine
4- [3 -(azetidin—1-y1)azabicyclo[3.2. 1]0ctan—8-y1]—5 -pheny1-thieno [2,3 -d]pyrimidine
N—isopropy1(5-pheny1thien0 [2,3 -d]pyrimidin—4-y1)azabicyc10[3.2.1]0ctan—3-amine
-(2-isopropoxy-3 -pyridy1)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -
d]pyrimidine
-(2-meth0xypheny1)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidine
N,N—dimethy1[4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—
-y1]benzamide
th0xy-3 -pyridy1)[4-(2-pyrr01idinyleth0xymethyl)piperidy1]thieno[2,3 -
midine
N,N—dimethy1[4-[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thieno[2,3 -d]pyrimidin—
-y1]benzamide
2-methy1-N—[[8-(5-pheny1thien0[2,3-d]pyrimidin—4-y1)azabicyclo[3 .2. 1 —3-
yl]methy1]propan—2-amine
N—[[8-(5-pheny1thieno[2,3-d]pyrimidin—4-yl)azabicyc10[3.2. 1]octan—3-y1]methy1]propan—
2-amine
-pheny1—4-[3-(pyrr01idiny1methy1)azabicyclo[3.2. 1]0ctan—8-y1]thieno[2,3-
d]pyrimidine
4- ny1—2-(trifluor0methy1)thieno [2,3 -d]pyrimidin—4-y1]morpholine
1-[4-[3-(cyc10butylamin0)azabicyclo[3.2.1]octany1]pheny1-thieno[2,3-d]pyrimidin-
2-y1]pyrr01idinecarb0xamide
4-[3-(cyc10butylamin0)azabicyclo[3.2.1]0ctan—8-y1]pheny1—thien0[2,3-d]pyrimidine
carbonitrile
4-[3-(cyc10buty1amino)azabicyclo[3.2. 1]0ctan—8-y1]-N,N-dimethy1pheny1—thieno[2,3-
d]pyrimidinecarboxamide
-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidyl](trifluor0methy1)thien0[2,3 -
d]pyrimidine
N—cyclobutyl-S- [5 - [2-(trifluoromethoxy)pheny1]thieno [2,3 -d]pyrimidiny1]—8-
azabicyc10[3.2.1]0ctan—3-amine
N—cyclobutyl[5-(2-meth0xyphenyl)thien0[2,3-d]pyrimidin—4-y1]—8-
azabicyc10[3.2.1]0ctan—3-amine
4-[3-(cyc10butylamin0)azabicyclo[3.2. 1]octan—8-y1]-N-methy1—5-pheny1—thieno[2,3-
d]pyrimidinecarboxamide
N—cyclobutyl-S-[5-(0-t01y1)thieno[2,3-d]pyrimidiny1]azabicyclo[3.2.1]0ctan—3-amine
N—cyclobutyl[5-(2-meth0xypyridy1)thien0[2,3-d]pyrimidin—4-y1]—8-
azabicyc10[3.2.1]0ctan—3-amine
N—cyclobutyl-S-[5-(5-fluor0methoxypyridy1)thieno[2,3-d]pyrimidin—4-yl]—8-
azabicyc10[3.2.1]0ctan—3-amine
4- [3 - [cyclobutyl(methy1)amin0] azabicyclo [3 .2. 1 ]0ctan—8-y1] imethy1—5-pheny1-
thieno[2,3-d]pyrimidinecarboxamide
2-(2-azabicyc10[2.2.1]heptan—5-yloxy)[3-meth0xyazabicyc10[3.2.1]0ctan—8-y1]—5-
phenyl-thieno [2,3 -d]pyrimidine
8-[2-(2-azabicyc10[2.2.1]heptan—5-y10xy)pheny1-thieno[2,3-d]pyrimidin—4-yl]0xa
azabicyclo[3.2.1]0ctane
N—cyclobutyl[5-(2-methoxypheny1)thieno[2,3-d]pyrimidin—4-yl]-N-methy1
azabicyc10[3.2.1]0ctan—3-amine
N—cyclobutyl-S- [5-(2-meth0xy-3 -pyridy1)thieno [2,3 -d]pyrimidin—4-y1]-N-methy1—8-
azabicyc10[3.2.1]0ctan—3-amine
2-(2-azabicyc10[2.2.1]heptan—5-yloxy)[3-(meth0xymethy1)azabicyclo[3.2.1]0ctan—8-
yl] pheny1-thieno [2,3 imidine
N,N—dimethy1—5-pheny1—4-[3-pyrr01idin—1-y1azabicyc10[3.2.1]0ctan—8-yl]thien0[2,3-
d]pyrimidinecarboxamide
N—isopropyl-S-pheny1[3-pyrr01idin—1-y1azabicyclo[3.2. 1]0ctan—8-y1]thieno[2,3-
d]pyrimidinecarboxamide
N—isopropyl-S-pheny1[3-pyrr01idin—1-y1azabicyclo[3.2. 1]0ctan—8-y1]thieno[2,3-
midinecarboxamide
N,N—dimethy1—5-pheny1—4-[3-(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2. n—8-
y1]thieno[2,3-d]pyrimidinecarb0xamide
N—isopropyl-S-pheny1[3-(2-pyrr01idin—1-ylethoxymethyl)azabicyclo[3.2.1]0ctan—8-
y1]thieno[2,3-d]pyrimidinecarb0xamide
2-cyc10pr0py1—5-(2-meth0xypheny1)[4-(2-pyrr01idin—1-yleth0xymethy1)
piperidy1]thien0[2,3-d]pyrimidine
N—cyclobutyl-S- [5-pheny1—2-(trifluor0methy1)thien0 [2,3 -d]pyrimidiny1]—8-
azabicyc10[3.2.1]0ctan—3-amine
2-cyc10propy1pheny1—4- [4-(2-pyrr01idin— 1 -yleth0xymethy1)piperidy1]thieno [2,3 -
d]pyrimidine
N—methyl-S-pheny1[3-(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2.1]0ctan—8-
y1]thieno[2,3-d]pyrimidinecarb0xamide
-(2-meth0xypheny1)[3-(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2.1]0ctan—8-
eno[2,3 -d]pyrimidine
-(2-meth0xypyridy1)[3-(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2.1]0ctan—8-
y1]thieno[2,3 -d]pyrimidine
WO 72694
N,N—dimethyl [4- [3 -(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2. 1]0ctan—8-
y1]thieno[2,3 -d]pyrimidiny1]benzamide
(2-methoxypyridy1)thieno[2,3-d]pyrimidin—4-y1]azabicyclo[3.2.1]0ctan—3-
y1]methan01
2-(2-azabicyc10[2.2.1]heptan—5-yloxy)[3-(meth0xymethy1)azabicyclo[3.2.1]0ctan—8-
yl] -N,N-dimethy1—5-pheny1-thien0 [2,3 imidinecarboxamide
N—[[8-[5-(2-meth0xypheny1)thieno[2,3-d]pyrimidin—4-y1]azabicyclo[3.2. 1]0ctan—3-
y1]methy1]cyclobutanamine
1-[5-pheny1—4-[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-
yl]imidazolidin—2-0ne
2-[5-pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-y1]—
1,2-thiazolidine 1,1-di0xide
1-(2-ethy1—5-pheny1-thien0 [2,3 -d]pyrimidin—4-y1)-N,N-dimethy1-piperidin—4-amine
[8-[4-(3-methoxyazabicyclo[3.2.1]octany1)(2-methoxypheny1)thien0[2,3-
d]pyrimidin—2-y1]azabicyclo[3.2. 1]0ctan—3-y1]methan01
8-[4-[3-(meth0xymethy1)azabicyclo[3.2.1]0ctan—8-y1](2-methoxypheny1)thien0[2,3-
d]pyrimidin—2-yl]azabicyc10[3.2.1]0ctan—3-01
1-[5-(2-chlor0pheny1)(3-meth0xyazabicyclo[3.2.1]0ctan—8-y1)thien0[2,3-d]pyrimidin—
2-y1]piperidinecarb0xamide
1-[5-(2-chlor0pheny1)(3-meth0xyazabicyclo[3.2.1]0ctan—8-y1)thien0[2,3-d]pyrimidin—
4-y1]piperidinecarb0xamide
8-[5-(2-ch10r0pheny1)(3-meth0xyazabicyclo[3.2.1]octan—8-y1)thieno[2,3-d]pyrimidin—
2-y1]azabicyclo[3.2.1]0ctan—3-01
1-[4-[3-(meth0xymethy1)azabicyclo[3 .2. 1 ]0ctan—8-y1](2-meth0xypheny1)thien0[2,3-
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
8-[4-(3-meth0xyazabicyclo[3.2.1]octany1)(2-meth0xypheny1)thien0[2,3-
d]pyrimidin—2-y1]azabicyclo[3.2. 1]0ctan—3-01
4-[4-[3-(methoxymethy1)azabicyclo[3 .2. 1 ]0ctan—8-y1](2-meth0xypheny1)thien0[2,3-
d]pyrimidin—2-y1]piperazin—2-one
3-meth0xyazabicyclo[3.2.1]octany1)(2-meth0xypheny1)thien0[2,3-
d]pyrimidin—2-y1]0xaazabicyclo[3 .2. 1]0ctane
4-[4-(3-methoxyazabicyclo[3.2.1]octan—8-y1)(2-meth0xypheny1)thien0[2,3-
d]pyrimidin—2-y1]piperazin—2-one
WO 72694
3-methoxyazabicyclo[3.2.1]octany1)(2-meth0xypheny1)thieno[2,3-
d]pyrimidin—Z-yl]piperidinecarb0xamide
4-[5-(2-chlor0pheny1)(3-meth0xyazabicyclo[3.2. 1]0ctan—8-y1)thien0[2,3-d]pyrimidin—
2-y1]piperazin—2-0ne
4-[5-(2-chlor0pheny1)(3-meth0xyazabicyclo[3.2. 1]0ctan—8-y1)thien0[2,3-d]pyrimidin—
2-y1]piperazine-Z-carboxamide
1-[5-(2-chlor0pheny1)[3-(hydr0xymethy1)azabicyc10[3.2. 1]0ctan—8-y1]thieno[2,3-
d]pyrimidin—4-y1]piperidinecarb0xamide
4-[4-(3-methoxyazabicyclo[3.2.1]octan—8-y1)(2-meth0xypheny1)thien0[2,3-
d]pyrimidin—Z-yl]piperazine-Z-carboxamide
8- [2- [3 -(meth0xymethy1)azabicyclo [3 .2. 1 ]0ctan—8 -y1] (2-meth0xypheny1)thien0 [2,3 -
d]pyrimidin—4-y1]0xaazabicyclo[3 .2. 1]0ctane
1-[4-(3-methoxyazabicyclo[3.2.1]octany1)(2-meth0xypheny1)thieno[2,3-
midin—Z-y1]pyrr01idinecarb0xamide
8-[2-(3-meth0xyazabicyclo[3.2. 1]octany1)(2-meth0xypheny1)thien0[2,3-
d]pyrimidin—4-y1]0xaazabicyclo[3 .2. 1]0ctane
4-[5-(2-meth0xypheny1)(3-0xaazabicyclo[3 .2. 1 ]octan—8-y1)thien0[2,3-d]pyrimidin—2-
y1]piperazine-Z-carboxamide
1-[5-(2-meth0xypheny1)(3-oxaazabicyclo[3.2. n—8-y1)thieno[2,3-d]pyrimidin—2-
y1]piperidinecarb0xamide
8-[5-(2-methoxypheny1)(3-oxaazabicyclo[3 .2. 1 ]octan—8-y1)thien0[2,3-d]pyrimidin—2-
yl azabicyclo[3.2.1]0ctan—3-01
2-meth0xypheny1)(3-oxaazabicyclo[3.2. 1]octan—8-y1)thieno[2,3-d]pyrimidin—2-
yl]pyrr01idinecarb0xamide
8-[5-(2-methoxypheny1)(3-oxaazabicyclo[3 .2. 1 ]octan—8-y1)thien0[2,3-d]pyrimidin—4-
yl]oxaazabicyclo[3.2.1]0ctane
4-[5-(2-meth0xypheny1)(3-0xaazabicyclo[3.2.1]0ctan—8-y1)thieno[2,3-d]pyrimidin—2-
yl]piperazin—2-one
1-[5-(2-meth0xypheny1)(3-oxaazabicyclo[3.2. 1]octan—8-y1)thieno[2,3-d]pyrimidin—2-
yl]pyrr01idin—3-01
4-(3 -meth0xyazabicyclo [3 .2. 1 ]0ctan—8-y1)(2-methoxypheny1)thieno[2,3 -d]pyrimidine-
2-carb0nitrile
4- [3 -(meth0xymethy1)azabicyclo [3 .2. 1 ]0ctan—8-yl] (2-methoxypheny1)thieno [2,3 -
d]pyrimidine-Z-carbonitrile
2,4-bis(3-meth0xyazabicyclo[3.2.1]octany1)(2-methoxypheny1)thien0[2,3-
d]pyrimidine
4-[5-(2-chloropheny1)(3-meth0xyazabicyclo[3.2. 1]0ctan—8-y1)thien0[2,3-d]pyrimidin—
2-y1]morpholine-Z-carboxamide
4-[4-(3-methoxyazabicyclo[3.2.1]octan—8-y1)(2-meth0xypheny1)thien0[2,3-
d]pyrimidin—Z-yl]morpholine-Z-carboxamide
1-[5-(2-chloropheny1)(3-0xaazabicyclo[3.2. 1]octan—8-y1)thieno[2,3-d]pyrimidin—2-
y1]piperidinecarb0xamide
1-[5-(2-chloropheny1)(3-0xaazabicyclo[3.2. 1]octan—8-y1)thieno[2,3-d]pyrimidin—4-
y1]piperidinecarb0xamide
2-chloropheny1)(3-hydr0xyazabicyclo[3.2. 1]0ctan—8-y1)thien0[2,3-d]pyrimidin—
4-y1]pyrr01idinecarb0xamide
4-[2-[3-(hydr0xymethy1)azabicyclo[3.2.1]0ctan—8-y1](2-meth0xypheny1)thieno[2,3-
d]pyrimidin—4-y1]piperazin—2-one
1-[2-(3-hydr0xyazabicyclo[3.2.1]octany1)(2-meth0xypheny1)thien0[2,3-
d]pyrimidin—4-y1]pyrrolidinecarb0xamide
1-[5-(2-chloropheny1)(3-0xaazabicyclo[3.2. 1]octan—8-y1)thieno[2,3-d]pyrimidin—4-
y1]pyrr01idine-3 -carb0xamide
4-[5-(2-chlor0pheny1)(3-0xaazabicyclo[3.2.1]0ctan—8-y1)thien0[2,3-d]pyrimidin—2-
yl]piperazine-Z-carboxamide
4-[5-(2-chlor0pheny1)(3-0xaazabicyclo[3.2.1]0ctan—8-y1)thien0[2,3-d]pyrimidin—4-
yl]piperazine-Z-carboxamide
2-meth0xypheny1)(3-0xaazabicyclo[3 .2. 1 ]octan—8-y1)thien0[2,3-d]pyrimidin—2-
'~<1]morpholine-Z-carboxamide
2-methoxypheny1)(3-0xaazabicyclo[3 .2. 1 —8-y1)thien0[2,3-d]pyrimidin—4-
'~<1]morpholine-Z-carboxamide
4-[5-(2-chlor0pheny1)(3-0xaazabicyclo[3.2.1]0ctan—8-y1)thien0[2,3-d]pyrimidin—2-
'~<1]morpholine-Z-carboxamide
8-[5-(2-ch10r0pheny1)(3-oxaazabicyclo[3 .2. 1 ]octan—8-y1)thieno[2,3-d]pyrimidin—2-y1]—
8-azabicyclo[3.2.1]0ctan—3-01
1-[5-(2-chloropheny1)(3-0xaazabicyclo[3.2. 1]octan—8-y1)thieno[2,3-d]pyrimidin—2-
yl]pyrr01idinecarb0xamide
8-[5-(2-ch10r0pheny1)(3-0xaazabicyclo[3.2.1]0ctan—8-yl)thien0[2,3-d]pyrimidin—4-y1]—
3-oxaazabicyclo[3.2.1]0ctane
WO 72694
4-[5-(2-chloropheny1)(3-oxaazabicyclo[3.2.1]octany1)thieno[2,3-d]pyrimidin
y1]piperazinone
8-[5-(2-chloropheny1)morpholino-thieno[2,3-d]pyrimidiny1]oxa
azabicyclo[3.2.1]octane,
1-[5-(2-chloropheny1)(3-oxaazabicyclo[3.2.1]octany1)thieno[2,3-d]pyrimidin
yl]pyrrolidin—3-ol,
N-[[8-[5-(2-methoxypyridy1)thieno[2,3-d]pyrimidiny1]azabicyclo[3.2.1]octan
yl]methyl] cyclobutanamine.
In one embodiment, the compound of the invention is not 2-[5-pheny1[4-(2-pyrrolidin
ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidiny1] - 1 ,2-thiazolidine 1 ,1-dioxide or
1-(2-ethy1pheny1-thieno [2,3 -d]pyrimidin—4-y1)-N,N-dimethy1-piperidin—4-amine.
In one ment, the compound of the invention is selected from:
4-[4-[2-(1-methy1pyrro1idiny1)ethoxymethy1]piperidy1]pheny1-thieno[2,3 -
d]pyrimidine
-methy1[4-[2-(1-methy1pyrro1idiny1)ethoxymethy1]piperidy1]thieno[2,3 -
d]pyrimidine
4-[4-[2-(1-methy1pyrrolidin—2-y1)ethoxymethyl]piperidy1]thieno[2,3 -d]pyrimidine
5 ,6-dimethy1[4-[2-(1-methy1pyrro1idiny1)ethoxymethy1]piperidy1]thieno[2,3 -
d]pyrimidine
-pheny1[4-(2-pyrrolidin—1-y1ethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidine
4-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] ethy1]morpholine
4-[4-[(1-methy1pyrrolidin—2-y1)methoxymethy1]piperidy1]pheny1-thieno[2,3 -
d]pyrimidine
N,N—dimethy1[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methoxy]propan— 1 -
amine
4-[4-(cyclobutoxymethy1)piperidy1]pheny1-thieno[2,3 -d]pyrimidine
4-[4-[2-(1-methy1piperidy1)ethoxymethy1]piperidy1]pheny1-thieno[2,3 -d]pyrimidine
3 0 methy1[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methoxy]ethanamine
4-[4-[(1-methy1pyrrolidin—3 -y1)oxymethy1]—1-piperidy1]pheny1-thieno[2,3 -d]pyrimidine
4-[4-[(1-methy1piperidyl)oxymethy1]piperidy1]pheny1-thieno[2,3 -d]pyrimidine
1 -(2-dimethy1aminoethyloxymethy1)piperidy1]pheny1-thieno[2,3 -d]pyrimidin
y1]pyrrolidinecarboxamide
4- [4-(isopr0p0xymethy1)piperidy1] pheny1-thieno [2,3 -d]pyrimidine
-pheny1 [4-(tetrahydr0furan—3 methy1)piperidy1]thieno[2,3 -d]pyrimidine
-(3 -fluoropheny1)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -
midine
-ethy1methy1[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thieno[2,3 -d]pyrimidine
4-[2-[[1-(6-isopropy1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy]ethy1]m0rpholine
-(4-fluorophenyl)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidine
4- [2- [[ 1 - [5 -(4-fluor0pheny1)thieno[2,3 -d]pyrimidin—4-y1]—4-
piperidy1]methoxy]ethyl]morpholine
4- [4- [2-(3 -fluor0pyrrolidin—1-y1)eth0xymethy1]—1-piperidyl]pheny1-thien0[2,3 -
d]pyrimidine
4-[2-[[1-(5-ethy1methy1-thien0[2,3 -d]pyrimidiny1)
piperidy1]methoxy]ethyl]morpholine
5-ethy1—6-methy1—4-[4-[2-(1-methy1pyrro1idiny1)ethoxymethy1]piperidy1]thien0[2,3 -
d]pyrimidine
6-isopropy1[4-[2-(1-methy1piperidy1)eth0xymethyl]piperidy1]thieno[2,3 -
d]pyrimidine
4- [4- [2-(3 ,3 r0pyrrolidin—1-y1)eth0xymethy1]—1-piperidy1]pheny1—thien0[2,3 -
d]pyrimidine
-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] ethyl] 0xa—5 -
azabicyc10[2.2. 1]heptane
4-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] ethyl]piperazin—2-one
1-[2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] ethy1]pyrr01idine-3 -
carboxamide
N—[l-[2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-yl)piperidyl]meth0xy] ethy1]pyrr01idin-3 -
y1]acetamide
1-[2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methoxy] pyrrolidine
amide
4- [4- [2- [(3R)-3 -fluoropyrrolidiny1]eth0xymethy1]—1-piperidyl]pheny1-thien0[2,3 -
d]pyrimidine
4- [4- [2- [(3 S)-3 -fluor0pyrrolidiny1]eth0xymethy1]— 1-piperidy1]pheny1—thien0[2,3 -
d]pyrimidine
-ethy1—6-methy1—4-[4-[2-(1-methy1—2-piperidyl)eth0xymethy1]piperidy1]thien0[2,3 -
d]pyrimidine
-(3 pheny1)[4-[2-(1-methylpyrr01idin—2-y1)eth0xymethy1]piperidyl]thien0[2,3 -
d]pyrimidine
-(3 -fluoropheny1)[4-[2-(1-methy1—2-piperidy1)eth0xymethyl]piperidy1]thien0[2,3 -
d]pyrimidine
-pheny1—4-[6-(2-pyrr01idin—1-yleth0xymethy1)azabicyc10[3. 1 .0]hexan—3-y1]thien0[2,3-
d]pyrimidine
4-[2-[[3-(5-pheny1thien0[2,3-d]pyrimidin—4-yl)azabicyc10[3.1.0]hexan—6-
yl]methoxy]ethy1]m0rpholine
4-[6-[2-(1-methy1pyrro1idin—2-y1)eth0xymethy1]azabicyc10[3.1 .0]hexan—3-y1]—5-pheny1-
thieno[2,3-d]pyrimidine
4-[6-[2-[(3 S)flu0r0pyrrolidiny1]ethoxymethyl]azabicyc10[3.1.0]hexan—3-y1]—5-
phenyl-thieno [2,3 -d]pyrimidine
4-[6-[2-[(3R)fluor0pyrrolidin—1-y1]eth0xymethy1]azabicyc10[3.1 .0]hexan—3-y1]—5-
phenyl-thieno [2,3 -d]pyrimidine
(2R)[2-[[3-(5-pheny1thien0[2,3-d]pyrimidin—4-y1)azabicyc10[3. 1 .0]hexan—6-
h0xy]ethy1]pyrr01idinecarboxamide
(2S)[2-[[3-(5-pheny1thien0[2,3-d]pyrimidinyl)azabicyc10[3.1.0]hexan—6-
y1]meth0xy]ethy1]pyrr01idinecarboxamide
N,N—dimethy1[4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—
-y1]benzenesulfonamide
(2R)[2-[[3-[5-(4-flu0r0pheny1)thieno[2,3-d]pyrimidin—4-y1]azabicyc10[3.1 .0]hexan—6-
h0xy]ethy1]pyrr01idinecarboxamide
5-(4-nitropheny1)[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidine
u0r0pheny1)[6-[2-[(3 S)fluor0pyrr01idin— th0xymethy1]—3-
azabicyc10[3.1.0]hexan—3-y1]thien0[2,3-d]pyrimidine
-[2-[[3-[5-(4-fluor0pheny1)thieno[2,3-d]pyrimidin—4-y1]azabicyc10[3.1.0]hexan—6-
y1]meth0xy]ethyl] 0xa—5-azabicyc10 [2 .2. 1 ]heptane
1-cyc10pr0py1-N—[[ 1 -(5-pheny1thieno[2,3-d]pyrimidin—4-y1)
piperidyl]methy1]methanamine
4- [4- [(3 -methy1pyrrolidin—1-y1)methy1]—1-piperidy1]pheny1—thieno[2,3 -d]pyrimidine
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methy1]pr0panamine
2,2-difluor0-N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methyl]ethanamine
2-meth0xy-N—(2-meth0xyethy1)-N—[[ 1 -(5-pheny1thieno[2,3 -d]pyrimidiny1)
dy1]methy1]ethanamine
[1-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)
piperidyl]methy1amino]cyclopentyl]methanol
1- [[ 1 -(5 -pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methy1]piperidin-3 -01
2-pheny1—4-[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidyl]methy1]morpholine
3 -pheny1 [[ 1 -(5-pheny1thien0 [2,3 -d]pyrimidinyl)piperidy1]methylamino]pr0pan—1-01
2-(1-methy1pyrro1idin—2-y1)-N—[[1-(5-phenylthien0[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
2-methy1m0rpholin0-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidyl]methy1]propan— 1 -amine
N,N—dimethy1—1-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methy1]piperidin-3 -
amine
1-(2-fury1)-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]methanamine
N',N'-diisopr0py1—N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]ethane-
1 ,2-diamine
N'-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methyl]ethane-1 ,2-diamine
(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]cyclobutanamine
[1-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]pyrrolidin—2-yl]methanol
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl](2-pyridy1)methanamine
(3 S ,4S)[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methy1] r01idin— 1 -y1-
pyrrolidin-3 -01
4- [4- [(3 xypyrrolidin—1-y1)methy1]—1-piperidy1]pheny1—thien0[2,3 -d]pyrimidine
(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl](2-thieny1)methanamine
4- [4- [ [3 -(4-flu0r0pheny1)pyrrolidin—1-y1]methy1]—1-piperidy1]pheny1—thien0[2,3 -
d]pyrimidine
N,N,N'-trimethy1-N'-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl] ethane-
1 mine
N,N,N'-trimethy1-N'-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methy1]pr0pane-
1,3-diamine
4-[4-(azetidin—1-y1methy1)piperidy1]pheny1—thieno[2,3 -d]pyrimidine
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]cyclopropanamine
N,N—dimethy1—1-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidyl]methyl]piperidin—4-
amine
-pheny1 [4- [(3 -pyrr01idin—1-y1pyrr01idin—1-y1)methy1]—1-piperidy1]thieno[2,3 -
d]pyrimidine
N— [[ 1 - [5-(4-flu0r0pheny1)thieno [2,3 -d]pyrimidin—4-y1]—4-
piperidy1]methy1]cyclopropanamine
N— [[ 1 - [5-(4-flu0r0pheny1)thieno [2,3 -d]pyrimidin—4-yl]piperidy1]methy1]cyclobutanamine
1- [[ 1 - [5 -(4-fluor0pheny1)thieno [2,3 -d]pyrimidin—4-y1] piperidy1]methy1] -N,N-dimethy1—
piperidin—3 -amine
2-(1 -methy1—2-piperidy1)-N—[[ 1 -(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)
piperidy1]methy1]ethanamine
(3R)-N,N—dimethy1—1-[[1-(5-pheny1thieno[2,3 imidin—4-y1)
piperidyl]methy1]pyrrolidinamine
tert-butyl2-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)
piperidyl]methylamino]ethy1]pyrr01idinecarb0xylate
N—methyl[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1] -N-(pyrr01idin—2-
ylmethyl)methanamine
N—[(1-methy1pyrro1idin—2-y1)methy1][1-(5-pheny1thien0[2,3 imidin—4-y1)
dy1]methanamine
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]pyrr01idin—2-y1—
ethanamine
N—methyl-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1]methyl]pyrr01idin—2-
anamine
2-(1-ethy1pyrr01idin—2-y1)-N-methy1-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)
piperidy1]methy1]ethanamine
2-(1-is0pr0py1pyrrolidin—2-yl)-N-methy1—N—[[1-(5-pheny1thieno[2,3 imidin—4-y1)
piperidy1]methy1]ethanamine
1-[2-[2-[methy1—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)
piperidyl]methyl]amino] pyrr01idiny1] ethanone
(3 S)[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]piperidin—3-amine
1-methy1[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methylamino]pyrrolidin—
2-one
4- [4- [ [(3 S)-3 -flu0r0pyrrolidiny1]methy1]—1-piperidyl]pheny1-thieno[2,3 -d]pyrimidine
2-[methy1—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methy1]amino]
pyrrolidiny1-ethan0ne
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperidy1]methy1]pr0penamine
WO 72694
[1-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]pyrr01idin—3 -y1]methan01
N—[1-[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1] cyclopropanamine
1-methy1—N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidyl]methy1]piperidin
amine
(2,5-dimethy1pyrr01idin— 1 -y1)methy1]— 1 -piperidy1]pheny1—thieno[2,3 -d]pyrimidine
-pheny1—4-[4-[[4-(triflu0r0methy1)piperidy1]methy1]—1-piperidyl]thien0[2,3 -d]pyrimidine
2-[(2S)methy1pyrrolidin—2-y1]-N-[[1-(5-phenylthien0[2,3 -d]pyrimidin—4-y1)
piperidy1]methy1]ethanamine
N—methy1(1-methy1pyrr01idin—2-y1)-N—[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
N—[[1-(5-pheny1thieno[2,3 -d]pyrimidin—4-y1)piperidyl]methyl] tetrahydr0furan—2-y1-
ethanamine
2-cyc10pr0py1—N—[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methyl]ethanamine
2-(1-methy1pyrrolidin—3 -y1)-N-[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
2-[[1-(5-pheny1thien0[2,3 -d]pyrimidin—4-y1)piperidy1]methylamino]pyrr01idin—1-y1—
ethanone
(2S)[[1-(5-pheny1thien0[2,3 -d]pyrimidiny1)piperidy1]methy1]pyrrolidine
carboxamide
2-[2-hydr0xyethy1-[[1-[2-(4-methy1piperazin—1-y1)-5 -pheny1-thieno [2,3 -d]pyrimidiny1]—4-
dyl]methy1]amino] ethanol
4-[4-[(isopropylamin0)methy1]piperidy1]pheny1—N—(2-pyrr01idin—1-y1ethy1)thien0[2,3 -
d]pyrimidin—2-amine
4- [4- [(2-meth0xyethylamino)methy1] piperidy1] pheny1-N—(2-pyrr01idin— 1 -
ylethy1)thien0[2,3 -d]pyrimidin—2-amine
4-[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—N—(2-
pyrrolidiny1ethy1)thien0[2,3 -d]pyrimidin—2-amine
N,1-dimethy1—N—[[1-[2-(4-methy1piperazin—1-y1)pheny1—thien0[2,3 -d]pyrimidin—4-y1]—4-
piperidyl]methy1]pyrrolidinamine
N,1-dimethy1—N—[[1-(5-pheny1—2-piperazin—1-y1-thieno[2,3 -d]pyrimidiny1)
piperidyl]methy1]pyrrolidinamine
-[2-(4-methy1piperazin—1-y1)pheny1—thien0[2,3 -d]pyrimidiny1]—4-
piperidy1]methy1amin0]cyclopentyl]methanol
N—[[1-[2-(4-methy1piperazin—1-y1)pheny1—thien0[2,3 -d]pyrimidiny1]—4-
dy1]methyl] ( 1 -methylpyrr01idin—2-y1)ethanamine
methy1—1-[[1-[2-(4-methy1piperazin—1-y1)pheny1—thieno[2,3 -d]pyrimidin—4-y1]—4-
piperidyl]methyl]piperidin—3-amine
N—[[1-[2-(4-methy1piperazin—1-y1)pheny1—thien0[2,3 -d]pyrimidiny1]—4-
piperidyl]methyl]cyclobutanamine
4- [4- [ [3 -(dimethy1amin0)piperidy1]methy1] - 1 idy1] pheny1—N—(2-pyrrolidin
ylethy1)thien0[2,3 -d]pyrimidin—2-amine
ethoxyethy1) [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]—5-
phenyl-thieno [2,3 -d]pyrimidin—2-amine
N—(cyclopropylmethy1)[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]—
-pheny1-thieno [2,3 -d]pyrimidinamine
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
2-[methyl-[4-[4-[[methy1—(1-methy1pyrr01idin—3 -y1)amin0]methy1] piperidy1] pheny1-
thieno [2,3 -d]pyrimidin—2-y1] amino] acetamide
N—[[1-[2-[4-(2-methoxyethyl)piperazin—1-y1]pheny1-thieno[2,3 -d]pyrimidiny1]—4-
piperidy1]methyl] -N, 1 -dimethy1—pyrrolidin—3 -amine
1- [4- [4- [ [3 -(dimethy1amino)- 1 idy1]methy1] piperidy1] pheny1-thien0 [2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
4- [4- [ [3 thy1amin0)piperidy1]methy1] piperidy1] -N-(2-methoxyethy1)pheny1-
thieno [2,3 -d]pyrimidin—2-amine
4-[4-[4-[(cyclobutylamino)methy1]piperidy1]pheny1-thieno[2,3 -d]pyrimidin—2-
yl]piperazin—2-one
4-[4-[(cyclobutylamino)methyl]piperidy1]-N-(2-meth0xyethy1)pheny1—thieno[2,3 -
d]pyrimidin—2-amine
4-[4-[(cyclobutylamin0)methyl]piperidy1]pheny1—N—(2-pyrrolidin—1-ylethy1)thieno[2,3 -
d]pyrimidin—2-amine
1-[4-[4-[(cyclobutylamin0)methyl]piperidy1]pheny1—thieno[2,3 imidin—2-
y1]pyrr01idine-3 -carb0xamide
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]piperidinecarboxamide
1- [4- [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1]—1-piperidy1]pheny1—thieno[2,3 -
d]pyrimidin—2-y1]pyrrolidinecarb0xamide
N—methy1 [4- [ [methyl-( 1 -methy1pyrr01idin—3 -y1)amin0]methy1] piperidy1] pheny1-
thieno [2,3 -d]pyrimidinecarboxamide
N—isopropy1 [4- [ [methyl-( 1 -methy1pyrrolidin-3 -y1)amino]methy1] piperidy1] ny1-
thieno [2,3 -d]pyrimidinecarboxamide
-isopropyl-N,N—dimethy1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
-isopr0py1—N—methy1—4-[4-(2-pyrrolidinylethoxymethy1)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
N,N—dimethy1phenyl[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
N,N—dimethy1—4-[4-[[methy1-(1-methy1pyrr01idiny1)amino]methy1] piperidy1] pheny1—
thieno [2,3 -d]pyrimidinecarboxamide
-(3 -flu0r0pheny1)-N—isopropy1[4-(2-pyrr01idin— 1 -yleth0xymethy1)
piperidy1]thien0 [2,3 -d]pyrimidinecarboxamide
5-(3 -flu0r0pheny1)-N,N—dimethy1[4-(2-pyrr01idin— 1-ylethoxymethyl)
piperidy1]thien0 [2,3 imidinecarboxamide
[5-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-y1]—
pyrrolidiny1—methanone
N—isopropyl-S-pheny1[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -
d]pyrimidinecarboxamide
N—methyl-S-pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidyl]thien0[2,3 -
d]pyrimidinecarboxamide
3 -pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -b]pyridine
2-brom0pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -b]pyridine
3 -pheny1[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -b]pyridine
carbonitrile
-pheny1—2-[4-(2-pyrr01idin—1-ylethy1)piperaziny1]thien0[2,3 imidine
2-(1-methy1pyrro1idin—2-y1)-N—[[1-(5-phenylthien0[2,3 -d]pyrimidiny1)
piperidy1]methy1]ethanamine
(2R)[2-[4-(5-pheny1thieno[2,3 imidin—2-y1)piperazin— 1 -y1] ethy1]pyrr01idine
amide
-pheny1[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thien0[2,3 imidine
-pheny1 [3 -(2-pyrr01idin—1-ylethoxymethy1)pyrr0lidiny1]thien0[2,3 -d]pyrimidine
(3R)[2-[4-(5-pheny1thieno[2,3 -d]pyrimidiny1)piperazin—1-y1]ethy1]pyrrolidine-3 -
carboxamide
2- [4- [2- [(3R)-3 -fluoropyrrolidiny1]eth0xymethy1]—1-piperidyl]pheny1—thien0[2,3 -
d]pyrimidine
-(4-fluorophenyl)[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thieno[2,3 -
d]pyrimidine
[1-(5-pheny1thien0[2,3 -d]pyrimidin—2-y1)piperidy1]methoxy] ethy1]pyrr01idine-3 -
carboxamide
-[2-[[1-(5-pheny1thieno[2,3 -d]pyrimidin—2-y1)piperidy1]methoxy] ethyl] 0xa—5 -
yc10[2.2. 1]heptane
N—[5-pheny1—2- [4-(2-pyrr01idin— 1 -yleth0xymethy1)piperidy1]thien0[2,3 -d]pyrimidin—6-
y1]acetamide
heny1—2-[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-
yl]pyrr01idin—2-0ne
5-isopr0py1—2-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -d]pyrimidine
1- [5-pheny1—2- [4-(2-pyrr01idin— 1 -yleth0xymethy1)piperidy1]thieno [2,3 -d]pyrimidin—6-
yl]pyrr01idin—2-0ne
-isopr0py1—2-[4-(2-pyrr01idin—1-yleth0xymethy1)piperidy1]thien0[2,3 -d]pyrimidine
4- [3 -[(1-methy1pyrrolidin—3 -y1)methoxy]propyny1]pheny1—thien0[2,3 -d]pyrimidine
5-pheny1—4- [3 -(2-pyrr01idin—1-yleth0xy)pr0pyny1]thien0[2,3 -d]pyrimidine
N—[5-pheny1—4- [4-(2-pyrr01idin— 1 -yleth0xymethy1)- 1 idy1]thieno [2,3 -d]pyrimidin—6-
tamide
1-[5-pheny1—4-[4-(2-pyrr01idin—1-ylethoxymethy1)piperidy1]thieno[2,3 -d]pyrimidin—6-
yl]pyrr01idin—2-0ne
5-pheny1—4- [(1 S ,5R)-3 -(2-pyrr01idin—1-yleth0xymethy1)azabicyclo[3.2.1]0ctan—8-
y1]thieno[2,3 -d]pyrimidine
[8-(4-m0rph01inopheny1—thieno [2,3 -d]pyrimidin—2-y1)azabicyclo [3 .2. 1] octan—3 -
y1]methan01
1-methy1pyrro1idin—2-y1)ethy1](5-pheny1thien0[2,3 -d]pyrimidiny1)piperidine
carboxamide
-pheny1—4-[4-(2-pyrr01idin—1-yleth0xymethyl)piperidy1]thien0[2,3 -d]pyrimidine
carbonitrile and
N—benzyl-S-pheny1[4-(2-pyrr01idinyleth0xymethy1)piperidy1]thien0[2,3 -
d]pyrimidin—6-amine.
In one embodiment, there is a compound of formula (I)
A Z? (I)
? or a pharmaceutically acceptable derivative thereof, wherein:
A is 0 or S;
X is N or CR31i;
V is N or CR31I1;
Z is N or CR3w;
? wherein one or two of V, X and Z are N;
R' is selected from optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted aryl, and optionally substituted heteroaryl;
R2 is selected from H, halo, —CN, trifluoromethyl, optionally substituted alkyl, optionally
substituted alkoxy, , —NR6C(0)R7, —NR6S(0)2R7, —S(0)2NR4R5, —CONR4R5, —0O2127,
? optionally substituted oxazolinyl, —SR14, —S(0)R14 and —S(0)2R14;
R31 is —(NRaRb)—J;
Each of R311, R3111, and R31V is independently selected from H, halo, —CN, oromethyl,
optionally tuted alkyl, optionally substituted alkoxy, optionally substituted
heterocycloalkoxy, optionally substituted heterocycloalkylalkyl, —NR6C(0)R7, —NR6S(0)2R7, —
? S(0)2NR4R5, —CONR4R5, ally substituted ene—CONR4R5, —CO2R7, —NRI°RI —CE-C—
J, optionally substituted cycloalkyl-J and td)_J,
wherein Ra and Rb are linked to form an optionally substituted 4 to 7 ed
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C i lene, —
NR6—, —0—, or —S(0),—, wherein the optionally bridged, optionally substituted heterocycloalkyl
? ring is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl,
ydro-1,3-oxazinyl, hexahydropyrimidinyl, 1,4-thiazanyl, azepanyl, 1,4-oxaazepanyl, and 1,4-
thieazepanyl;
wherein Rc and Rd are linked to form an optionally substituted 4 to 7 membered
heterocycloalkyl ring, which is optionally bridged by a bond, optionally substituted C1 _2alkylene, —
NR6—, —0—, or —S(0)z--;
J is —(CR12R13)q—L—M—W,
wherein
q is 0, 1 or 2;
L is —0—; and
M is —(CR12R13)t—;
t is 0, 1,2 or 3;
? W is selected from the group ting of optionally substituted alkoxy, optionally
substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and
—NR8R9,
wherein when W is optionally substituted cycloalkyl it may optionally be bridged by a
bond or optionally substituted Ci _2alkylene, and
? wherein when W is optionally substituted heterocycloalkyl it may optionally be bridged by
a bond, optionally substituted Ci_2alkylene, —NR6—, —0—, or —S(0)z—;
z is 0, 1 or 2;
R4 and R5 are, at each instance, independently ed from H, optionally substituted
alkyl, optionally substituted aryl, ally tuted heteroaryl, and optionally substituted
? cycloalkyl, or are linked to form an optionally substituted heterocycloalkyl;
R6 and R7 are, at each instance, independently selected from H and optionally substituted
alkyl, or are linked to form an optionally substituted heterocycloalkyl;
R8 and R9 are, at each instance, independently ed from ally substituted alkyl,
optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted
? heteroaryl, and optionally substituted cycloalkyl;
R1° and R11 are, at each instance, independently selected from H, optionally substituted
alkyl, optionally substituted aryl, optionally tuted heterocycloalkyl, optionally substituted
heteroaryl, and optionally substituted cycloalkyl;
R12 and R13 are, at each instance, independently ed from H, hydroxy, and optionally
? substituted alkyl, or may be linked to form an optionally substituted cycloalkyl ring, or may
together form =0; and
R14 is optionally substituted alkyl,
n the al substituents are independently ed from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NO2, -CN, -CO2H, -CO2C1-
HArbOnterwoven WRPortbl \DCC\IIBR \75887321.doc.x-23/03/2015
6alkyl,? -SO3H,? -SOC1 _6a1kyl,? -S02C1 _6alkyl,? -NHSO2C _6alkyl,? -NC1 _6alkylSO2C _
6alkyl, -SO2NH2, -SO2NHC1 _6alkyl, -SO2N(C1 _6alky1)2, -NHSO2NH2, -NHSO2NHC1 _
6alkyl, -NHSO2N(C1 _6alky1)2, -NC1_6alkylSO2N142, -NCI_6alkylSO2NHCi _6alkyl, -NCI _
6alkylSO2N(Ci 1)2, -C(=0)H, C1 _6alkyl, -NHC(=0)C1 _6alkyl, -NC1 lC(=0)Ci _
6alkyl,? Ci _6alkylenedioxy,? =0,? -N(Ci _
6alkyl)2, -C(=0)NH2, -C(=0)NHC1 _6alkyl, -C(=0)N(Ci _6alky1)2, -NHC(=O)NH2, -NHC(=0)NHCI _
6alkyl, -NHC(=0)N(C1 _6alky1)2, -NC1 _6alkylC(=0)NH2, -NC1 _6alkylC(=0)NHC1 l, -NC
6alkylC(=0)N(C1 _
)2, -C(=NH)NH2, -C(=NH)NHCi _6alkyl, -C(=NH)N(C1 _6alky1)2, -C(=NC1 _6alkyl)NH2, -C(=N
? C1 _6alkyONHC1 _6alkyl, -C(=NC1 _6alkyl)N(C1 _6alky1)2, -C1 _6alkyl, -C3_6cycloalkyl, -C3_6heterocycloa
lkyl, 2-imidazolidinonyl, 1-C1 _6alky1imidazolidinonyl, C1 _6alky1C3_6heterocycloalkyl, aryl,
yl, CI _6alkoxyaryl, -C1 _6alkylene-NHSO2C1 _6alkyl, -C1 _6alkylene-NC1.6alkylS02C1-
6alkyl, -C1 _6alkylene-SO2NH2, -C1 lene-SO2NHC1 _6alkyl, -Ci_6alkylene-SO2N(C1 _6alkyl)2, -
ZtH,? -Ci _6alkylene-ZtH, -Zt-C3_6cycloalkyl, or -C(=0)NHC1 _6alkylene-ZH wherein
? Zt is independently 0, S, NH or N(C1 _6alkyl).
Chemical Groups
Halo
The term en” (or “halo”) includes fluorine, chlorine, bromine and iodine (or ,
, bromo, and iodo).
Alkyl, ne, l, alkynyl, cycloalkyl etc.
The terms “alkyl”, “alkylene99 SE
or “alkynyl” are used herein to refer to both
, alkenyl”,
straight and branched chain acyclic forms. Cyclic analogues thereof are referred to as
cycloalkyl, etc.
The term “alkyl” includes monoyalent, straight or branched, saturated, acyclic hydrocarbyl
groups. Alkyl may be C1_1oalkyl, or C1_6alkyl, or C1_4alkyl. Examples e methyl, ethyl,
n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl.
The term “cycloalkyl” includes monovalent, saturated, cyclic hydrocarbyl .
Cycloalkyl may be C3_10cycloalkyl, or C3_6cycloalkyl. Examples include cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl. A cycloalkyl may optionally be “bridged”, which
occurs when ring carbon atoms are further linked by a bond, or by one or more carbon
atoms. Typical bridges are one or two carbon atoms, e.g. methylene or ethylene groups.
When a ring is bridged, the substituents recited for the ring may also be present on the
bridge.
The term “alkoxy” means alkyl-O-. Examples include methoxy, , n-propoxy, i-
propoxy, n-butoxy, s-butoxy, xy, n-pentoxy, and oxy.
The term “alkenyl” includes monoyalent, straight or branched, unsaturated, acyclic
hydrocarbyl groups haVing at least one carbon-carbon double bond at any point along the
carbon chain and, optionally, no carbon-carbon triple bonds. l may be C2_1oalkenyl, or
C2_6alkenyl, or C2_4alkenyl. es include l and propenyl.
The term “cycloalkenyl” includes monoyalent, lly unsaturated, cyclic hydrocarbyl
groups haVing at least one carbon-carbon double bond and, optionally, no carbon-carbon
triple bonds. Cycloalkenyl may be C3_10cycloalkenyl, or C5_10cycloalkenyl. Examples
include cyclohexenyl and benzocyclohexyl.
The term “alkynyl” includes monoyalent, straight or branched, unsaturated, acyclic
hydrocarbyl groups haVing at least one carbon-carbon triple bond at any point along the
carbon chain and, optionally, no carbon-carbon double bonds. Alkynyl may be C2_10alkynyl,
or C2_6alkynyl, or C2_4alkynyl. Examples include ethynyl and propynyl.
The term ene” includes divalent, straight or branched, saturated, acyclic hydrocarbyl
groups. Alkylene may be C1_1oalkylene, or C1_6alkylene, or C1_4alkylene, such as methylene,
ethylene, n-propylene, i-propylene or t-butylene groups.
The term “alkenylene” es divalent, straight or branched, unsaturated, acyclic
hydrocarbyl groups having at least one carbon-carbon double bond and, optionally, no
carbon-carbon triple bonds. Alkenylene may be C2_1oalkenylene, or kenylene, or
C2_4alkenylene.
Heteroalkyl etc.
The term “heteroalkyl” es alkyl groups in which up to three carbon atoms, or up to
two carbon atoms, or one carbon atom, are each replaced independently by O, S(O)Z (z = 0, l
or 2) or N, provided at least one of the alkyl carbon atoms remains. The alkyl group
may be C-linked or -linked, i.e. it may be linked to the remainder of the molecule
through a carbon atom or through 0, S(O)Z or N.
The term “heterocycloalkyl” includes cycloalkyl groups in which up to three carbon atoms,
or up to two carbon atoms, or one carbon atom, are each replaced independently by O, S(O)Z
or N, provided at least one of the cycloalkyl carbon atoms remains. Examples of
heterocycloalkyl groups include oxiranyl, thiaranyl, aziridinyl, oxetanyl, thiatanyl,
azetidinyl, ydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, tetrahydropyranyl,
tetrahydrothiopyranyl, piperidinyl, l,4-dioxanyl, 1,4-oxathianyl, morpholinyl, ydro-
l,3-oxazinyl, l,4-dithianyl, piperazinyl, dropyrimidinyl, l,4-thiazanyl, oxepanyl,
thiepanyl, azepanyl, l,4-dioxepanyl, athiepanyl, 1,4-oxaazepanyl, 1,4-dithiepanyl,
1,4-thieazepanyl and 1,4-diazepanyl. The cycloalkyl group may be C-linked or N-
linked, i.e. it may be linked to the remainder of the molecule through a carbon atom or
through a nitrogen atom. A heterocycloalkyl may optionally be “bridged”, which occurs
when ring carbon or en atoms are further linked by a bond or one or more atoms (6.g.
C, O, N, or S). Typical s include, but are not limited to, one carbon atom, two carbon
atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. When a ring is
bridged, the substituents recited for the ring may also be present on the bridge. A cycloalkyl
bridged by one or more atoms including a heteroatom (lie. 0, N, or S) may be viewed as a
heterocycloalkyl with a carbon bridge. Examples of bridged heterocycloalkyl groups
include azabicyclohexanyl, (e.g. 3-azabicyclo[3.l.0]hexanyl), azabicycloheptanyl (e.g. 2-
azabicyclo[2.2.l]heptanyl), azabicyclooctanyl (e.g. 8-azabicyclo[3.2.l]octanyl), and 2-oxa—
-azabicyclo[2.2.l]heptane (or 5-aza—2-oxabicyclo[2.2.l]heptane). The values given herein
in terms such as “4 to 7 membered heterocycloalkyl ring” refer specifically to the number of
atoms present in the ring; any ing” atoms are counted separately.
The term “heteroalkenyl” includes alkenyl groups in which up to three carbon atoms, or up
to two carbon atoms, or one carbon atom, are each replaced independently by O, S(O)Z or N,
provided at least one of the l carbon atoms remains. The alkenyl group may be
C-linked or hetero-linked, i.e. it may be linked to the remainder of the molecule through a
carbon atom or through 0, S(O)Z or N.
The term “heterocycloalkenyl” es cycloalkenyl groups in which up to three carbon
atoms, or up to two carbon atoms, or one carbon atom, are each replaced independently by
O, S(O)Z or N, provided at least one of the cycloalkenyl carbon atoms remains. Examples of
heterocycloalkenyl groups include 3,4-dihydro-2H-pyranyl, 5dihydro-2H-pyranyl, 2H-
pyranyl, l,2,3,4-tetrahydropyridinyl and 1,2,5 rahydropyridinyl. The heterocycloalkenyl
group may be C-linked or N-linked, i.e. it may be linked to the remainder of the molecule
h a carbon atom or through a nitrogen atom.
The term “heteroalkynyl” includes alkynyl groups in which up to three carbon atoms, or up
to two carbon atoms, or one carbon atom, are each replaced independently by O, S(O)Z or N,
provided at least one of the alkynyl carbon atoms remains. The heteroalkynyl group may be
C-linked or hetero-linked, i.e. it may be linked to the remainder of the molecule through a
carbon atom or through 0, S(O)Z or N.
The term oalkylene” includes alkylene groups in which up to three carbon atoms, or
up to two carbon atoms, or one carbon atom, are each replaced independently by O, S(O)Z or
N, provided at least one of the alkylene carbon atoms s.
The term “heteroalkenylene” includes alkenylene groups in which up to three carbon atoms,
or up to two carbon atoms, or one carbon atom, are each replaced independently by O, S(O)Z
or N, provided at least one of the alkenylene carbon atoms s.
The term “heterocycloalkoxy” means heterocycloalkyl-O-.
The term “heterocycloalkylalkyl” means alkyl substituted with a heterocycloalkyl group.
Aryl
The term “aryl” includes monoyalent, aromatic, cyclic hydrocarbyl groups, such as phenyl
or naphthyl (e. g. l-naphthyl or 2-naphthyl). In general, the aryl groups may be monocyclic
or polycyclic fused ring aromatic groups. Preferred aryl groups are C6-C14aryl.
Other examples of aryl groups are monoyalent derivatives of aceanthrylene, acenaphthylene,
acephenanthrylene, cene, azulene, chrysene, coronene, thene, fluorene, as-
2012/052842
indacene, s-indacene, indene, alene, ovalene, perylene, ene, phenanthrene,
picene, pleiadene, pyrene, pyranthrene and rubicene.
The term “arylalkyl” means alkyl substituted with an aryl group, 6.g. benzyl.
Heteroaryl
The term “heteroaryl” includes monoyalent, heteroaromatic, cyclic arbyl groups
additionally ning one or more heteroatoms independently selected from O, S, N and
NRN, where RN is selected from H, alkyl (6.g. C1_6alkyl) and cycloalkyl (e.g. C3_6cycloalkyl).
In l, the heteroaryl groups are monocyclic or polycyclic (e.g. bicyclic) fused ring
heteroaromatic groups. A heteroaryl groups may contain 5-13 ring members (preferably 5-10
members) and 1, 2, 3 or 4 ring heteroatoms independently selected from O, S, N and NRN, or
may be a 5, 6, 9 or 10 membered, e. g. 5-membered monocyclic, 6-membered clic, 9-
membered fused-ring bicyclic or 10-membered fused-ring bicyclic.
Monocyclic aromatic groups include heteroaromatic groups containing 5-6 ring
members and 1, 2, 3 or 4 atoms selected from O, S, N or NRN.
Examples of 5-membered monocyclic aryl groups are pyrrolyl, furanyl, thiophenyl,
pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, lyl, 1,2,3 triazolyl, 1,2,4
triazolyl, 1,2,3 oxadiazolyl, 1,2,4 oxadiazolyl, 1,2,5 oxadiazolyl, 1,3,4 oxadiazolyl, 1,3,4
thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5 triazinyl, 1,2,4 triazinyl,
1,2,3 triazinyl and tetrazolyl.
Examples of 6-membered monocyclic heteroaryl groups are pyridinyl, pyridazinyl,
pyrimidinyl and pyrazinyl.
Bicyclic heteroaromatic groups include fused-ring heteroaromatic groups containing 9-13
ring s and 1, 2, 3, 4 or more heteroatoms selected from O, S, N or NRN.
Examples of 9-membered fused-ring bicyclic heteroaryl groups are uranyl,
hiophenyl, indolyl, benzimidazolyl, indazolyl, benzotriazolyl, pyrrolo[2,3-b]pyridinyl,
pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[4,5-
b]pyridinyl, imidazo[4,5-c]pyridinyl, pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3-c]pyridinyl,
pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, isoindolyl, indazolyl, purinyl,
indolininyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrazolo[1,2-a]pyridinyl,
pyrrolo[1 ,2-b]pyridazinyl and imidazo[ 1 ,2-c]pyrimidinyl.
Examples of bered fused-ring bicyclic heteroaryl groups are quinolinyl,
isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 1,6-naphthyridinyl, 1,7-
yridinyl, 1 ,8-naphthyridinyl, 1 ,5 -naphthyridinyl, 2,6-naphthyridinyl, 2,7-
naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-
d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl, [3,4-b]pyrazinyl,
pyrimido[5,4-d]pyrimidinyl, pyrazino[2,3-b]pyrazinyl and pyrimido[4,5-d]pyrimidinyl.
The term “heteroarylalkyl” means alkyl substituted with a heteroaryl group.
General
Unless indicated explicitly otherwise, where combinations of groups are referred to herein as
one moiety, e. g. arylalkyl, the last mentioned group contains the atom by which the moiety
is ed to the rest of the molecule.
Where reference is made to a carbon atom of an alkyl group or other group being replaced
by O, S(O)Z or N, what is ed is that:
—CH— —N—
I 1s replaced by
—CH= is replaced by —N=;
EC-H is replaced by EN; or
—CH2- is replaced by —0—, —S(O)Z— or —NRN-.
By way of clarification, in relation to the above mentioned heteroatom containing groups
(such as heteroalkyl etc.), where a numerical of carbon atoms is given, for instance C3.
6heteroalkyl, what is intended is a group based on C3_6alkyl in which one of more of the 3-6
chain carbon atoms is replaced by O, S(O)Z or N. Accordingly, a C3_6heteroalkyl group, for
example, will contain less than 3-6 chain carbon atoms.
Substitution
Groups of the compounds of the invention (e. g. alkyl, cycloalkyl, , alkenyl,
cycloalkenyl, alkynyl, alkylene, alkenylene, heteroalkyl, heterocycloalkyl, heteroalkenyl,
cycloalkenyl, heteroalkynyl, heteroalkylene, heteroalkenylene, heterocycloalkoxy,
heterocycloalkylalkyl, aryl, arylalkyl, arylheteroalkyl, heteroaryl, heteroarylalkyl or
heteroarylheteroalkyl groups etc.) may be substituted or unsubstituted. Typically,
substitution involves the notional replacement of one or more hydrogen atoms on a
designated atom (e.g. a carbon atom or a nitrogen atom) with one or more substituent groups
(provided that the designated atom’s normal valency is not exceeded), or two en
atoms in the case of substitution by :0. Alternatively, in the case of bivalent substituent
groups such as kylenedioxy, tution involves the notional replacement of a
hydrogen atom on a designated atom and a en atom on an adjacent atom with the
substituent group.
Where an “optionally tuted” group is indeed substituted, there will generally be 1 to 5
substituents on the group, or 1 to 3 substituents, or 1 or 2 tuents, or 1 substituent. The
substituents are independently selected from halo, trihalomethyl, trihaloethyl,
omethoxy, trihaloethoxy, -OH, -NOZ, -CN, -COzH, _6alkyl, -SO3H, -SOC1_
6alkyl, -SOZC1_6alkyl, C1_6alkyl, alkylSOZC1_6alkyl, -SOZNH2, -SOZNHC1_
6alkyl, -SOZN(C1_6alkyl)2, -NHSOZNH2, -NHSOZNHC1_6alkyl, -NHSOZN(C1_6alkyl)2, -NC1_
6alkylSOZNH2, -NC1_6alkylSOZNHC1.6alkyl, -NC1.6alkylSOZN(C1_6alkyl)2, -C(=O)H,
-C(=O)C1_6alkyl, -NHC(=O)C1_6alkyl, -NC1.6alkle(=O)C1_6alkyl, C1_6alkylenedioxy , =O,
-N(C1_6alkyl)2, -C(=O)NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2, -NHC(=O)NH2,
-NHC(=O)NHC1_6alkyl, -NHC(=O)N(C1_6alkyl)2, -NC1_6alkle(=O)NH2, -NC1_
6alkle(=O)NHC1_6alkyl, -NC1_6alkle(=O)N(C1.6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
-C(=NC1.6alkyl)NHC1_6alkyl, 1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl,
eterocycloalkyl, 2-imidazolidinon—3 -yl, l-C1-6alkylimidazolidinon-3 -yl,
C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, -C1-6alkylene—NHSOZC1-6alkyl,
-C1-6alkylene—NC1.6alkylSOZC1_6alkyl, -C1_6alkylene—SOZNH2, lkylene—SOZNHC1_
6alkyl, -C1-6alkylene—SOZN(C1.6alkyl)2, —ZtH, —Zt-C1_6alkyl, -C1_6alkylene—ZIH, —
Zt-C3_6cycloalkyl, or NHC1_6alkylene—ZtH wherein Z1 is independently O, S, NH or
N(C1_6alkyl). lkyl” and “C1_6alkylene” in the above substituents may optionally be
replaced by “C1_6heteroalkyl” and “C1_6heteroalkylene” respectively.
In one embodiment, the tuents are independently selected from halo, trihalomethyl,
trihaloethyl, trihalomethoxy, trihaloethoxy, -OH, -NOZ, -CN, -COzH, -COZC1_6alkyl, -SO3H,
-SOC1_6alkyl, -SOZC1_6alkyl, -NHSOZC1_6alkyl, -NC1_6alkylSOZC1_6alkyl, -SOZNH2,
-SOZNHC1_6alkyl, -SOZN(C1_6alkyl)2, NH2, -NHSOZNHC1_6alkyl, -NHSOZN(C1_
6alkyl)2, -NC1_6alkylSOZNH2, -NC1.6alkylSOZNHC1_6alkyl, -NC1_6alkylSOZN(C1.6alkyl)2,
-C(=O)H, -C(=O)C1_6alkyl, -NHC(=O)C1_6alkyl, -NC1_6alkle(=O)C1.6alkyl, C1-
6alkylenedioxy , =O, -N(C1_6alkyl)2, -C(=O)NH2, -C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2,
-NHC(=O)NH2, -NHC(=O)NHC1_6alkyl, -NHC(=O)N(C1_6alkyl)2, -NC1_6alkle(=O)NH2,
-NC1-6alkle(=O)NHC1.6alkyl, alkle(=O)N(C1.6alkyl)2, -C(=NH)NH2,
-C(=NH)NHC1_6alkyl, -C(=NH)N(C1_6alkyl)2, -C(=NC1_6alkyl)NH2,
-C(=NC1.6alkyl)NHC1_6alkyl, -C(=NC1.6alkyl)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl,
eterocycloalkyl, 2-imidazolidinon—3 -yl, l-C1-6alkylimidazolidinon-3 -yl,
C1-6alkle3.6heterocycloalkyl, aryl, haloaryl, C1_6alkoxyaryl, —ZtH, —Zt-C1_6alkyl, -C1_
6alkylene—ZtH, —Zt-C3_6cycloalkyl, or -C(=O)NHC1_6alkylene—ZtH wherein Z1 is
independently O, S, NH or N(C1_6alkyl). “C1_6alkyl” and “C1_6alkylene” in the above
substituents may optionally be replaced by “C1_6heteroalkyl” and “C1_6heteroalkylene”
respectively.
In another embodiment, the substituents are independently selected from halo, trihalomethyl,
trihaloethyl, -OH, -NOZ, -CN, -COZH, -COZC1_6alkyl, -SO3H, -SOC1_6alkyl, -SOZC1_6alkyl,
-NHSOZC1_6alkyl, -SOZNH2, -SOZNHC1_6alkyl, C1_6alkyl)2, -C(=O)H, C1_
6alkyl, O)C1_6alkyl, -NC1-6alkle(=O)C1_6alkyl, =O, -N(C1_6alkyl)2, -C(=O)NH2,
-C(=O)NHC1_6alkyl, -C(=O)N(C1_6alkyl)2, -C1_6alkyl, -C3_6cycloalkyl, -C3_6heterocycloalkyl,
aryl, haloaryl, —ZtH, —Zt-C1_6alkyl, -C1_6alkylene—ZIH or _6cycloalkyl, wherein Z1 is
independently O, S, NH or N(C1_6alkyl).
Where a group has at least 2 ons which may be tuted, the group may be
substituted by both ends of an alkylene or heteroalkylene chain to form a cyclic moiety.
The molecular weight of the nds of the invention may, optionally, be less than
1000 g/mole, or less than 950 g/mole, or less than 900 g/mole, or less than 850 g/mole, or
less than 800 g/mole, or less than 750 , or less than 700 g/mole, or less than 650
g/mole, or less than 600 g/mole, or less than 550 g/mole, or less than 500 g/mole.
The compounds of the invention may include any isotopes of the atoms comprised in the
compounds. Examples include 2H and 3H, and 13C and 14C.
Pharmaceutically acceptable derivatives
The term “pharmaceutically acceptable derivative” includes any pharmaceutically acceptable
salt, solvate, hydrate or prodrug of a compound of the invention. In one embodiment, the
pharmaceutically acceptable derivatives are pharmaceutically acceptable salts, solvates or
hydrates of a compound of the invention.
The term "pharmaceutically able" is employed herein to refer to those compounds,
materials, compositions, and/or dosage forms which are, within the scope of sound medical
judgment, suitable for use in contact with the tissues of human beings and animals without
excessive toxicity, tion, allergic response, or other problem or complication,
commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts
The term “pharmaceutically acceptable salt” includes a derivative of a compound of the
invention that is a salt prepared from pharmaceutically acceptable xic acids or bases
including inorganic or c acids and bases.
Compounds of the invention which contain basic, e. g. amino, groups are capable of forming
pharmaceutically acceptable salts with acids. Pharmaceutically able acid addition salts
of the compounds of the invention may include, but are not limited to, those of inorganic
acids such as hydrohalic acids (6.g. hydrochloric, hydrobromic and hydroiodic acid), sulfuric
acid, sulfamic acid, nitric acid, and phosphoric acid. Pharmaceutically acceptable acid
addition salts of the nds of the invention may include, but are not limited to, those of
organic acids such as aliphatic, aromatic, carboxylic and sulfonic classes of organic acids,
examples of which include: aliphatic monocarboxylic acids such as formic acid, acetic acid,
propionic acid or c acid; aliphatic hydroxy acids such as lactic acid, citric acid, tartaric
acid or malic acid; oxylic acids such as oxalic acid, maleic acid, hydroxymaleic acid,
fumaric acid or succinic acid; aromatic carboxylic acids such as benzoic acid, p-
chlorobenzoic acid, 2-acetoxybenzoic acid, phenylacetic acid, ylacetic acid or
triphenylacetic acid; aromatic hydroxyl acids such as o-hydroxybenzoic acid, p-
hydroxybenzoic acid, l-hydroxynaphthalenecarboxylic acid or 3 hydroxynaphthalene
carboxylic acid; and sulfonic acids such as methanesulfonic acid, ethanesulfonic acid,
ethanedisulfonic acid, onic acid, benzenesulfonic acid, toluenesulfonic acid. Other
pharmaceutically acceptable acid addition salts of the compounds of the invention include,
but are not limited to, those of ascorbic acid, glycolic acid, onic acid, furoic acid,
glutamic acid, anthranilic acid, salicylic acid, mandelic acid, embonic c) acid,
pantothenic acid, stearic acid, sulfanilic acid, algenic acid, and galacturonic acid.
Compounds of the invention which contain acidic, e.g. carboxyl, groups are capable of
forming pharmaceutically acceptable salts with bases. In one embodiment, pharmaceutically
acceptable basic salts of the nds of the invention include, but are not limited to,
metal salts such as alkali metal or alkaline earth metal salts (e. g. , potassium,
magnesium or calcium salts) and zinc or aluminium salts. In one embodiment,
pharmaceutically acceptable basic salts of the compounds of the invention include, but are
not limited to, salts formed with ammonia or ceutically acceptable organic amines or
heterocyclic bases such as ethanolamines (e.g. diethanolamine), benzylamines, N—methyl-
glucamine, amino acids (6.g. lysine) or pyridine.
lts of acids and bases may also be formed, 6.g. hemisulphate salts.
Pharmaceutically acceptable salts of compounds of the invention may be prepared by
methods well-known in the art. For instance, such salts can be prepared by reacting the free
acid or base forms of these compounds with a stoichiometric amount of the appropriate base
or acid in water or in an c solvent, or in a mixture of the two. Generally, nonaqueous
media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. For a
review of ceutically acceptable salts, see Stahl and Wermuth, Handbook of
Pharmaceutical Salts: Properties, Selection and Use (Wiley-VCH, im, Germany,
2002).
Solvates & hydrates
The compounds of the invention may exist in both unsolvated and solyated forms. The term
“solvate” includes molecular complexes (6. g. crystals) comprising a compound of the
invention and one or more pharmaceutically acceptable solvent molecules such as water or
C1_6 alcohols, e. g. ethanol. The term “hydrate” means a “solvate” where the t is water.
Prodrugs
The invention es prodrugs of the compounds of the invention. Prodrugs are tives
of compounds of the invention (which may have little or no pharmacological activity
themselves), which can, when administered in vivo, be converted into compounds of the
invention.
Prodrugs can, for example, be produced by replacing functionalities present in the
compounds of the invention with riate moieties which are metabolized in vivo to form
a compound of the ion. The design of prodrugs is well-known in the art, as discussed
in Bundgaard, Design of Prodrugs 1985 (Elsevier), The Practice of Medicinal Chemistry
2003, 2nd Ed, 561-585 and Leinweber, Drug Metab. Res. 1987, 18: 379.
Examples of prodrugs of compounds of the invention are esters and amides of the
nds of the invention. For example, where the compound of the invention contains a
ylic acid group ), the hydrogen atom of the carboxylic acid group may be
replaced to form an ester (6.g. the hydrogen atom may be replaced by lkyl). Where the
compound of the invention contains an alcohol group (-OH), the en atom of the
alcohol group may be replaced in order to form an ester (6. g. the hydrogen atom may be
replaced by —C(O)C1_6alkyl. Where the compound of the invention contains a primary or
secondary amino group, one or more hydrogen atoms of the amino group may be replaced in
order to form an amide (e.g. one or more hydrogen atoms may be replaced by -C(O)C1_
6alkyl).
Amorphous & crystallineforms
The compounds of the invention may exist in solid states from amorphous h to
crystalline forms. "Amorphous" refers to a solid form of a molecule, atom, and/or ions that
is not crystalline. Different crystalline forms (“polymorphs”) have the same chemical
composition but different spatial ements of the molecules, atoms, and/or ions forming
the crystal. All such solid forms are included within the invention.
Purity
The compounds of the invention may, subsequent to their ation, be ed and
d to obtain a composition containing an amount by weight equal to or greater than
99% of said nd ("substantially pure" compound), which is then used or formulated as
described .
Isomericforms
Compounds of the invention may exist in one or more geometrical, optical, omeric,
diastereomeric and tautomeric forms, including but not limited to cis- and trans-forms, E-
and Z-forms, R-, S- and meso-forms, keto-, and enol-forms. All such isomeric forms are
included within the invention. The isomeric forms may be in isomerically pure or enriched
form (6.g. one enantiomer may be present in excess, also known as a scalemic mixture), as
well as in mixtures of isomers (e.g. racemic or diastereomeric mixtures).
If one enantiomer is present in a greater amount that its corresponding enantiomer, the
enantiomeric excess may be expressed as a percentage of the whole. For instance, a 98:2
e of one enantiomer to another has a 96 % enantiomeric excess of the first omer.
The enantiomeric excess may be at least 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %,
45 %, 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 % or up to 100 % (Le.
omerically pure, up to the detection limit of purity).
The invention therefore provides:
° stereoisomeric mixtures of compounds of the invention;
0 a diastereomerically enriched or diastereomerically pure isomer of a compound of
the invention; or
° an enantiomerically enriched or enantiomerically pure isomer of a compound of the
invention.
The ses for preparation can utilize racemates, enantiomers, or diastereomers as
starting materials. Where appropriate, isomers can be prepared by the application or
adaptation of known methods (6. g. asymmetric synthesis). When diastereomeric or
enantiomeric products are prepared, they can be separated by conventional methods for
example, chromatographic or fractional crystallization.
ic labeling
The invention includes pharmaceutically acceptable isotopically—labelled compounds of the
invention n one or more atoms are replaced by atoms having the same atomic number,
but an atomic mass or mass number different from the atomic mass or mass number usually
found in nature.
Examples of isotopes suitable for inclusion in the compounds of the invention include
isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as
36Cl, fluorine, such as 18F, iodine, such as 123I and 1251, en, such as 13N and 15N, oxygen,
such as 15O, 17O and 18O, phosphorus, such as 32F, and sulphur, such as 358. Certain
isotopically—labelled compounds of the invention, for example, those incorporating a
radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The
ctive isotopes 3H and 14C are particularly useful for this purpose in view of their ease
of incorporation and ready means of detection. Substitution with r isotopes such as 2H
may afford certain therapeutic advantages resulting from r metabolic stability, for
example, increase in viva half-life or reduced dosage requirements, and hence may be
preferred in some circumstances.
Substitution with on emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in
on Emission Topography (PET) studies for examining ate receptor occupancy.
Isotopically-labelled compounds of the invention can lly be prepared by conventional
techniques known to those skilled in the art or by processes analogous to those described
herein using an appropriate isotopically-labelled reagent in place of the non-labelled reagent
previously employed.
Treatment ofDiseases and Conditions
nds of the invention are inhibitors of Kir3.1 and/or Kir3.4.
The invention provides a compound of the invention for use in therapy. The invention
further provides a pharmaceutical composition comprising a compound of the invention in
combination with a pharmaceutically acceptable excipient.
The invention further provides a method for the treatment of a disease or condition mediated
by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that es inhibition of Kir3.l
and/or Kir3.4 or any heteromultimers thereof, comprising the step of administering a
therapeutically effective amount of a compound of the invention to a patient. The invention
also provides the use of a compound of the ion for the manufacture of a medicament
for the treatment of a disease or condition mediated by Kir3.l and/or Kir3.4 or any
heteromultimers thereof, or that requires inhibition of Kir3.l and/or Kir3.4 or any
multimers thereof The invention also provides a compound of the invention for use in
a method for the ent of a disease or condition ed by Kir3.1 and/or Kir3.4 or any
heteromultimers thereof, or that requires inhibition of Kir3.l and/or Kir3.4 or any
heteromultimers thereof
Preferred compounds of the invention have an IC50 in the Kir3.l/3.4 Electrophysiology
Method (described below) of<100 uM, <10 uM, <3 uM, <l uM, < 100 nM, or <10 nM.
Diseases and conditions mediated by Kiri] and/or 4 or heteromultimers thereof /
requiring inhibition ofKiri] and/or [(173.4 or heteromultimers thereof
The invention is useful for the treatment of a disease or condition mediated by Kir3.1 and/or
Kir3.4 or any heteromultimers thereof, or that requires inhibition of Kir3.l and/or Kir3.4 or
any heteromultimers thereof In particular, the heteromultimer may be the heterotetramer
/3.4. The invention therefore has use in:
0 the treatment of cardiovascular diseases, such as atrial fibrillation (AF), atrial flutter
(AFL), entricular (AV) dysfunction and rial node (SAN) ction;
0 the prevention of recurrence of supraventriclar arrhythmias including AF and AFL;
0 the maintenance of sinus rhythm;
0 the termination and version of supraventriclar arrhythmias;
o the treatment of sinus node dysfunction;
0 the treatment ofAV node dysfunction, including AV block;
0 the treatment of conduction dysfunction;
0 the tion or reversal of atrial structural and ionic remodeling;
o the prevention of thrombosis, oembolism and thromboembolic es, such
as stroke, myocardial infarction, and peripheral vascular diseases;
0 the improvement of cardiac contractility;
o the treatment of metabolic diseases, such as diabetes mellitus;
0 the modulation of neuro-endocrine function;
0 the modulation of the secretion of pituitary hormones;
0 the treatment of neurological and neuropsychiatric disorders, such as pain,
depression, anxiety, attention deficit/hyperactivity disorder and epilepsy; and
o the treatment of cancer, such as breast cancer.
eutic definitions
As used herein, ment” includes curative, modulative (i. e. arresting the pment of
a disease state) and prophylactic treatment. As used , a “patient” means an animal,
such as a mammal, such as a human, in need of treatment.
The amount of the compound of the invention administered should be a therapeutically
effective amount Where the compound or derivative is used for the treatment of a disease or
condition, or its modulation, and a prophylactically effective amount where the compound or
derivative is used for the prevention of a disease or condition.
The term “therapeutically ive amount” used herein refers to the amount of compound
needed to treat or rate a targeted disease or condition. The term ylactically
effective amount” used herein refers to the amount of compound needed to prevent a
targeted disease or condition. The exact dosage will generally be dependent on the patient’s
status at the time of administration. s that may be taken into consideration when
determining dosage include the severity of the e state in the patient, the general health
of the patient, the age, weight, gender, diet, time, frequency and route of administration,
drug ations, reaction sensitivities and the patient’s tolerance or response to therapy.
The precise amount can be determined by routine experimentation, but may ultimately lie
with the judgement of the clinician. Generally, an effective dose will be from 0.01
mg/kg/day (mass of drug compared to mass of patient) to 1000 day, e.g. 1 mg/kg/day
to 100 day.
Compounds of the invention may be administered in a single daily dose, or the total daily
dosage may be administered in divided doses of two, three, or four times daily. The daily
oral dosage of the active ingredient may be between 3 and 600 mg either administered once
daily or in divided doses administered twice daily. Alternatively, the active ingredient may
be administered in doses of 10-20 mg stered twice daily or 40 to 100 mg administered
once daily. Alternatively, the active ingredient may be administered a dose of 12.5 mg twice
a day or 75 mg once a day. Alternatively, the active ingredient may be stered in
doses of 3, 10, 30, 100, 300, and 600 mg administered either once or twice a day.
Compositions may be administered individually to a patient or may be administered in
combination with other agents, drugs or hormones.
stration & Formulation
General
For pharmaceutical use, the compounds of the invention may be administered as a
medicament by enteral or parenteral routes, including intravenous, intramuscular,
subcutaneous, transdermal, airway (aerosol), oral, intranasal, , vaginal and topical
(including buccal and sublingual) administration. The compounds of the invention should be
assessed for their biopharmaceutical properties, such as solubility and solution stability
(across pH), permeability, etc., in order to select the most appropriate dosage form and route
of administration for treatment of the proposed indication.
The compounds of the invention may be administered as crystalline or amorphous products.
The compounds of the ion may be administered alone or in combination with one or
more other compounds of the invention or in ation with one or more other drugs (or
as any combination thereof). Generally, they will be administered as a formulation in
association with one or more ceutically acceptable excipients. The term ient”
includes any ingredient other than the compound(s) of the invention which may impart either
a functional (6. g. drug release rate controlling) and/or a non-functional (e. g. processing aid
or diluent) characteristic to the formulations. The choice of excipient will to a large extent
depend on factors such as the particular mode of administration, the effect of the excipient
on solubility and ity, and the nature of the dosage form.
Typical pharmaceutically acceptable excipients include:
° diluents, e. g. lactose, dextrose, sucrose, ol, sorbitol, cellulose and/or glycine;
° lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or
polyethyleneglycol;
° binders, e.g. ium aluminium silicate, starch paste, gelatin, tragacanth,
methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone;
° disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent
mixtures; and/or
0 absorbants, colorants, flavors and/or sweeteners.
A gh sion of pharmaceutically acceptable excipients is available in Gennaro,
Remington: The Science and Practice of Pharmacy 2000, 20th edition (ISBN: 0683306472).
ingly, the present invention provides a pharmaceutical composition comprising a
compound of the invention and a pharmaceutically acceptable excipient.
Compounds of the invention can also be administered in the form of me ry
systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar
vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol,
stearylamine, or phosphatidylcholines.
Compounds of the invention may also be d with soluble polymers as targetable drug
carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer,
droxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or
hyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the
compounds of the present invention may be coupled to a class of biodegradable polymers
useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic
acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy
butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and
crosslinked or amphipathic block copolymers of hydrogels.
Dosage forms (pharmaceutical compositions) may contain from about 1 milligram to about
500 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions
the active ingredient will typically be present in an amount of about 05-95% by weight
based on the total weight of the composition.
Oral stration
The compounds of the invention may be administered . Oral administration may
involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal,
lingual, or sublingual administration by which the compound enters the blood stream
directly from the mouth.
Formulations suitable for oral administration e solid plugs, solid microparticulates,
olid and liquid (including le phases or dispersed s) such as tablets; soft
or hard capsules containing multi- or nano-particulates, liquids (e. g. aqueous solutions, or
solutions in a digestible oil, such as soybean oil, cottonseed oil or olive oil), emulsions or
powders; lozenges (including liquid-filled); chews; gels; fast sing dosage forms;
powders; granules; films; ovules; sprays; and buccal/mucoadhesive patches.
Formulations suitable for oral administration may also be designed to deliver the compounds
of the invention in an immediate release manner or in a rate-sustaining manner, wherein the
release profile can be delayed, pulsed, controlled, sustained, or delayed and sustained or
modified in such a manner which optimises the therapeutic y of the said compounds.
Means to deliver compounds in a rate-sustaining manner are known in the art and include
slow release polymers that can be formulated with the said compounds to l their
release.
Examples of rate-sustaining polymers include degradable and non-degradable polymers that
can be used to e the said compounds by diffusion or a combination of diffusion and
polymer erosion. Examples of rate-sustaining polymers include hydroxypropyl
cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium
ymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, m gum,
polymethacrylates, polyethylene oxide and polyethylene glycol.
Liquid (including multiple phases and dispersed systems) formulations include emulsions,
suspensions, solutions, , tinctures and elixirs. Such formulations may be presented as
fillers in soft or hard es (made, for example, from gelatin or
hydroxypropylmethylcellulose) and typically se a carrier, for example, water, ethanol,
polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more
emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by
the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in issolving, fast-disintegrating
dosage forms such as those bed in Liang and Chen, Expert Opinion in Therapeutic
Patents 2001, 11(6): 981-986.
The formulation of tablets is discussed in H. man and L. Lachman, Pharmaceutical
Dosage Forms: Tablets 1980, vol. 1 (Marcel Dekker, New York).
Parenteral administration
The compounds of the ion can be administered parenterally.
The compounds of the invention may be administered directly into the blood stream, into
subcutaneous tissue, into muscle, or into an internal organ. Suitable means for administration
include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral,
ternal, intracranial, intramuscular, intrasynovial and subcutaneous. Suitable devices
for administration include needle (including microneedle) injectors, needle-free injectors and
infusion techniques.
Parenteral ations are typically aqueous or oily solutions and may include, as carriers,
water, a le oil, saline, aqueous dextrose (glucose) and related sugar solutions, and/or
glycols such as propylene glycol or hylene glycols. Where the solution is aqueous,
excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts,
carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some
applications, they may be more suitably formulated as a sterile non-aqueous solution or as a
dried form to be used in conjunction with a le vehicle such as sterile, pyrogen-free
water (WFI).
Solutions for parenteral stration may contain a water-soluble salt of the active
ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing
agents such as sodium bisulflte, sodium sulfite, or ic acid, either alone or combined,
are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In
addition, parenteral solutions can contain preservatives, such as benzalkonium de,
methyl- or propylparaben, and butanol.
eral formulations may include implants d from degradable polymers such as
polyesters (i. e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone,
polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be
administered via surgical incision into the subcutaneous , muscular tissue or directly
into specific .
The preparation of parenteral formulations under sterile conditions, for example, by
lyophilisation, may readily be accomplished using standard pharmaceutical techniques well
known to those skilled in the art.
The solubility of compounds of the invention used in the preparation of parenteral solutions
may be increased by the use of appropriate formulation ques, such as the oration
of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and
cyclodextrins.
Inhalation & intranasal administration
The compounds of the invention can be administered intranasally or by inhalation, typically
in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with
lactose, or as a mixed component particle, for example, mixed with olipids, such as
phosphatidylcholine) from a dry powder r, as an aerosol spray from a pressurised
container, pump, spray, atomiser (preferably an er using electrohydrodynamics to
produce a fine mist), or nebuliser, with or without the use of a suitable lant, such as
l,l,l,2-tetrafluoroethane or l,l,l,2,3,3,3-heptafluoropropane, or as nasal drops. For
intranasal use, the powder may comprise a bioadhesive agent, for e, chitosan or
cyclodextrin.
The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or
suspension of the compound(s) of the invention comprising, for e, ethanol, aqueous
ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the
active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic
acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronised to a
size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved
by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling,
supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray
Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and
cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of
the compound of the invention, a suitable powder base such as e or starch and a
performance er such as l leucine, mannitol, or magnesium stearate. The lactose may
be anhydrous or in the form of the monohydrate, ably the . Other suitable
excipients include n, glucose, maltose, sorbitol, l, fructose, sucrose and
trehalose.
Formulations for d/intranasal administration may be formulated to be immediate
and/or modified release using, for example, PGLA. Modified release formulations include
delayed-, ned-, pulsed-, controlled-, targeted and programmed release.
Transa’ermal administration
Suitable formulations for transdermal application include a therapeutically effective amount
of a compound of the invention with carrier. Advantageous rs include absorbable
pharmacologically acceptable solvents to assist passage through the skin of the host.
Characteristically, transdermal devices are in the form of a bandage comprising a backing
member, a reservoir ning the nd optionally with rs, optionally a rate
controlling barrier to deliver the compound of the skin of the host at a controlled and
ermined rate over a prolonged period of time, and means to secure the device to the
skin.
Combination Therapy
A compound of the invention may be administered alone, or may be administered in
combination with another therapeutic agent (i. e. a different agent to the compound of the
invention). The nd of the invention and the other therapeutic agent may be
administered in a therapeutically effective amount.
The compound of the t invention may be administered either simultaneously with, or
before or after, the other eutic agent. The compound of the present ion and the
other therapeutic agent may be administered separately, by the same or different route of
administration, or together in the same pharmaceutical composition.
In one embodiment, the invention provides a product comprising a compound of the
invention and another therapeutic agent as a combined preparation for simultaneous,
separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a
disease or condition mediated by Kir3.l and/or Kir3.4 or any heteromultimers thereof, or that
requires inhibition of Kir3.l and/or Kir3.4 or any heteromultimers f Products provided
as a combined preparation include a composition comprising the compound of the invention
and the other therapeutic agent together in the same pharmaceutical composition, or the
compound of the invention and the other therapeutic agent in separate form, 6. g. in the form
of a kit.
The invention es a ceutical composition comprising a compound of the
invention and another therapeutic agent. Optionally, the pharmaceutical composition may
WO 72694
comprise a pharmaceutically acceptable excipient, as described above in “Administration &
Formulation”.
The invention es a kit comprising two or more te pharmaceutical itions,
at least one of which contains a compound the invention. The kit may comprise means for
separately retaining said compositions, such as a container, divided bottle, or divided foil
packet. An e of such a kit is a blister pack, as typically used for the packaging of
tablets, capsules and the like.
The kit of the invention may be used for stering different dosage forms, for example,
oral and parenteral, for stering the te compositions at different dosage intervals,
or for titrating the separate compositions t one another. To assist compliance, the kit of
the invention typically comprises directions for stration.
In the combination ies of the invention, the compound of the invention and the other
therapeutic agent may be manufactured and/or formulated by the same or different
manufacturers. Moreover, the compound of the invention and the other therapeutic may be
brought together into a combination therapy: (i) prior to release of the combination product
to physicians (e.g. in the case of a kit comprising the compound of the invention and the
other therapeutic agent); (ii) by the physician themselves (or under the guidance of the
physician) shortly before stration; (iii) in the patient themselves, 6. g. during
sequential administration of the compound of the invention and the other therapeutic agent.
The compound of the invention and the other therapeutic agent may be combined in a single
dosage unit. Optionally, they may be formulated such that although the active ingredients
are combined in a single dosage unit, the physical contact between the active ingredients is
minimized. For example, one active ingredient may be enteric coated. By enteric coating
one of the active ingredients, it is possible not only to minimize the contact between the
combined active ingredients, but also, it is possible to control the release of one of these
components in the intestinal tract such that one of these components is not released in
the stomach but rather is released in the ines. One of the active ingredients may also be
coated with a material which effects a sustained-release throughout the gastrointestinal tract
and also serves to minimize physical contact between the ed active ingredients.
Furthermore, the sustained-released component can be additionally enteric coated such that
the release of this component occurs only in the intestine. Still r approach can involve
the formulation of a combination product in which the one component is coated with a
sustained and/or enteric release polymer, and the other component is also coated with a
polymer such as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) or other
appropriate materials as known in the art, in order to further separate the active ents.
The polymer coating serves to form an additional barrier to interaction with the other
component.
Accordingly, the invention es the use of a compound of the invention in the
manufacture of a medicament for treating a disease or condition mediated by Kir3.l and/or
Kir3.4 or any heteromultimers thereof, or that requires inhibition of Kir3.l and/or Kir3.4 or
any heteromultimers thereof, n the medicament is prepared for administration with
another therapeutic agent. The invention also provides the use of another therapeutic agent in
the manufacture of medicament for treating a disease or ion mediated by Kir3.1 and/or
Kir3.4 or any heteromultimers thereof, or that requires inhibition of Kir3.l and/or Kir3.4 or
any heteromultimers thereof, wherein the medicament is prepared for administration with a
compound of the ion.
The ion also provides a compound of the invention for use in a method of treating a
e or condition mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that
requires inhibition of Kir3.l and/or Kir3.4 or any heteromultimers thereof, wherein the
compound of the ion is prepared for administration with another therapeutic agent.
The invention also provides another therapeutic agent for use in a method of treating a
disease or condition mediated by Kir3.1 and/or Kir3.4 or any multimers thereof, or that
requires inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof, wherein the other
therapeutic agent is prepared for administration with a compound of the ion. The
invention also provides a compound of the invention for use in a method of treating a disease
or condition mediated by Kir3.l and/or Kir3.4 or any heteromultimers thereof, or that
requires inhibition of Kir3.l and/or Kir3.4 or any multimers thereof, wherein the
compound of the invention is administered with another therapeutic agent. The invention
also provides another therapeutic agent for use in a method of treating a disease or condition
mediated by Kir3.l and/or Kir3.4 or any heteromultimers thereof, or that requires inhibition
of Kir3.1 and/or Kir3.4 or any heteromultimers thereof, wherein the other eutic agent is
administered with a compound of the invention.
The invention also provides the use of a compound of the invention in the cture of a
medicament for treating a disease or condition mediated by Kir3.l and/or Kir3.4 or any
heteromultimers thereof, or that es inhibition of Kir3.l and/or Kir3.4 or any
heteromultimers thereof, wherein the patient has previously (e.g. within 24 hours) been
treated with another therapeutic agent. The invention also provides the use of another
therapeutic agent in the manufacture of a ment for treating a e or condition
mediated by Kir3.1 and/or K,r3.4 or any heteromultimers thereof, or that requires inhibition of
Kir3.1 and/or Kir3.4 or any heteromultimers thereof, wherein the patient has previously (e.g. within
24 hours) been treated with a compound of the invention.
In one embodiment, the other therapeutic agent is selected from other antiarrhythmic , such
? as n-Williams class 1, class II, class III, or class IV agents, or from other cardiovascular
The reference in this specification to any prior publication (or information derived from it), or to
any matter which is known, is not, and should not be taken as an acknowledgment or admission or
any form of suggestion that that prior ation (or information derived from it) or known matter
? forms part of the common general dge in the field of endeavour to which this specification
relates.
Throughout this specification and the claims which follow, unless the context requires otherwise,
the word "comprise", and variations such as "comprises" and "comprising", will be understood to
imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of
? any other integer or step or group of rs or steps.
Synthesis
Compounds of formula (1) may be prepared by conventional routes, for example those set out in
Schemes 1 to 21 shown below.
SCHEME 1
>,)n
nds of formula (ii) where R31 is NR8R9, —(NRaRb)—J (e.g.? *? ), -CN, or alkoxy
and where R', R2, R8, R9, n, D and J are as defined above may be prepared ing to scheme 1
from compounds of formula (i) via displacement of the 4-chloro substituent by a suitable
nucleophilic s. Typically, this reaction is performed in the presence of a base, for example,
? triethylamine or potassium carbonate, ing standard methods familiar to those skilled in the art
such as reaction in solvents such as tetrahydrofuran, toluene, acetonitrile or dimethylformamide, at
a range of temperatures from ambient to reflux temperature or via microwave irradiation.
SCHEME 2
R1 R31
R1 R3I
/ x / x
R2 / | ——>
R2 / l
Z C1 A \Z R3111
(iii) (iv)
Compounds of formula (iv) Where 11311115 NRloR“, —(NRcRd)—J (e.g. >x< ), -CN, or
alkoxy and where R1, R2, R31, R10, R“, n, D and J are as defined above may be prepared
according to scheme 2 from compounds of formula (iii) via displacement of the 2-chloro
substituent by a suitable nucleophilic species. Typically, this reaction is med in the
presence of a base, for example, triethylamine or potassium carbonate, utilising standard
methods familiar to those skilled in the art such as reaction in solvents such as
ydrofuran, toluene, acetonitrile or dimethylformamide, at a range of temperatures from
ambient to reflux ature or via microwave irradiation.
SCHEME 3
D (a D (a
| |
)n “f )n
R1 N HN—G R1 N
(vii)
/ /
R2 / j\ R24%
A \Z R3 A
III \Z R3
(vi)
nds of a (vi) may be prepared according to scheme 3 by reaction of
compounds of formula (v) Where L* is defined as a suitable leaving group, for example,
bromine, chlorine, iodine, tosylate, or mesylate. Typically, this reaction is performed in the
presence of a base, for e, triethylamine or ium carbonate, utilising standard
methods familiar to those skilled in the art such as reaction in solvent such as
tetrahydrofuran, acetonitrile or dichloromethane at a range of atures from ambient to
reflux temperature or via microwave irradiation. Compounds of formula (vii) are known
compounds or may be prepared by standard published methods familiar to those skilled in
the art.
SCHEME 4
1 N M/W
/ / x
R2 k ( q
A I
Z R3111
(viii) )n
R1 N
| / / x
HN—G R2
O I
// .. \
(V11) A
Z R3HI
(Vi)
R1 N
(1X)
Compounds of formula (vi) where q is 0 or 1 may also be prepared from the corresponding
aldehyde (viii) or ketone (ix) according to scheme 4 via a ive amination. The reaction
may be performed in a one pot procedure with in situ formation and reduction of the imine
or via a two stage s where the imine is isolated and purified prior to reduction. Imine
formation is performed under acid catalysis, suitable catalysts include acetic acid. The
ion may be performed using standard methods such as reaction in solvent such as
tetrahydrofuran, itrile, dichloromethane or toluene at a range of temperatures from -
°C to reflux temperature with a suitable reductant such as sodium triacetoxyborohydride
or sodium cyanoborohydride, the reduction may also be performed using catalytic
hydrogenation or in the presence of phenylsilane and dibutyltin dichloride. Compounds of
formula (vii) are known compounds or may be prepared by standard published methods
familiar to those skilled in the art.
SCHEME 5
D K/
R1 N
/ / x
D (Fq/
I I
)n Z R3111
R1 N (viii)
oxidation //0
/ / x
A R1 N
Z R3111
(1X)
Compounds such as (viii) and (ix) may be prepared from the corresponding alcohols (x)
according to scheme 5 via an oxidation. Typically, this reaction is performed in the presence
of an t, for e, pyridinium chlorochromate or Dess-Martin inane, utilising
standard methods ar to those skilled in the art such as reaction in solvent such as
tetrahydrofuran, acetonitrile or dichloromethane at a range of temperatures from -10°C to
reflux temperature or via ave irradiation.
SCHEME 6
U (L
( q ( q
D D
| |
)n T )n
R1 N OH R1 N
(Xi)
/ ifimfl—> / / x
R2 R2
A xR3111
(xii)
Compounds of formula (xii) may be prepared according to scheme 6 by reaction of
compounds of a (V) Where L* is defined as a suitable leaving group, for example,
bromine, chlorine, iodine, te, or te. It is understood that the reverse case also
holds true in that (V) may bear the hydroxyl and (xi) the g group. Typically, this
reaction is performed in the presence of a base, for example, sodium hydride, sodium
hydroxide or potassium carbonate, utilising standard methods familiar to those d in the
art such as reaction in solvent such as tetrahydrofuran, toluene, acetonitrile or
dimethylformamide, or a mixture of solvents such as toluene/water in the presence of a
phase-transfer catalyst such as tetrabutyl ammonium bromide, at a range of temperatures
from ambient to reflux temperature or via microwave irradiation. Compounds of formula
(xi) are known compounds or may be prepared by standard published methods familiar to
those skilled in the art.
SCHEME 7
OH L*
\ Dr
)n )n
R1 N R1 N
. /
A l A \zrR3111
Compounds of formula (V) where L* is a halogen may be prepared according to scheme 7
from compounds of formula (x) Via reaction with a suitable nating agent. For
example, when L* is bromine, suitable reagents include phosphorous tribromide or
orous oxybromide or when L* is chlorine, le ts include phosphorous
pentachloride, phosphorous oxychloride or l chloride. The halogenation reaction may
also be performed using Appel (Appel R, 1975) conditions in the presence of
carbontetrabromide and triphenylphosphine when L* is bromine, or carbontetrachloride and
triphenylphosphine when L* is chlorine. The halogenation may be performed in solvent such
as tetrahydrofuran, acetonitrile, dichloromethane or e, or in neat t, at a range of
temperatures from -10°C to reflux temperature.
Compounds of formula (V) where L* is an O-alkyl, or O-aryl sulfonyl leaVing group may be
synthesized from compounds of formula (x). Typically, this reaction is performed in the
presence of a suitable sulfonylchloride such as tolunesulfonyl chloride or methanesulfonyl
chloride and in the presence of base such as triethylamine or ium carbonate utilising
standard methods familiar to those skilled in the art such as reaction in solvent such as
tetrahydrofuran, toluene, acetonitrile or dichloromethane at a range of temperatures from -
°C to reflux temperature.
2012/052842
SCHEME 8
OH OH
( q
R1 i j)n K
/ (xiv)
R2 /
R2 l
A \zj\ —> \k
R3III A
(xii)
Compounds of formula (x) may be prepared according to scheme 8 from compounds of
formula (xii). Typically, this reaction is performed in the presence of a base, for example,
triethylamine or potassium carbonate, utilising standard methods familiar to those skilled in
the art such as reaction in solvent such as ydrofuran, toluene, itrile or
dimethylformamide, at a range of temperatures from ambient to reflux temperature or Via
microwave irradiation. Compounds of formula (xiv) are known compounds or may be
prepared by standard published methods ar to those skilled in the art.
SCHEME 9
R1 R3I
Br / ‘
z R3Ill
(xviii)
R1 R3I
/ / Ix
Alkyl '0 A \zAR3111
(XVI)
y NHRARS
NHR4R5
/ / x
\ J\ R3131
HO A
z R3
(XV)
Compounds of formula (xvii) may be prepared according to scheme 9 via the reaction of
compounds of formula (xv) with amines of formula NHR4R5. lly, this reaction is
carried out using a coupling reagent such as l-ethyl(3-dimethylaminopropyl)-
carbodiimide (EDC) or 2-(7-aza—lH—benztriazole-l-yl)-l,l,3,3-tetramethyluronium
orophosphate (HATU) utilising standard methods familiar to those skilled in the art
such as reaction in solvent such as tetrahydrofuran, acetonitrile or dimethylformamide at a
range of temperatures from ambient to reflux temperature.
Compounds of formula (xv) may be prepared according to scheme 9 via hydrolysis of an
alkyl ester. Typically, this reaction is carried out using s acid or base, at a range of
temperatures from ambient to reflux temperature. Suitable acids e hydrochloric acid
and suitable bases include sodium hydroxide or lithium hydroxide.
Compounds of formula (xvii) may also be sised directly from compounds of formula
(xvi) and amines of formula NHR4R5. Typically this reaction is carried out using
hylaluminium utilising standard methods familiar to those skilled in the art such as
reaction in solvent such as tetrahydrofuran, toluene, acetonitrile or dimethylformamide, at a
range of temperatures from ambient to reflux temperature or via microwave irradiation.
Compounds of formula (xvi) may be synthesised from compounds of a (xviii) via
reaction with an organolithium base and reaction of the resulting anion derived from
bromine/lithium ge with a chlorocarbonate, preferably methyl chloroformate.
Compounds of formula (xviii) may be synthesised by adapting procedures found in
W02004/111057.
SCHEME 10
1 RI
/ / Buchwald ion
X \N /
| ——>
0 \ k
A 3
3 O:< 7
(XX)
(XIX)
Compounds of formula (xx) may be prepared according to scheme 10 via the reaction of
compounds of formula (xviii) and amides of form HNC(O)R7 using the procedure of
Buchwald er al. Typically, this on is carried out using a palladium coupling reagent
such as tris(dibenzylideneacetone) dipalladium utilising standard methods familiar to those
d in the art, such as reaction in solvent such as tetrahydrofuran, acetonitrile or
dimethylformamide at a range of temperatures from ambient to reflux temperature or via
microwave irradiation.
SCHEME 11
R1 R1
Zinc
/ / x
R2 :Zj\Cl—> R2 \ZJ\CI
(xxi) (XXll)
R2 / I
Z R3111
(xxiii)
Compounds of formula (xxiii) where R3III is NRIOR“, —(NRcRd)—J (e.g * ), —
CN, or alkoxy and where R1, R2, R10, R11 D and J are as defined above may be prepared
, n,
according to scheme 11 from compounds of formula (xxi) via cement of the 2-chloro
substituent by a suitable nucleophilic species. Typically, this on is performed in the
presence of a base, for example, triethylamine or potassium carbonate, utilising standard
s familiar to those skilled in the art such as reaction in solvents such as
tetrahydrofuran, toluene, acetonitrile or dimethylformamide, at a range of temperatures from
ambient to reflux ature or via microwave irradiation.
Compounds of formula (xxii) may be prepared according to scheme 11 from compounds of
formula (xxi) via selective reduction of the 4-chloro position. Typically, this reaction is
performed in the ce of reducing metal, for example, Zinc, utilising standard methods
familiar to those skilled in the art such as on in solvents such as ethanol in the ce
of aqueous ammonia, at a range of temperatures from ambient to reflux temperature or via
microwave irradiation.
2012/052842
SCHEME 12
1\|/I/
W L
| ( q
( q
Cl ‘ ‘
R1 R1
(XXV)
R2 / I R2 / |
\ \
A A
Z R3111 Z R3111
(XXiV) (XXVi)
nds of formula (XXVi) may be prepared according to scheme 12 via reaction of
compounds of formula (xxiv) with ene compounds of formula (XXV) using the method
of Sonogashira coupling (Chinchilla er al, 2007; Berg er al, 2006). Typically, this reaction
is carried out using a palladium coupling reagent such as tris(dibenzylideneacetone)
dipalladium utilising standard methods familiar to those skilled in the art, such as reaction in
solvent such as tetrahydrofuran, acetonitrile or dimethylformamide at a range of
temperatures from ambient to reflux temperature or via microwave irradiation.
SCHEME 13
W W
M/ M/
OH W O O
(l/61 WK ( q ( q
D L* D D
(xxviii)
(xxx)
11 —> n ' ’ n
N N N
I H
PG PG
(xxvii) (XXiX)
W 1 c1
“I“ R
O / x
R2 /
D S \zlR3111
(xxxi)
(xxxn)..
R1 N
/ / x
R2 |
Z R3111
nds of formula (xxxii) may be prepared according to scheme 13 via reaction of
compounds of formula (xxx) with compounds of formula (xxxi). Typically, this reaction is
performed in the presence of a base, for example, triethylamine or potassium carbonate,
utilising standard methods familiar to those skilled in the art such as reaction in solvents
such as tetrahydrofuran, e, acetonitrile or dimethylformamide, at a range of
temperatures from ambient to reflux temperature or via microwave irradiation.
Compounds of formula (xxx) may be prepared ing to scheme 13 via the deprotection
of nitrogen compounds of a (xxix). Suitable nitrogen protecting groups (PG) are
familiar to those skilled in the art and may e those removed by hydrogenation such as
benzyl, and oxycarbonyl (CBZ) or those removed by ent with acid such as tert-
butoxy carbonyl (BOC). A list of suitable protecting groups may be found in Greene et al
(1999).
Compounds of formula (xxix) may be prepared according to scheme 13 by reaction of
compounds of formula (xxvii) with compounds of formula (xxviii) where L* is defined as a
suitable leaving group, for example, bromine, chlorine, iodine, tosylate, or mesylate. It is
understood that the reverse case also holds true in that (xxviii) may bear the hydroxyl and
(xxvii) the leaving group. Typically, this reaction is performed in the presence of a base, for
example, sodium hydride, sodium hydroxide or potassium carbonate, utilising standard
methods familiar to those skilled in the art such as reaction in solvent such as
ydrofuran, toluene, acetonitrile or ylformamide, or a mixture of solvents such as
toluene/water in the presence of a phase-transfer catalyst such as tetrabutyl ammonium
bromide, at a range of temperatures from ambient to reflux temperature or via ave
irradiation. Compounds of a (xxviii) are known compounds or may be prepared by
standard hed methods familiar to those skilled in the art.
SCHEME 14
RI Br R? R1 R13
/ / X
LDA / / X R—D*
Br I 1 / X
—> —>/ \ | I
A \
Z R3 A 3 \
Z R A Z R3
(XXXV) (XXXiV) i)
Compounds of formula (xxiii) where R1 is aryl or heteroaryl may be prepared from
compounds of formula (xxxiv) via an organometallic cross-coupling reaction. Suitable
reactions for this transformation may include Suzuki couplings, where D* is a boronic acid,
boronic acid ester, or borate salt; or Stille couplings where D* is a trialkyl tin moiety.
Typically, the reaction is performed under catalysis in the presence of a palladium coupling
reagent, for example tetrakis(triphenylphosphine) Palladium(0) and utilising standard
methods ar to those skilled in the art, such as on in solvent such as
tetrahydrofuran, acetonitrile or dimethylformamide at a range of temperatures from ambient
to reflux temperature or via microwave ation.
Compounds of formula (xxxiv) may be prepared from compounds of formula (xxxv) via a
base-catalysed migration of a bromine atom using the method cited in W02004/ 111057.
Suitable bases include organolithium compounds such as m ropyl amide in a
t such as diethyl ether or tetrahydrofuran. The reaction may be performed at a range of
temperatures from -78°C to 0°C.
SCHEME 15
R R1
/ / X
Alkyl—O A
z R1311
(XV!) \
hydmlySis
R1 RI R
o /
/ / X
|)< 4R5 m
\ X RLN \
A 3
HO A 3
(XV)
Compounds of formula (xvii) may be ed according to scheme 15 via the reaction of
compounds of formula (xv) with amines of formula NHR4R5. Typically, this reaction is
d out using a coupling reagent such as 1-ethyl(3-dimethylaminopropyl)-
carbodiimide (EDC) or 2-(7-aza—lH—benztriazole-l-yl)-l,1,3,3-tetramethyluronium
hexafluorophosphate (HATU) utilising standard methods familiar to those d in the art
such as reaction in t such as tetrahydrofuran, acetonitrile or dimethylformamide at a
range of temperatures from ambient to reflux temperature in the presenceof an organic base,
for example, N,N—diisopropylethylamine.
nds of formula (xv) may be prepared according to scheme 15 via hydrolysis of an
alkyl ester. Typically, this reaction is carried out using aqueous acid or base, at a range of
temperatures from ambient to reflux temperature. Suitable acids include hydrochloric acid
and suitable bases include sodium hydroxide or lithium hydroxide. In the case where R3111 is
a substituted alkoxy group and the substitution described in scheme 2 is performed under
ly basic conditions concomitant hydrolysis of the r may also occur to give (xv)
directly. Compounds of formula (xvii) may also be synthesised ly from compounds of
formula (xvi) and amines of formula NHR4R5. Typically this reaction is carried out using
trimethylaluminium utilising standard methods familiar to those skilled in the art such as
reaction in solvent such as tetrahydrofuran, toluene, acetonitrile or dimethylformamide, at a
range of atures from ambient to reflux temperature or via microwave ation.
Compounds of formula (xvi) may be prepared from compounds of formula (xxxVi) using the
methods described in s 1 and 2.
Compounds of formula (xxxVi) may be prepared from compounds of formula (xxxvii) via
treatment with an organlithium base, for example, lithium diisopropylamide in a solvent, for
example, ydrofuran at a range of temperature from -78°C to 0°C and quenching of the
resulting anion with a chlorocarbonate typically methyl chloroformate. Compounds of
formula (xxxvii) may be prepared according to the methods ofW02004/111057.
SCHEME 16
(xxxviii)
Xa R111 1
H2N(xli)
—> /
Compounds of formula (xliii) where R3III is NR10R11,—(NRCRd)—J(e.g >x< ), -CN,
or alkoxy and where R1, R2, R31, R10, R“, n, D and J are as defined above may be prepared
according to scheme 16 from compounds of formula (i) or (xlii) via displacement of a
suitable leaving-group such as a ro or 4-trifluorosulfonate substituent by a suitable
nucleophilic species. Typically, this reaction is performed in the ce of a base, for
example, triethylamine or potassium carbonate, utilising standard methods familiar to those
skilled in the art such as reaction in solvents such as tetrahydrofuran, toluene, acetonitrile or
dimethylformamide, at a range of temperatures from ambient to reflux temperature or via
microwave irradiation.
Compounds of formula (xlii) may be prepared via the reaction of compounds of formula (xl)
with trifluoromethanesulfonic ide in a solvent for example, dichloromethane or
ydrofuran and in the presence of a base, for example, pyridine. Compounds of formula
(i)(a) may be prepared via the reaction of compounds of a (xl) with a suitable
nating agent for example, phosphorous oxychloride or diphenylphosphoryl chloride.
Typically, this reaction is performed in a neat on of the chlorinating reagent at
temperatures ranging from 50°C to reflux temperature.
Compounds of formula (xl) may be prepared via cyclisation of nds of formula
(xxxviii) with an amidate of formula (xxxix). Typically, the on is performed in a
suitable solvent, for example ethanol and at reflux temperature of the t.
Compounds of formula (i) may be prepared via cyclisation of nds of formula
ii) with primary amides of formula (xli) in the presence of a chlorinating agent for
example, phosphorous trichloride. Typically, this reaction is performed in a solvent, for
example toluene at temperatures ranging from 60°C to reflux temperature.
SCHEME 17
Compounds of formula (xlvi) where R3111 is NRIOR“, —(NRcRd)—J (e.g * ), -CN,
or alkoxy and where R1, R2, R31, R10, R“, n, D and J are as defined above may be prepared
according to scheme 17 from compounds of formula (xlv) via displacement of a suitable
leaving-group (L*) for example, an alkyl sulfone, by a suitable nucleophilic species.
lly, this reaction is performed in the presence of a base, for example, triethylamine or
potassium carbonate, utilising rd methods familiar to those skilled in the art such as
reaction in solvents such as ydrofuran, toluene, acetonitrile or dimethylformamide, at a
range of temperatures from ambient to reflux temperature or via microwave ation.
nds of formula (xlvii) may be prepared from compounds of formula (xliv) via
treatment of compounds of formula (xlv) with a suitable reductant, for example, sodium
borohydride in a solvent, for example, ethanol. Typically, this reaction is performed at a
range of temperatures from 0°C to 25°C.
2012/052842
Compounds of formula (xlv) Where R31 is NRSRQ, —(NRaRb)—J (e.g. * ), -CN, or
alkoxy and where R1, R2, R8, R9, n, D and J are as defined above may be prepared according
to scheme l7from compounds of formula (xliv) via displacement of a suitable leaving-group
(L) for example, and alkyl sulfone by a suitable philic species. Typically, this reaction
is performed in the presence of a base, for e, triethylamine or potassium carbonate,
utilising standard methods familiar to those skilled in the art such as reaction in solvents
such as ydrofuran, toluene, acetonitrile or dimethylformamide, at a range of
temperatures from ambient to reflux temperature or via microwave irradiation. Compounds
of formula (xliv) may be prepared according to the methods of W02005/121 149.
SCHEME 18
1 Cl 3
R R1 RI
/ / IN 0
R2 2
/ N o
R /
\ UL
s /Alkyl —* I
N__ o S \N O/Alkyl
(X11111) (liii)
1 Cl i
R1 R13
R /
/ N O
\ J\/\ R2 /
N 0H
(xl1x) \M
N OH
l (liv)
R1 R13 i
/ / R1
\ / N o
NJ\/\
OH R2 /
(lii)
Compounds of formula (lii) may be prepared according to scheme 18 from compounds of
a (li) via displacement of a le leaving-group L* for example, a methansulfonyl,
toluenesulfonyl, iodo, bromo or chloro group by a suitable nucleophile Nuc-H, for e,
an amino or alkoxy group. Typically, this reaction is performed in the presence of a base, for
example, triethylamine or potassium carbonate, utilising standard methods familiar to those
skilled in the art such as reaction in solvents such as tetrahydrofuran, toluene, acetonitrile or
dimethylformamide, at a range of temperatures from ambient to reflux temperature or Via
microwave irradiation. Compounds of formula (li) where L* is defined as a suitable g
group, for example, methansulfonyl, esulfonyl, iodo, bromo, or chloro, may be
prepared from compounds of formula (1) using standard methods familiar to those skilled in
the art, for example reaction with a sulfonyl chloride or a suitable halogenating agent such as
thionyl chloride or phosphorous tribromide.
Compounds of formula (1) where R31 is NRSRQ, —(NRaRb)—J (e.g., >x< ), -CN, or
alkoxy and where R1, R2, R8, R9, n, D and J are as defined above may be prepared according
to scheme 18 from compounds of formula (xlix) via displacement of a suitable leaving-
group, for example, an alkyl sulfone, by a suitable nucleophilic species. Typically, this
reaction is performed in the presence of a base, for example, triethylamine or potassium
carbonate, utilising standard methods ar to those skilled in the art such as reaction in
solvents such as tetrahydrofuran, toluene, acetonitrile or dimethylformamide, at a range of
temperatures from ambient to reflux temperature or via ave irradiation. Compounds
of a (xlix) may be prepared via ion of compounds of formula (xlviii). Suitable
reductants include m aluminium hydride in anhydrous solvent, typically
tetrahydrofuran or diethyl ether at a range of temperatures from -78°C to 0°C. Compounds
of a (xlviii) may be prepared according to the methods ofW02004/111057.
Compounds of formula (IV) may be prepared from compounds of formula (liv) via an amide
formation. lly, this may be performed by conversion of compounds of formula (liv) to
their corresponding acid chloride tives by treatment with a le chlorinating agent
sucgh as thionyl chloride or oxalyl chloride, optionally in the presence of a solvent for
example dichloromethane. The acid chloride is then treated with an amine in the presence of
base, typically pyridine, optionallyin the presence of solvent, for e dichloromethane
to give the amide (1v). atively, compounds of formula (IV) may be prepared via the
on of compounds of formula (liv) with amines of formula NHR4R5. Typically, this
reaction is carried out using a coupling reagent such as l-ethyl(3-dimethylaminopropyl)-
carbodiimide (EDC) or 2-(7-aza—lH—benztriazole-l-yl)-l,l,3,3-tetramethyluronium
hexafluorophosphate (HATU) utilising standard methods ar to those skilled in the art
such as reaction in solvent such as tetrahydrofuran, acetonitrile or dimethylformamide at a
range of temperatures from ambient to reflux temperature in the presenceof an organic base,
for example, N,N—diisopropylethylamine.
Compounds of formula (liv) may be ed according to scheme 18 via hydrolysis of an
alkyl ester (liii). Typically, this reaction is carried out using aqueous acid or base, at a range
of temperatures from ambient to reflux temperature. Suitable acids include hloric acid
and suitable bases include sodium hydroxide or lithium hydroxide.
Compounds of formula (liii) where R3I is NRSRQ, —(NRaRb)—J (e.g >x< ), -CN, or
alkoxy and where R1, R2, R8, R9, n, D and J are as defined above may be ed according
to scheme x from compounds of formula (xlviii) via displacement of a suitable leaving-
group for example, a 4-chloro, by a suitable nucleophilic species. Typically, this reaction is
performed in the presence of a base, for example, triethylamine or potassium carbonate,
ing standard methods familiar to those skilled in the art such as reaction in ts
such as tetrahydrofuran, toluene, acetonitrile or dimethylformamide, at a range of
temperatures from ambient to reflux temperature or via microwave irradiation.
SCHEME 19
R1 R1 R1 R1
Buchwald amination
/ / X 4—» R1 / / X
Br I R\ N l
\ IllH( ')5 x1x R4/ \
Z R1311 R A
z R1311
Compounds of formula (lvii) may be prepared according to scheme 19 via the reaction of
nds of formula (lxvi) and amines of form NHR4R5 using the procedure of ld
er al. Typically, this on is carried out in the presence of a palladium coupling reagent
and using standard methods familiar to those skilled in the art, such as reaction in solvent
such as tetrahydrofuran, acetonitrile or dimethylformamide at a range of temperatures from
ambient to reflux temperature or via microwave irradiation.
SCHEME 20
Cl Nuc
(lviii)
Compounds of formula ) may be prepared according to scheme 20 from compounds of
formula (lvix) via displacement of a suitable g-group for example, a chloro group, by a
suitable nucleophile Nuc-H, for example, a substituted amino or alkoxy group. lly,
this reaction is performed in the presence of a base, for example, triethylamine or potassium
carbonate, ing standard methods familiar to those skilled in the art such as reaction in
solvents such as tetrahydrofuran, toluene, acetonitrile or dimethylformamide, at a range of
temperatures from ambient to reflux temperature or via microwave irradiation.
SCHEME 21
(1X)
Compounds of formula (lx) may be ed from compounds of formula (lvi)(a) via the
introduction of a cyano group under catalytic conditions. Typically, the source of the
cyanide group is zinc cyanide and the catalyst is formed from a palladium complex, for
e, that formed from the combination of tris(dibenzylideneacetone) dipalladium with
diphenylphosphino ferrocene. The reaction is med in a solvent, preferably
dimethylformamide at a range of temperatures from ambient to reflux ature or via
microwave irradiation.
General
The term “comprising” encompasses “including” as well as “consisting” e. g. a composition
“comprising” X may consist exclusively ofX or may include ing additional e.g. X +
The word “substantially” does not exclude “completely” 6. g. a ition which is
“substantially free” from Y may be tely free from Y. Where ary, the word
“substantially” may be omitted from the definition of the invention.
The term “about” in relation to a numerical value x means, for example, xi10%.
MODES FOR CARRYING OUT THE INVENTION
Experimental Section
Many of the starting materials referred to in the reactions described below are available from
commercial sources or can be made by methods cited in the literature references. Synthetic
methods can also be found in reviews; [2,3-d]pyrimidines for example, can be found
in references cited in WO2004/111057 and reference such as Han et al (2010).
Synthetic s for thieno[2,3-d]pyridines may be found in WO2006/06l642 and
references such as Gewald et al (1979) Munchof et al (2004), Barker et al (1985), Charvat et
al (1995) and articles cited therein.
The following starting materials were synthesized using the ures described in
WO2004/111057:
4-Chloro-5—phenyl—thien0[2, 3-07pyrimidine
4-Chlor0(3-flu0r0phenyl)-thien0[2,3-d]pyrimidine
4-Chlor0(4-flu0r0phenyl)-thien0[2,3-d]pyrimidine
2, 4-Dichl0r0phenyl—thien0[2, rimidine
Methyl 4-ch10r0phenyl-thien0[2,3-d]pyrimidine-(S—carboxylate
6-Br0m0ch10r0phenyl—thien0[2, 3-d]pyrimidine
4-ch10r0isopropyl—thien0[2, 3-07pyrimidine
4-Chl0r0-5, 6-dimethyl—thien0[2, 3-07pyrimidine
2, 4-dichlor0-5—cyclohexyl—thien0[2, 3-07pyrimidine
4-Chl0r0ethylphenyl—thien0[2, 3-07pyrimidine
4-Chl0r0cyclohexyl-thien0[2, 3-07pyrimidine
l 16
WO 72694
2, 4-dichlor0-5—(4-flu0r0phenyl)thien0[2, 3-07pyrimidine
methyl 2—[4-chl0r0-5—(4-flu0r0phenyl)thien0[2,3-d]pyrimidin-2—yl]acerate
The ing starting materials were synthesized using the procedures described in
W02006/06l642:
r0phenyl-thien0[2, 3-1)]pyridine
The following starting materials were synthesized using the ures described in
W02005/121149:
2, 4-Bz'smethylsulph0nyl)phenyl—fur0[2, 3-61]-pyrimidine
Analytical methods
HPLC analysis was conducted using the following s:
AGILENT 61 10/1200 LCMS system
Solvent : [HZO-0.l% HCOZH : MeCN—0.05% HCOZH : HZO-0.l% , 10-95%
gradient 3min, 95% 3-5min, 5.5-5.8min 95%-20% gradient; 6min 5%; Column:
Phenomenex Gemini 50x4.6 mm id, 3 micronC18 e phase; Flow rate: 0.75mL/min.
UV detection 220/254nm, MS Electrospray (+ve and —ve mode).
Preparative HPLC purification was conducted in the following manner:
Solvent : [MeCN—0.05% HCOZH : HZO-0.l% HCOZH], 5-95% gradient 12min, 95% 3min;
Waters X-Bridge 100x19 mm id. C18 reverse phase; Flow rate: l6mL/min unless
otherwise indicated.
HPLC: Agilent HPLC with Waters XBridge C18, 5 um, 100 mm x 19 mm id. column and a
flow rate of l6ml/minute. With two Gl36lA prep pumps, a G2258A duel loop auto sampler,
a G1315 diode array detector and a G3064B prep fraction collector. Analysed by
ChemStation 3. Solvents, (acidic method) water with 0.01% formic acid and acetonitrile
with 0.05% formic acid or (basic ) water with 0.1% ammonia and acetonitrile.
Method a:
Time minutes 0 12 15 15 .5
itrile concentration % 5 95 95 5
Method b:
Time minutes 0 1.5 13.5 14 15 15.5 16
Acetonitrile concentration % 5 40 65 98 98 5 5
Method c:
Time minutes 0 1.5 14 14.5 15 15.5
Acetonitrile concentration % 5 50 75 95 95 5
Method d:
Time minutes 0 1.5 14 14.5 15 15.5
Acetonitrile concentration % 5 50 65 95 95 5
Method e:
Time s 0 1 1 12 15 15
Acetonitrile concentration % 5 35 95 95 5
Method f:
Time minutes 0 1.5 12 15 15 .5
Acetonitrile concentration % 5 50 95 95 5
Method g:
Time minutes 0 1 1 1 1.5 14.5 15
Acetonitrile concentration % 5 55 95 95 5
HPLC: Agilent HPLC with Phenomenex Gemini-NX, 5 um, 100 mm x 30mm i.d. column
and a flow rate of 40m1/minute. With two G1361A prep pumps, a G2258A duel loop auto
sampler, a G1315 diode array detector and a G3064B prep fraction collector. ed by
ChemStation 3. Solvents, (acidic method) water with 0.01% formic acid and acetonitrile
with 0.05% formic acid or (basic method) water with 0.1% ammonia and acetonitrile.
Method 1:
Time s 0 12 15 15 .5
Acetonitrile concentration % 5 95 95 5
Method 2:
Time minutes 0 1.5 13.5 14 15 15.5 16
Acetonitrile tration % 40 65 98 98 5 5
Method 3:
Time minutes 1.5 14 14.5 15 15.5
Acetonitrile tration % 50 75 95 95 5
Method 4:
Time minutes 1.5 14 14.5 15 15.5
Acetonitrile concentration % 50 65 95 95 5
Method 5:
Time minutes ll 12 15 15
Acetonitrile concentration % 35 95 95
Method 6:
Time minutes 1.5 12 15 15.5
Acetonitrile concentration % 50 95 95
Method 7:
Time s ll 11.5 14.5 15
Acetonitrile concentration % 55 95 95
Proton and carbon NMR were acquired on a Bruker Advance 300 at 300 and 75 mHz
respectively.
Method A
Synthesis of 2-(I-methylpyrrolidin-Z-yl)-N—[[I-(5-phenylthien0[2,3-d]pyrimidin-4—yl)-4—
piperidyUmethyUethanamine (Example 58)
i) [4-(5-Phenyl-thieno[2,3-d]pyrimidinyl)-piperidinyl]-methanol
4-Chlorophenyl-thieno[2,3-d]pyrimidine (l g, 4.05 mmol) was dissolved in ethanol (15
ml) to give a yellow solution. To this was added triethylamine (1.7 ml, 12.2 mmol) and 4-
dinemethanol (0.58 g, 5 mmol). The reaction mixture was heated to 50 °C and stirred
for 1.5 hours until no 4-chlorophenyl-thieno[2,3-d]pyrimidine was present by TLC. The
reaction mixture was allowed to cool to room temperature before being poured over ice
water (50:50 mix). The resultant precipitate was collected by filtration to give the product as
a pale yellow solid (1.23 g, yield 90%). LCMS: RT = 4.05 min, M+1 = 326.
The following compounds were synthesised according to the method described using the
appropriate ng materials:
(4-flu0r0phenyl)thien0[2, 3-07pyrimidinyl]azabicyclo[3. I . 0]hexan-6—yl]methanol
[I-[5-(4-nitr0pheny0thien0[2, 3-07pyrimidinyl]piperidyl]methanol
[3-(5—phenylthien0[2, 3-d]pyrimidinyDazabicycl0[3. I. 0]hexan-6—yl]methan0l
[I-[5-(3-flu0r0phenyl)thien0[2, 3-07pyrimidinyl]piperidyl]methanol
[I-(5-ethylmethyl—thien0[2, 3-07pyrimidinyDpzperidyl]methanol
[I-(6-is0pr0pylthien0[2, 3-07pyrimidinyDpzperidyl]methanol
[I-(5—methylthien0[2, 3-d]pyrimidinyDpzperidyl]methanol
[I-(5—phenylthien0[2, 3-d]pyrimidiny0azetidinyl]methanol
[I-(5—phenylthien0[2, 3-d]pyrimidinpryrrolidinyl]methanol
[I-(5—phenylthien0[2, 3-d]pyrimidinyDpzperidyl]methanol
[5-phenyl—I-(5—phenylthien0[2, 3-d]pyrimidinpryrrolidinyl]methanol
[5-methyl—I-(5—phenylthien0[2, 3-d]pyrimidinpryrrolidinyl]methanol
[I-(5, 6-dimethylthien0[2, 3-07pyrimidinyDpzperidyl]methanol
is0pr0pylthien0[2, 3-07pyrimidinyDpzperidyl]methanol
[8-(5—phenylthien0[2, 3-d]pyrimidinyD-8—azabicycl0[3. 2. I]octanyl]methanol
I-(5—phenylthien0[2, 3-d]pyrimidin-4—yl)pzperidin0Z
I-(5—phenylthien0[2, 3-d]pyrimidin-4—yl)pzperidin0Z
I-(5—phenylthien0[2, rimidiny0pyrr0lidin0l
[3-[5-(4-flu0r0phenyl)thien0[2, 3-07pyrimidinyl]azabicyclo[3. I . 0]hexan-6—yl]methanol
[(3R)-I-(5—phenylthien0[2, 3-d]pyrimidinpryrrolidinyl]methanol
2—(5—phenylthien0[2, 3-d]pyrimidinyD-2—azabicycl0[2. 2. I]heptan-5—01
yclohexylthien0[2, 3-d]pyrimidin-4—yl)-2—azabicyclo[2. 2. I]heptan-5—01
[(SS)-I-(5—phenylthien0[2, 3-d]pyrimidinyl)pyrrolidinyl]methanol
[I-(5—methylthien0[2, 3-d]pyrimidinpryrrolidinyl]methanol
ii) 4-(4-Bromomethyl-piperidin- l -yl)phenyl-thieno [2,3 -d]pyrimidine
[4-(5-Phenyl-thieno[2,3-d]pyrimidinyl)-piperidinyl]-methanol (8 g, 24.6 mmol) and
tetrabromomethane (12.2 g, 36.9 mmol) were dissolved in dry dichloromethane (40 ml) at 0
°C to give a yellow solution. To this was added nylphosphine (0.089 g, 0.338 mmol) in
ns. The reaction mixture was cooled with ice before the brown solution was left to stir
for 2.5 hours. After this there was no [4-(5-phenyl-thieno[2,3-d]pyrimidinyl)-piperidin
WO 72694
yl]-methanol present by LCMS or TLC. The reaction mixture was d through silica
before solvent was removed in vacuo to give a crude e (14.24 g). This was purified
through a plug of silica, eluted with l ether before further purification by flash
chromatography. The product was collected and concentrated to give a cream solid (7.63 g,
yield 80%). LCMS: RT = 5.3min, M+1: 389.8.
The following compounds were synthesised according to the method described using the
appropriate starting materials:
4—[3-(bromomethyD-I-piperidyl]-5—phenyl—thien0[2, 3-07pyrimidine
4—[3-(bromomethpryrrolidin-I-yl]-5—phenyl—thien0[2, 3-61]pyrimidine
4—[3-(bromomethyDazetidin-I-yl]-5—phenyl—thien0[2, 3-07pyrimidine
4—[4—(bromomethyl)-2—phenyl—pyrr0lidin-I-yl]-5—phenyl—thien0[2, 3-07pyrimidine
4—[4—(bromomethyD-I-piperidyl]-5, 6-dimethyl—thien0[2, 3-61]pyrimidine
4—[4—(bromomethyD-I-piperidyl]-5—is0pr0pyl—thien0[2, 3-61]pyrimidine
4—[3-(brom0methy0-8—azabicycl0[3. 2. I]octanyl]-5—phenyl—thien0[2, 3-07pyrimidine
4—[4—(bromomethyD-I-piperidyl]-5—methyl—thien0[2, 3-07pyrimidine
4—[3-(bromomethpryrrolidin-I-yl]-5—methyl—thien0[2, 3-61]pyrimidine
iii) 2-(1-methylpyrrolidinyl)-N-[[l-(5-phenylthieno[2,3 -d]pyrimidinyl)piperidyl]
methyl]ethanamine (Example 58)
4-[4-(Bromomethyl)-l-piperidyl]phenyl-thieno[2,3-d]pyrimidine (13.8 g, 35.5 mmol), 2-
(1-methylpyrrolidin—2-yl)ethanamine (5.47 g, 42.6 mmol) and potassium ate (7.37 g,
53.3 mmol) were heated in acetonitrile (100 mL) in the microwave at 150°C for 30 s
in 8 x 20 mL microwave vials. The reaction mixtures were combined and diluted with DCM
(250 mL). The organic was washed with water (250 mL) and concentrated at reduced
pressure. The resulting residue was purified by flash chromatography, eluting with a
gradient of DCM to 1 DCM / MeOH / NH40H to afford the target nd (4.0 g)
and mixed fractions. LCMS [M+H]+ = 436.0
Other compounds prepared by Method A as described for example (iii) using the appropriate
starting materials are listed in TABLE 1.
Method B
Synthesis of I-[4—[4—[[methyl-(I-methylpyrrolidin-S-yl)amin0]methyl]-I-piperidyl]-5—
phenyl—thien0[2, 3-d]pyrimidin-Z-yl]pyrrolidinecarb0xamide (Example 120)
i) [1-(2-chlorophenyl-thieno [2,3 -d]pyrimidinyl)piperidyl]methanol
4-Piperidinemethanol (987 mg, 8.57 mmol) was added to a stirred suspension of 2,4-
dichlorophenyl-thieno[2,3-d]pyrimidine (2 g, 7.14 mmol) and ylamine (2.18 ml,
.7 mmol) in dry ethanol (15 ml) at room temperature. Reaction was warmed to 40 0C and
the resulting solution d for ~2h. Reaction was allowed to cool to room ature and
poured onto ice/water (50 ml). The resulting suspension was d and the solid dried in a
vacuum oven at 40 0C. The desired compound was obtained as a pale yellow solid (2.4 g,
93%). LCMS: (M+1) 360, RT = 4.69 min.
The following compounds were synthesised according to the method described using the
appropriate starting materials:
[I-(2—chlor0-5, 6-dimethyl—thien0[2, 3-07pyrimidin-4—yDpzperidyl]methanol
[I-(2—chlor0-5—isopropyl—thien0[2, 3-07pyrimidin-4—y0-4—p1peridyl]methanol
ii) 1-(2-chlorophenyl-thieno[2,3-d]pyrimidinyl)piperidinecarbaldehyde
Pyridinium chlorochromate (898 mg, 4.17 mmol) was added to a stirred solution of [1-(2-
chlorophenyl-thieno[2,3-d]pyrimidinyl)piperidyl]methanol (1 g, 2.78 mmol) in dry
dichloromethane (15ml) at room temperature. The ing mixture was stirred for 2h and
then eluted through a pad of silica (eluting ethyl acetate). The solvent was evaporated to give
the 1-(2-chlorophenyl-thieno[2,3-d]pyrimidinyl)piperidinecarbaldehyde as a pale
yellow solid (1 g, quantitative yield). Product was used in the subsequent reaction t
further purification. LCMS: (M + H)+ 358, RT = 4.98 min.
The following compounds were synthesised according to the method described using the
appropriate ng als:
I—(2-ch10r0is0pr0pyl—thien0[2, 3-d]pyrl'midiny0pzperidinecarbaldehyde
I—(2-ch10r0-5, 6-dimethyl—thien0[2, 3-d]pyrl'midiny0piperidinecarbaldehyde
iii) N— [[ l -(2-chlorophenyl-thieno [2,3 -d]pyrimidinyl)piperidyl]methyl] -N, l -
dimethyl-pyrrolidinamine
Sodium triacetoxyborohydride (1.54 g, 7.28 mmol) was added to a stirred solution of l-(2-
phenyl-thieno[2,3-d]pyrimidinyl)piperidinecarbaldehyde (1.3 g, 3.64 mmol),
N, N’-dimethylaminopyrrolidine (519 ul, 4.00 mmol) and acetic acid (240 ul, 4.00 mmol)
in dry dichloromethane (20 ml) at room temperature. The solution was stirred for ~2h, after
which time the reaction had reached completion. Water (20 ml) was added and the organic
layer separated, the aqueous phase was extracted with dichloromethane (x3) and the
combined organics washed with brine, then dried (MgSO4) and ated. The crude
residue was purified by flash column chromatography (0 to 5% 7.0M OH in
dichloromethane). N— [[ l -(2-chloro-5 -phenyl-thieno [2,3 -d]pyrimidinyl)
piperidyl]methyl] -N, l -dimethyl-pyrrolidin-3 -amine
was isolated as a pale yellow oil (1.25 g, 76%). LCMS: (M + H)+ 456.2, RT = 2.99.
The following compounds were synthesised according to the method described using the
appropriate starting als:
[I-[[I-(Z-Chloro-5—phenyl—thien0[2, 3-d]pyrimidin-4—yl)-4—
piperidyUmethylamin0]cyclopentyl]methanol
N—[[I-(Z-Chloro-5—phenyl—thien0[2, 3-d]pyrimidin-4—yDpzperidyUmethyU-Z-(I-
methylpyrrolidin-Z-yl)ethanamine
N—[[I-(2—chlor0-5—phenyl—thien0[2, 3-07pyrimidin-4—yDpzperidyl]methyl]cyclobutanamine
I-[[I-(Z-Chloro-5—phenyl—thien0[2, 3-d]pyrimidin-4—yl)-4—piperidyl]methyU-N,N—dimethyl—
piperidin-S-amine
iv) 1- [4- [4- [ l-( 1 -methylpyrrolidin-3 -yl)amino]methyl] - l idyl] phenyl-
thieno[2,3-d]pyrimidinyl]pyrrolidinecarboxamide (Example 120)
N— [[ l -(2-chlorophenyl-thieno [2,3 -d]pyrimidinyl)piperidyl]methyl] -N, l -dimethyl-
pyrrolidinamine (100 mg, 0.219 mmol) and pyrrolidinecarboxamide (300 mg, 2.63
mmol) were stirred in dry acetonitrile (1.5 ml) and heated in a ave at 1400C for 0.5h.
The solvent was evaporated and the crude residue purified by flash column chromatography
(0 to 5% 7.0M NH3/MCOH in dichloromethane) to give l-[4-[4-[[methyl-(l-
methylpyrrolidin-3 -yl)amino]methyl] - l idyl] phenyl-thieno [2,3 -d]pyrimidin
yl]pyrrolidinecarboxamide as an off white solid (25 mg, 21%). m/z (M + H)+ 534.3, RT =
2.69 min.
Other nds prepared by Method B as described for example (iV) using the appropriate
starting materials are listed in TABLE 1.
Method C
sis of N,N—dimethyl-5—phenyl—4—[4—(Z-pyrrolidih-I-yleth0xymethyl)cycl0hexyl]
thieh0[2,3-d]pyrimidihecarb0xamide (Example 135)
i) Methyl 5-phenyl [4-(2-pyrrolidin- l -ylethoxymethyl)- l -piperidyl]thieno [2,3 -
d]pyrimidinecarboxylate
To a stirred solution of methyl 4-chlorophenyl-thieno[2,3-d]pyrimidinecarboxylate
(0.850 g, 2.80 mmol) in THF (50 mL), was added diisopropylethylamine (0.73 mL, 4.20
mmol) and 4-(2-pyrrolidin—l-ylethoxymethyl)piperidine (0.890 g, 4.20 mmol) in one
portion, and the reaction left to stir at room temperature for 2 hours. The reaction was
diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The on was
dried over sodium sulphate, d and concentrated under reduced pressure. The crude
material was purified by column chromatography using DCM: MeOH (0-25%) as eluent to
afford the named product (1.012 g, 75%). m/z [M+H]+ 481; RT = 3.03min.
The following compounds were synthesised according to the method described using the
riate starting materials:
methyl 5-is0pr0pyl—4—[4—(Z-pyrrolidih-I-ylethoxymethyl)-I-piperidyl]thieh0[2, 3-d]
pyrimidine-(S-carboxylate
methyl 5-phehyl[3- (Z-pyrrolidih-I-yleth0xymethyl)-8—azabicycl0[3. 2. hyl]
thieho[2, 3-d]pyrimidihecarb0xylate
methyl 5-phehyl[3- (Z-pyrrolidih-I-ylethoxymethyl)-8—azabicycl0[3. 2. I]octahyl]
thieho[2, 3-d]pyrimidihecarb0xylate
ii) N,N—dimethylphenyl [4-(2-pyrrolidin- l -ylethoxymethyl)cyclohexyl] thieno[2,3 -
d]pyrimidinecarboxamide (Example 13 5)
l 24
WO 72694
To a stirred on of methyl 5-phenyl[4-(2-pyrrolidin-l-ylethoxymethyl)-l-
piperidyl]thieno[2,3-d]pyrimidinecarboxylate (0.200 g, 0.42 mmol) in DCM (4 mL) was
added trimethylaluminium (0.63 mL, 1.26 mmol, 2M solution in hexane) and the reaction
stirred at room temperature for 15 minutes. Dimethylamine (0.63 mL, 1.26 mmol, 2M
solution in THF) was added and the reaction heated in a microwave at 100 0C for 2 hours.
The reaction was diluted with DCM (20 mL) and water (20 mL) and the organic phase
separated. The aqueous phase was further extracted with DCM (2 x 10 mL) and the
combined extracts dried over sodium te, filtered and concentrated under reduced
pressure. The crude material was purified by high performance liquid chromatography and
the pure fractions combined and evaporated under reduced pressure to afford the named
product (0.044 g, 22%). m/z [M+H]+ 494; RT = 2.62 min.
Other compounds prepared by Method C as described for example (ii) using the appropriate
starting materials are listed in TABLE 1.
Method D
Synthesis of N—isopropyl—5—phenyl—4—[4— rolidin-I-ylethoxymethyD-I-piperidyl]
thien0[2,3-d]pyrimidine—(S—carboxamide (Example 139)
i) 5-phenyl [4-(2-pyrrolidin— l -ylethoxymethyl)- l -piperidyl]thieno [2,3 -d]pyrimidine-
6-carboxylic acid
Lithium hydroxide monohydrate (0.08 g, 1.9 mmol) was added to a stirred solution of
methyl 5-phenyl [4-(2-pyrrolidin- l -ylethoxymethyl)- l idyl]thieno [2,3 imidine-
6-carboxylate (0.44 g, 0.91 mmol) in THF (10 mL) and water (10 mL). The mixture was
d for 2 hr. The organic t was evaporated and the remaining aqueous mixture was
extracted with EtOAc (3 x 10 mL). The aqueous layer was ied (to pH 3) with
concentrated hydrochloric acid and then extracted with DCM / MeOH 4:1 (3 x 25 mL). The
combined organic layers were dried (magnesium sulfate), filtered and evaporated to give the
target compound (0.08 g) as a light orange solid. m/z [M+H]+ 467.0. Retention time 2.80
min (LCMS method +ve 6 min).
The aqueous layer was evaporated to dryness. The residue was mixed with DCM and MeOH
(l:l), sonicated and filtered. The filtrate was evaporated to give the target compound (424
mg) as a yellow solid.
The following compounds were synthesised according to the method described using the
appropriate starting materials:
-is0pr0pyl—4—[4—(Z-pyrrolidin-I-ylethoxymethyD-I-piperidylfihienop, 3-d]pyrimidine-6—
ylic acid
-phenyl—4—[3-(Z-pyrrolidin-I-yleth0xymethyD-8—azabicyclo[3. 2. I]octanyl]thien0[2, 3-
midine-6—carb0xylic acid
ii) N—isopropylphenyl [4-(2-pyrrolidin- l -ylethoxymethyl)- l -piperidyl] thieno [2,3 -
d]pyrimidinecarboxamide (Example 139)
A mixture of 5-phenyl[4-(2-pyrrolidin-l-ylethoxymethyl)-l-piperidyl]thieno[2,3-
d]pyrimidinecarboxylic acid (70 mg, 0.15 mmol), HATU (l 14 mg, 0.30 mmol),
isopropylamine (30 uL, 0.35 mmol) and triethylamine (63 uL, 0.45 mmol) in DMF (5 mL)
was stirred at room temperature for 3 nights. The t was evaporated. The residue was
ved in EtOAc (5 mL) and water (5 mL). The layers were separated and the aqueous
was extracted with EtOAc (2 x 5 mL). The ed organic layers were dried (magnesium
sulfate), filtered and evaporated to give a brown solid. This was d by preparative
HPLC. ons containing target compound were combined and evaporated to give the
target compound (24.3 mg) as a brown solid. m/z [M+H]+ 508; RT = 2.94 min.
Other compounds prepared by Method D as described for example (ii) using the appropriate
starting materials are listed in TABLE 1.
Method E
Synthesis of N—[5—phenyl—4-[4-(Z-pyrrolidin-I-ylethoxymethyD-I-piperidylfihienop, 3-
d]pyrimidin-6—yl]acetamide (Example I 62)
i) 6-bromophenyl [4-(2-pyrrolidin— l -ylethoxymethyl)- l -piperidyl]thieno [2,3 -
d]pyrimidine
To a stirred solution of 6-bromochlorophenyl-thieno[2,3-d]pyrimidine
(0.820 g, 2.52 mmol) in THF (50 mL), was added diisopropylethylamine (0.65 mL, 3.78
mmol) and 4-(2-pyrrolidin—1-ylethoxymethyl)piperidine (0.801 g, 3.78 mmol) in one
portion, and the reaction left to stir at room temperature overnight. The on was diluted
with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The reaction was dried
over sodium sulphate, filtered and concentrated under reduced pressure. The crude material
was purified by column chromatography using DCM: MeOH (0-25%) as eluent to afford the
named product (0.828 g, 66%).
ii) N—[5-phenyl pyrrolidinylethoxymethyl)piperidyl]thieno [2,3 -
d]pyrimidinyl]acetamide (Example 162)
To a stirred mixture of 6-bromophenyl[4-(2-pyrrolidinylethoxymethyl)
piperidy1]thieno[2,3-d]pyrimidine (0.075 g, 0.15 mmol), cesium carbonate (0.102 g, 0.30
mmol), ide (0.019 g, 0.23 mmol), xantphos (0.014 g, 0.023 mmol) and
tris(dibenzylideneacetone) dipalladium (0.007 g, 0.008 mmol) sealed in a microwave tube
under an atmosphere of nitrogen, was added acetonitrile (2 mL) and 1,4-dioxane (2 mL).
The reaction was placed in a microwave reactor at 150 0C for 1 hour. The reaction was
concentrated under reduced re, diluted with ethyl acetate (20 mL) and water (20 mL),
the organic layer washed with brine, dried over sodium sulphate, filtered and concentrated
under d pressure. The crude material was purified by high performance liquid
chromatography and the pure fractions combined and evaporated under d pressure to
afford the named product (0.012 g, 17%). LCMS [M+H]+ = 480; RT = 2.82 min.
Other nds prepared by Method E as described for example (ii) using the appropriate
starting materials are listed in TABLE 1.
Method F
1) Synthesis of 5-phenyl—4—[4-(Z-pyrrolidin-I-ylethoxymethyD-I-pz'peridyUthienop,3-
midine (Example 5)
i) 5-phenyl [4-(2-pyrrolidin— 1 -ylethoxymethyl)piperidyl]thieno [2,3 -d]pyrimidine
(Example 5)
[1-(5-Phenylthieno[2,3-d]pyrimidinyl)piperidyl]methanol (100 mg, 0.31 mmol) was
dissolved in ous DMF (2 mL) under a nitrogen atmosphere. Sodium hydride (50 mg,
1.25 mmol, 60% w/w dispersion in mineral oil) was added and the mixture was stirred for 5
min. 1-(2-Chloroethy1)-pyrrolidine hydrochloride (105 mg, 0.62 mmol) was added and the
mixture was stirred for two nights. Further ns of sodium hydride (50 mg, 1.25 mmol,
60% w/w dispersion in mineral oil) and 1-(2-chloroethyl)-pyrrolidine hydrochloride (105
mg, 0.62 mmol) were added and the mixture was d overnight. It was d with
MeOH and then concentrated. The residue was dissolved in EtOAc (5 mL) and water (5
mL). The layers were separated and the aqueous was extracted with EtOAc (2 x 5 mL). The
combined organic layers were dried (magnesium sulfate), filtered and evaporated to give a
brown oil. This was purified by LCUV (basic method F). Collected fractions were analysed
by LCMS and fractions containing the target compound were combined and evaporated to
give the target compound (62 mg) as a white solid. m/z [M+H]+ 423.0. RT = 3.20 min . 1H
NMR (CDC13): 5 = 0.64 (2H, qd), 1.38 (2H, d), 1.44 - 1.80 (5H, m), 2.38 - 2.53 (6H, m),
2.57 (2H, t), 3.04 (2H, d), 3.42 (2H, t), 3.75 (2H, d), 7.14 (1H, s), 7.25 - 7.42 (5H, m), 8.51
(1H, s)
Other compounds prepared by Method F as described for example (i) using the appropriate
starting materials are listed in TABLE 1.
2) Synthesis 0f5-[2-[[2-(5-is0pr0pylthien0[2,3-d]pyrimidinyZ)
azabicyclo[2.2. anyl]0xy]ethyl]0xaazabicyclo[2.2.1]heptane
(Example 292)
i) tert—butyl 5-(2-tetrahydropyranyloxyethoxy)azabicyclo[2.2.1]heptane
carboxylate
Tert-butylhydroxyazabicyclo[2.2.1]heptanecarboxylate (1.5 g, 7.0 mmol) and
utylammonium bromide (0.35 g, 0.70 mmol) were stirred in sodium hydroxide (10 M)
(30 mL, 1600 mmol) / toluene (30 mL) and heated to 60 °C. 2-(2-
Bromoethoxy)tetrahydropyran (4.4 g, 21 mmol) was added in 4 portions over 2 hours and
heating continued overnight. Further 2-(2-bromoethoxy)tetrahydropyran (1 eq) was added
and the reaction heated for a further 3 hours. The reaction mixture was diluted with DCM,
washed with water, dried over NaZSO4 and concentrated in vacuo to afford a yellow oil. The
reaction e was purified by flash chromatography, g with DCM then 90/10
DCM/MeOH to afford tert-butyl(2-tetrahydropyranyloxyethoxy)
azabicyclo[2.2.1]heptanecarboxylate (1.08 g).
ii) 2-(2-azabicyclo[2.2.1]heptanyloxy)ethanol
Tert-butyl(2-tetrahydropyranyloxyethoxy)azabicyclo [2 .2. 1]heptanecarboxylate
(1.08 g, 3.16 mmol) was stirred overnight in 5 M hydrochloric acid (30 mL, 990 mmol) /
THF (30 mL) . The reaction mixture was basified with NaOH and washed with DCM. The
c was dried over NaZSO4 and concentrated in vacuo to afford 2-(2-
azabicyclo[2.2.1]heptan—5-yloxy)ethanol (350 mg). LCMS RT = 0.57 min. M+1 = 158.
iii) 2- [ [2-(5-isopropylthieno [2,3 -d]pyrimidinyl)azabicyclo [2 .2. 1 ]heptan—5 -
yl]oxy] ethanol
4-Chloroisopropyl-thieno[2,3-d]pyrimidine (0.35 g, 1.6 mmol), 2-(2-
azabicyclo[2.2.1]heptanyloxy)ethanol (0.39 g, 2.5 mmol), triethylamine (0.50 g, 0.70 mL,
4.9 mmol) and ethanol (3.95 g, 5 mL, 85.6 mmol) were combined and heated to 50 °C
overnight. The reaction mixture was trated in vacuo. The resulting residue was taken
up in DCM, washed with water, dried over NaZSO4 and concentrated in vacuo to afford
2- [ [2-(5-isopropylthieno [2,3 -d]pyrimidinyl)azabicyclo [2 .2. 1 ]heptan—5 -
yl]oxy]ethanol (562 mg). LCMS RT: 3.47 min. M+1 = 334.
iv) 2- [ [2-(5-isopropylthieno [2,3 -d]pyrimidinyl)azabicyclo [2 .2. 1 ]heptan—5 -
yl]oxy] ethyl esulfonate
2-[[2-(5-Isopropylthieno[2,3-d]pyrimidinyl)azabicyclo[2.2. 1]heptanyl]oxy] l
(0.56 g, 1.7 mmol) was stirred in DCM (13.25 g, 10 mL, 156.0 mmol) at 0°C. Triethylamine
(0.52 g, 0.71 mL, 5.0 mmol) was added. Methanesulfonyl chloride (0.29 g, 0.20 mL, 2.5
mmol) was added dropwise and the reaction allowed to warm slowly to room temperature
and stirred for 1 hour. The reaction mixture was diluted with DCM, washed with water,
dried over NaZSO4 and concentrated in vacuo to afford 2-[[2-(5-isopropylthieno[2,3-
d]pyrimidinyl)azabicyclo[2.2.l]heptanyl]oxy]ethyl methanesulfonate (0.747 g).
LCMS RT = 3.94 min. M+l = 412.
(v) [2—(5-is0pr0pylthien0[2, 3-d]pyrimidin-4—yl)-2—azabicyclo[2. 2. I]heptan-5—
yl]0xy]ethyl]-2—0xaazabicyclo[2.2. ne (Example 292)
2-[[2-(5-Isopropylthieno[2,3-d]pyrimidinyl)azabicyclo[2.2. l]heptanyl]oxy] ethyl
methanesulfonate (0.11 g, 0.27 mmol), 2-oxaazabicyclo[2.2.l]heptane hydrochloride
(0.072 g, 0.53 mmol) and potassium carbonate (0.11 g, 0.80 mmol) were combined in
methyl ethyl ketone (2 mL) / DMF (1 mL, 12.8) and heated in the microwave for 30 minutes
at 180 °C. The reaction mixture was diluted with DCM, washed with water, dried over
NaZSO4 and concentrated at d pressure. The resulting residue was purified by basic
prep HPLC (method 2) to afford 5-[2-[[2-(5-isopropylthieno[2,3-d]pyrimidinyl)
azabicyclo[2.2.l]heptanyl]oxy]ethyl]oxa—5-azabicyclo[2.2.l]heptane as a colourless
gum (20 mg). LCMS RT = 4.33 min. M+l = 415.
Other compounds prepared by Method F as described for example (V) using the appropriate
ng materials are listed in TABLE 1.
Method G
Synthesis 0f5—phenyl—2—[4— (Z-pyrrolidin-I-ylethoxymethyD-I-pz'peridyUthienop, 3-
d]pyrimidine (Example 148)
i) rophenyl-thieno[2,3-d]pyrimidine
2,4-Dichlorophenyl-thieno[2,3-d]pyrimidine (l g, 3.56 mmol) and zinc dust (2.34 g, 35.6
mmol) were combined and stirred in ethanol (10 mL). NH4OH (1 mL) was added and the
on heated to reflux for 2 hours. The reaction mixture was allowed to cool to room
temperature, diluted with ethyl acetate (50 mL) and filtered through celite. The filtrate was
washed with water (100 mL), dried over NaZSO4 and concentrated at reduced pressure. The
resulting residue was purified by flash chromatography, eluting with a gradient of petroleum
ether to
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1119703.5 | 2011-11-15 | ||
GBGB1119703.5A GB201119703D0 (en) | 2011-11-15 | 2011-11-15 | Compounds |
GBGB1214250.1A GB201214250D0 (en) | 2012-08-09 | 2012-08-09 | Compounds |
GB1214250.1 | 2012-08-09 | ||
PCT/GB2012/052842 WO2013072694A1 (en) | 2011-11-15 | 2012-11-15 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ626199A NZ626199A (en) | 2015-04-24 |
NZ626199B2 true NZ626199B2 (en) | 2015-07-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9290511B2 (en) | Thieno-pyrimidines, useful as potassium channel inhibitors | |
KR102517352B1 (en) | Heteroaromatic derivatives as NIK inhibitors | |
CA2897333C (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
EP2943485B1 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
AU2017209935B2 (en) | New substituted cyanoindoline derivatives as NIK inhibitors | |
EP3144308B1 (en) | Nitrogen-containing heterocyclic compound | |
TW201206923A (en) | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | |
WO2016126722A1 (en) | 3-alkyl bicyclic [4,5,0] hydroxamic acids as hdac inhibitors | |
KR102587619B1 (en) | Cyanoindoline derivatives as NIK inhibitors | |
WO2023066350A1 (en) | Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications | |
CA3012031A1 (en) | 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors | |
TW202310845A (en) | Heteroaryl derivative compounds, and uses thereof | |
NZ626199B2 (en) | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | |
WO2013072693A1 (en) | Thieno [2, 3 - c] pyrazoles for use as potassium channel inhibitors |